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ABSTRACT 
 Breast cancer mortality is invariably due to metastasis, the dissemination of cancer cells from 
the primary tumour to distant organs. This process is proposed to arise from the breast cancer stem 
cells (bCSCs), the minority of cells within a tumour that are capable of propagating new tumour 
growth. bCSCs are also associated with potentiating endocrine therapy resistance and therefore 
relapse after tamoxifen or anastrozole treatments. Tumour necrosis factor -related apoptosis inducing 
ligand (TRAIL) is an anti-cancer agent that induces apoptosis in bCSCs and has almost no toxicity to 
normal cells. However, there is an inherent resistance to TRAIL in vitro in a large proportion of breast 
cancer cell types due to the expression of the survival factor cellular FLICE-Like Inhibitory Protein (c-
FLIP). It has been shown that siRNA-mediated suppression of the gene for c-FLIP combined with TRAIL 
is effective in vitro at sensitising bCSCs to apoptosis in breast cancer cell lines.  
 To test whether these findings have direct clinical relevance for breast cancer patients, 
diagnostic biopsies; surgical breast resections and pleural effusions were collected from the clinic. 
Testing TRAIL alone in breast samples resulted in a decrease in the number of tumourspheres in 82% 
of tumours that have acquired endocrine resistance to tamoxifen and anastrozole. Importantly, TRAIL 
was efficient in vivo at decreasing primary tumour size in tumours that have acquired resistance to 
tamoxifen in vivo and number of metastases of an anastrozole-resistant sample. Additionally, TRAIL 
was also effective at decreasing bCSCs in triple negative metastatic tumours, corroborating studies 
supporting a relationship between a mesenchymal phenotype and TRAIL sensitivity. However, there 
was no correlation between TRAIL response and either ER or HER2 status in primary breast samples. 
 Furthermore, c-FLIP was suppressed, either genetically (siRNA) or pharmacologically (OH14) 
and combined with TRAIL treatment sensitised bulk and bCSCs to TRAIL in breast tumours from 
patients with metastatic disease irrespective of their estrogen receptor (ER)/HER2 status.  
As the tumour microenvironment can modulate drug responses, TRAIL treatment was 
investigated on breast cancer epithelial cells in the presence of cancer associated fibroblasts (CAFs) 
and CAFs-conditioned medium (CM). Short exposure to CAFs and CM sensitised MCF-7 and primary 
metastatic cells to TRAIL whereas a longer exposure to CM conferred resistance to TRAIL potentially 
due to an induction of epithelial-mesenchymal transition.  
With these results in primary cells, TRAIL could be a valuable treatment to the clinic for 
patients that have acquired resistance to endocrine treatments. Additionally, c-FLIP suppression and 
TRAIL treatment could be a promising therapeutic treatment at eliminating bCSCs in patients with 
metastatic disease. We hypothesise that a partial EMT confers resistance to TRAIL but a full EMT state 
is associated with resistance to TRAIL.  
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1. General Introduction 
Breast cancer is the most commonly diagnosed cancer in women around the world. It is also 
the main cause of death from cancer among women. In 2012, almost 1.7 million new cases of breast 
cancer were diagnosed (second most frequent cancer overall) representing roughly 12% of all new 
cancer cases and 25% of all cancers in women (Breast Cancer Statistics Worldwide, 2012; Jemal et al., 
2011). In the UK during 2014, there were 11,433 female and 75 male deaths from invasive breast 
cancer (Cancer research UK, 2017).  
Normal development and cancer progression have obvious parallels, evident even at the 
molecular level. In order to accomplish normal human development, complex signalling pathways 
have developed to allows cells to communicate with each other and their surrounding environment. 
Unsurprisingly, many of the same signalling pathways are (mis)used by tumours and cancer stem cells 
(Malhotra et al., 2011).  
1.1. Mammary gland 
The mammary gland derives from the apocrine glands and is a glandular organ that, during 
the lifetime of a female, undergoes many changes in function and structure. These changes include 
hormonal changes influenced by the menstrual cycle and the changes during pregnancy, lactation and 
involution of a functional mammary gland. During these different phases, the cells within the 
mammary gland proliferate, differentiate or apoptose in response to stimuli, due the reorganisation 
of the glandular tissue (Inman et al., 2015).   
1.1.1. Mammary Gland Development 
 The human breast consists of parenchymal and stromal cells such as: epithelial, adipose, 
fibroblasts, immune, lymphatic and vascular cells which, are important at specific phases of the 
mammary gland development. The parenchyma forms a structure of branching ducts responsible for 
the secretory ductules or acini (branching morphogenesis) development, whilst the stroma consists 
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mainly of adipose tissue that provides the environment for the development of the parenchyma 
(Inman et al., 2015). The primary ducts that reach the nipple form a complex of segmental and sub-
segmental ducts. These sub-segmental ducts lead to terminal duct formation, which further 
subdivides to form several terminal acini. A collection of acini arising from one terminal duct along 
with the surrounding introlobular stroma is named alveoli (secretory cells) (Javed and Lteif, 2013; 
Imnan, 2015). The mammary gland is then formed by a final arboreal, bi-layered ductal structure that 
is composed of an outer contractile myoepithelial cells layer and an inner apically oriented luminal 
epithelial cells layer that can be divided further into ductal luminal cells, coating the inside of the ducts, 
and alveolar luminal cells, which secrete milk during lactation (Javed and Lteif, 2013). Therefore, the 
cap cells (multipotent stem cells) at the tip of the terminal end buds (TEBs) generate transit cells of a 
myoepithelial/basal lineage on the outer side of the TEB and generate transit cells (body cells) of a 
luminal epithelial lineage to form the central TEB mass. The ductal lumen is formed as central body 
cells apoptose and outer cells differentiate into luminal epithelial cells (Figure 1.1). 
 The mammary epithelium that forms the nipple remains inactive until puberty. Hormones 
and other factors trigger the invasion of the ductal epithelium and acini development into the 
mammary fat pad. Enzymes of the extracellular-matrix degrade the stroma in front of the TEB to 
enable it to move through the fat pad, however this movement is not fully understood. This movement 
could potentially be explained by progressive cell division build up, causing cell bulk in front of the 
mass of body cells. Combining this with progressive apoptosis degrading cell bulk at the back of the 
mass of body cells, can create the impression of movement (Smalley and Ashworth, 2003).  
The invading front of the TEB high proliferative epithelial cells and exhibit some features of 
mesenchymal cells, suggesting that some degree of epithelial-to-mesenchymal transition (EMT) 
occurs at the TEB. However, unlike tumour cells, EMT genes involved during branching morphogenesis 
are highly regulated. When the fat pad is filled, this process stops when endogenous cytokine 
transforming growth factor – beta (TGF-β) is activated. This cytokine is responsible for cell growth, 
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proliferation and differentiation (Inman., 2015; Kalluri and Weinberg, 2009). Ductal elongation and 
complex branching originated at the site of the TEB, specifically at the site of the mammary stem cells 
in the cap cell layer.  
During puberty, there is no further breast development in males due to increasing levels of 
testosterone. However, 40% of these males may develop transient gynecomastia that is a transient 
enlargement of glandular and adipose tissue caused by a higher proportion of estrogen (Javed and 
Lfeit., 2013; Vandeven and Pensler, 2017). Other hormones implicated in prenatal and pubertal breast 
development are: placental hormones progesterone, growth hormone, insulin-like growth factors, 
prolactin, adrenal corticoids, and triiodothyronine (Javed and Lteif, 2013). 
 
 
Figure 1.1. Mammary gland development. A. Hormones involved in mammary gland development 
and formation and elongation of the terminal end bud (TEB) (adapted from Brisken and Ataca, 2015). 
| B. Cells composing the mammary gland (adapted from Sternlicht, 2006). 
A 
B 
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1.1.2. Progenitor and Mammary Stem Cells 
The ground-breaking work of DeOme’s laboratory (DeOme et al., 1959) showed that small 
fragments or hyperplastic mouse mammary epithelium are able to generate similar patterns when 
transplanted into de-epitheliased mammary fat pads. Additionally, these patterns were able to 
produce similar secondary patterns when re-transplanted, confirming the existence of cells within the 
mammary epithelium, which have: (i) the ability to self-renew; (ii) multipotency and (iii) perform cell-
autonomous actions which are all the features of stem cells (Reya et al., 2001). In the normal tissue, 
cell turnover is a characteristic of tissue maintenance. Stem cells give rise to transit-amplifying cells 
that are differentiating to produce mature cells that are incapable of further division (Valent et al., 
2012). Stem cells are present in many different somatic tissues and are important participants in their 
normal physiology.  It is crucial to understand whether the origin is in the progenitor cells (with lineage 
restriction that form the mammary gland) or in a mammary stem cell (MaSC) that is able to give rise 
to an entire mammary epithelium. Studies using the mouse mammary tumour virus (MMTV) allowed 
the investigation of the clonal origins of the mammary gland and demonstrated that the entire 
mammary epithelium is derived from a multipotent and self-renewing stem cell (Kordon and Smith, 
1998). In the adult mammary gland, the stem cell compartment is heterogeneous and is composed by 
both multipotent, long-term and short-term repopulating cells. These cells produce committed 
progenitor cells for the myoepithelial and luminal (ductal and alveolar) epithelial lineages. Luminal 
progenitors only produce ductal or alveolar cells. These ductal progenitors possibly comprise both 
hormone receptor (HR)-positive and HR-negative cells, while the early and late alveolar-restricted 
progenitors are likely to be HR-negative. Moreover, there may be a common luminal progenitor for 
these sub-lineages (Figure 1.2). Isolation of cellular populations from mouse and human mammary 
tissue corroborated hierarchical organisation. It is worth to mentioning two types of unipotent MaSCs 
(lum-SC and myo-SC) may exist (reviewed in Visvader and Stingl, 2014). 
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Isolation of MaSCs and progenitor cells, using antibodies and fluorescence activated cell 
sorting (FACS) allowed the discovery that both luminal epithelial (epithelial membrane antigen 
[EMA/25.5/MUC1] positive-population) and myoepithelial (common lymphoblastic leukemia antigen 
[CALLA/NEP/gp100]) populations are enriched with heterogeneous cellular identities (Mahendran et 
al., 1989; Dundas, et al. 1991).  As previously mentioned neither MaSCs nor progenitors express 
receptors for hormones, and HR-positive cells generally do not proliferate. Thus, hormones provoke 
morphological changes by acting on a complex regulatory network of paracrine signals and 
transcription factors to modulate the activity of MaSCs.  Study of human breast development is crucial 
to understand breast cancer progression and diagnosis, in particular acquired disorders that often 
have a basis in normal development (Smalley and Ashworth, 2003). 
 
 
Figure 1.2. Hypothetical model of the mammary epithelial hierarchy. Stem cell compartment is 
composed by multipotent long-term (LT-RCs) and short-term repopulating cells (ST-RCs). These 
produces committed progenitor cells for the myoepithelial and luminal (ductal and alveolar) epithelial 
lineages. Luminal progenitors only produce ductal or alveolar cells (Visvader and Stingl, 2014). 
 
 
1.1.3. Progression into Breast Cancer  
Studies have reported evidence showing additional signalling pathways and transcription 
factors which regulate specific aspects of the mammary cellular specification. Lineage specification 
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and homeostasis of mammary stem and progenitor cells is maintained by interactions among; steroid 
hormone-signalling pathways; lineage-specific transcription factors and signals derived from the 
surrounding microenvironment. Stem cells are thought to be the cell of cancer origin, due to their self-
renewing, long-lived and hence are likely to accumulate mutations during their lifetime (Smalley and 
Ashworth, 2003; Magee et al., 2012). It is hypothesised that tumours could arise from committed 
progenitor cells, with multipotent capacity to produce heterogeneity within the tumour. Stem cells 
may be the first cells to acquire the first genetic aberration and give rise to giving a predisposition to 
further mutations and triggering the disease (Dontu et al., 2003). Within the tumour, there are 
hormone-responsive and hormone-non-responsive cells, where expression of estrogen and 
progesterone is variable within each intrinsic molecular subtype. Whether tumours arise from 
transformed MaSCs (that acquire heterogeneity through clonal evolution) or can arise from 
committed progenitors or transit-amplifying cells, is still unknown. It is likely both mechanisms coexist 
with different propositions in each breast cancer subtype (Smalley and Ashworth, 2003).  
In more detail, cancer models propose that cancer stem cells (CSCs) arise from normal stem 
cells during cancer initiation. Mutations and/or epigenetic changes will induce alterations that 
deregulate cell production and then give rise to clonal expansion producing a malignant clone. These 
cells have acquired several aberrations and lack of normal differentiation features (Figure 1.3 A) 
(Valent et al., 2012). Other models propose that CSCs derive from an initially mutated or epigenetically 
altered progenitor cell thereby acquiring a proliferative advantage over the normal cells which is 
enough to create a persistent cancer clone. This mutated clone gives rise to several sub-clones that 
are controlled by the natural immune system and/or the environment of the surrounding tissue/organ 
and hence these do not produce an apparent malignancy. In a pre-malignant stage, cancer stem cells 
are pre-malignant stem cells. However, if one or more sub-clones acquires certain mutations and or/ 
epigenetic changes (indicated by colour changes), they produce a cancer phenotype. At that time, in 
a malignant stage, the cancer stem cells become cancer-initiating cells and can thus be called cancer 
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CSCs (indicated by black outlines) (Figure 3).  However, the other cancer subclones and their stem cells 
stay and produce “pre-malignant” and/or malignant subclones. The term pre-malignant cancer stem 
cells are thus best confined to cells shown or experimentally shown to be indicators of malignant stem 
cells, whereas those that may never transform further are more accurately defined as pre-malignant 
(Figure 1.3 B) (reviewed in Visvader and Stingl, 2014). 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 1.3. Models of cancer stem cell evolution | A. Theory that cancer stem cells derive from normal 
stem cells. | B.  Theory that cancer stem cells derive from stem or progenitor cells (Valent et al., 2012). 
 
 
1.2. Breast Cancer 
Breast cancer is a highly heterogeneous disease. This heterogeneity can be defined as either 
inter-tumour heterogeneity, which relates to the different breast cancer clinical entities, or as intra 
tumour heterogeneity, which relates to the heterogeneous cellular composition of individual tumours 
(Smalley et al., 2012).  Biological information (including morphological features, protein and gene 
expression), genetic information and the molecular techniques have both changed our understanding 
of the basic biology of breast cancer, and provided the platform for new methods of personalised 
prognostic and predictive testing. While traditional staging on the basis of tumour size and lymph node 
status remains the initial indicator, it has become clear that not all breast cancers presenting at the 
same stage have the same underlying biology or clinical behaviour. The knowledge of new biological 
markers has catapulted the development of many successful anti-cancer treatments. In fact, there are 
B 
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some successful examples in breast cancer. However, there is still a need to develop more effective 
treatments to improve patient survival rate. This goal can only be achieved by gaining a greater 
understanding of the biology of the disease, in order to drive the development of more effective and 
more specific targeted therapies. 
1.2.1. Aetiology of Breast Cancer 
Most established risk factors for breast cancer in humans are thought to induce risk through 
hormone-related pathways. Epidemiological and experimental evidence implicates estrogens in the 
aetiology of this disease (Pike et al., 1993). 
Estrogens mediate the relationship between breast cancer and many established risk factors 
through prolonged exposure to endogenous estrogen and progesterone, such as; early menarche and 
late menopause, exogenous estrogen and progesterone (the oral contraceptive pill) and hormone 
replacement therapy (Garcia-Closas et al., 2006, Collaborative Group on Hormonal Factors in Breast 
Cancer [CGHFBC], 1997; Beral, 2003).  
Additionally, estrogen replacement has been shown effective to treat vasomotor symptoms 
of menopause, with good improvements in symptom frequency and severity within weeks after 
starting with the hormone replacement therapy (HRT). However, HRT in postmenopausal women is 
clearly connected with an increased risk of breast cancer, which is higher for combined 
estrogen/progesterone therapy than for unopposed estrogen therapy alone (Shah and Wong, 2009). 
Furthermore, risk for breast cancer increases with age, being higher in the postmenopausal 
women (Key et al., 2002). Epidemiological studies have also firmly established associations with other 
reproductive factors, including nulliparity or low parity, late age at first birth, and breast feeding (Key 
et al., 2001). It has been proposed that there is a greater reduction in risk when giving birth at a young 
age compared giving births at an older age, meaning women who have their first before the age of 20 
years have a 30% lower risk than women whose first birth is after the age of 35 years (Choudhury et 
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al., 2013). The very high serum levels of estrogens and progesterone during pregnancy stimulate 
growth of the mammary epithelium, promoting its differentiation and reducing the number of 
epithelial structures that are most vulnerable to malignant transformation (Russo et al., 1979). Breast-
feeding is also associated with a modest decrease in risk for breast cancer, above and beyond that 
which is associated with multiple pregnancies. This effect might be due to the suppression of 
ovulation, reducing the exposure to ovarian hormones (CGHFBC, 2002). 
 Family history is also a known risk factor for developing breast cancer, although over 85% of 
patients with breast cancer have no family history of this disease (CGHFBC, 2001). Roughly 10%–30% 
of breast cancer cases are associated to hereditary factors. However, only 5%–10% of breast cancer 
cases are identified with a strong inherited component, while just a small fraction of these cases (4%-
5%) is explained by mutations in high dominant genes that are transmitted in an autosomal dominant 
manner. Lifetime risks of breast cancer are 80% higher among women carrying BRCA1 (breast cancer 
subtype 1, early onset) mutations, which are characterised by elevated cancer risk at younger ages. 
Female BRCA2 (breast cancer subtype 2, susceptibility protein) mutation carriers also face a lifetime 
risk around 26%–84% for breast cancer. The Checkpoint kinase 2 (CHEK2) gene is associated with 
increased risks of breast cancer. Another gene frequently mutated is ATM, it’s mutation heterozygotes 
are twice as likely to contract breast cancer risk compared to the general population. This risk is 
elevated by five times in women under the age of 50 (Apostolou et al., 2013).  
The histologic architecture of the benign breast lesions is strongly associated with the risk of 
breast cancer. Biopsies with nonproliferative features have a lower risk of breast cancer compared to 
histological features of biopsies with proliferative changes but no atypia or atpypcal hyperplasia. 
Histologic features, the age at biopsy, and the degree of family history are highly related with the risk 
of breast cancer after the diagnosis of benign breast disease. Women with nonproliferative lesions 
have no increased preposition to breast cancer. However, this risk increases if they present a strong 
family history.  The high risk of cancer in the ipsilateral breast in the first 10 years after the diagnosis 
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of the benign breast condition (especially in women with atypia) corroborates the presence of 
precursors in some women (Hartmann et al., 2005). 
A high amount of adipose tissue within the mammary gland is linked to a higher cancer 
progression due to the increased expression of the Hypoxia-Induced Factor-1α (HIF-1α). HIF-1 and HIF-
2) are responsible for the adaptation to decreased oxigen availability in breast cancer tumours. HIF-
1α leads to a loss of ER α protein and the high activation of HIF’s seems to increase metastasis and 
worsen the prognosis of patient survival due to an increase in tumour angiogenesis (Rausch et al., 
2017).  
Furthermore, benign ovarian cysts (including mainly seromucinous, functional cysts, and 
endometriomas) can affect women during their reproductive age. These conditions have been linked 
to infertility and irregular and anovulatory menstrual cycles. Therefore, ovarian cysts reflect hormonal 
abnormalities, particularly impaired levels of female steroid hormones, which may also influence 
breast cancer risk. Additionally, it is known that bilateral oophorectomy reduces breast cancer risk 
(Swerdlow  and Jones, 2007).  
More recent studies have attributed various lifestyle-related factors to an increased risk for 
breast cancer, such as moderate alcohol consumption and obesity (Baan et al., 2007; Parkin et al., 
2011). This association is probably due to the relationship between body mass index and endogenous 
estrogen concentrations, since, in postmenopausal women, circulating estrogen concentrations are 
dependent on the extraglandular production of estrogen in the adipose tissue. Physical activity has 
also been correlated with a reduced risk for breast cancer in both premenopausal and 
postmenopausal women (Baan et al., 2007; Parkin et al., 2011; Vainio & Bianchini, 2002). 
1.2.2. Breast Cancer Molecular Subtypes 
Morphologically and biologically, breast cancer is a heterogeneous disease that comprises a 
number of molecular subtypes (Simpson et al., 2005). This inter-heterogeneity can be hypothesised 
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using three models: (1) “mutation-of-origin” model; (2) “cell-of-origin model and (3) both models 
combined. The first model suggest that all tumour subtypes arise from a common precursor cell, a 
bipotent MaCSC (Figure 1.3).  This MaCSC had specific genetic/epigenetic alterations acquired during 
tumourigenesis that affects cell capacity to commit to a luminal or basal lineage. In this model, 
common and recurrent mutations would be expected in each subtype. In fact, gene sequencing has 
shown basal and luminal tumours show specific and generally non-overlapping mutations (Koboldt et 
al., 2012).  The second model proposes that cell differentiation is firmly encoded during 
tumourigenesis. Therefore, luminal progenitors would give rise to luminal-type tumours and 
basal/myoepithelial progenitor cells would give rise to basal-like tumours. Studies corroborate with 
this demonstrating that luminal-like tumours show characteristics of normal luminal epithelial cells 
(cytokeratins 8, 18, 19 ,7; MUC1; EPCAM; CD24 and ERα) and basal tumours shows characteristics or 
normal basal progenitors (cytokeratins 5,6, and 17; CD44, CD49f; laminin and p63). Furthermore, this 
model is supported by in vitro experiments where transforming different cell lines with the same panel 
of oncogenes develop tumours with different features and phenotypes that are reminiscent of the 
cell-of-origin (Visvader, 2009; Perou et al., 2010). Taking this, a third model mixing both theories has 
been proposed. It is likely that both models coexist with different propositions in each breast cancer 
subtype. (Smalley and Ashworth, 2003; Gross et al., 2016)  
Actually, numerous gene expression clusters representing genes associated with these 
different breast cancer subtypes have been described. With the support of hierarchical clustering 
analyses, five classical distinct molecular subgroups of invasive breast cancer based on these genetic 
signatures were reported: normal breast-like; basal-like, luminal A, luminal B, human epidermal 
growth factor receptor 2 (HER2) and normal breast-like (Sørlie et al., 2001).  
Normal breast-like subtype tumours are poorly characterised and have been grouped into the 
classification of intrinsic subtypes with fibroadenomas and normal breast samples. These tumours 
express gene characteristics of adipose tissue presenting an intermediate prognosis between luminal 
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and basal-like cancers and usually do not respond to neoadjuvant chemotherapy. Despite these 
tumours not expressing ER, PR and HER2 they are not included in the triple-negative subtype because 
they are negative for CK5 and EGFR. The normal breast-like remains inexact, since it is believed that 
they could be a technical artifact from high contamination with normal tissue during the microarrays 
(Weigelt et al., 2010).  
 Estrogen is the most important and dominant biomarker for breast cancer classification. ER 
positive tumours comprise up to 75% of all breast cancer patients, and constitute 65% and 80%, , 
patients under and above 50 years, respectively (Anderson et al., 2002). Luminal A is the most 
prevalent subtype and is characterised by the expression of estrogen receptor (ER) and progesterone 
receptor (PgR) in cancer cells, whereas the luminal B subtype is characterized by lower levels of ER 
and PgR expression and can have HER2 overexpression. Progesterone is an ovarian steroid hormone 
that is important for normal breast development during puberty but also for lactation and 
breastfeeding. Progesterone functions are mainly mediated by classical PgR-A and -B isoforms 
expressed in the breast and reproductive organs but also in the brain where progesterone controls 
reproductive behavior progesterone/PgR isoforms are responsible for the development of the TEBs or 
acini located at the ends of ducts that will become the milk-producing structures in the lactating 
mammary gland. Interestingly, PgR isoform expression can not be induced in response to estrogen 
unless EGF is present, suggesting the existence of important cross talk between EGFR and/or HER2 
family members and both hormone receptors (Daniel et al., 2011).  
 The major biological distinction between luminal A and B is the proliferation signature, 
including genes such as CCNB1, MKI67, and MYBL2, which have higher expression in luminal B 
tumours than in luminal A tumours. MKI67 encodes the nuclear marker of proliferation Ki67 which is 
heavily used to distinguish between luminal A and B. Ki67 is associated with worse prognosis for breast 
cancer patients (Cheang et al., 2009).  
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 The association of HER2 in breast cancer was first discovered in 1987 (Slamon et al., 1987). 
The HER family proteins are type I transmembrane growth factor receptors that function to activate 
intracellular signalling pathways in response to extracellular signals. HER2 is formed by an extracellular 
ligand binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain 
(reviewed in Moasser, 2007). The growth stimuli including ligands bind to EGFR an HER2 activating a 
cascade of intracellular signals mainly via the PI3K/Akt/mTOR and the MAPK/ERK pathways. The mTOR 
phosphorylates downstream kinases including the S6 kinase, which phosphorylates and activates ER, 
which can regulate the transcription of many genes including GFR ligands, cyclin, VEGF and PARP 
(Metha and Tripathy, 2014). Overall, HER2 is absent or expressed at low-levels in benign breast 
conditions. However, HER2 is amplified and over-expressed in high-grade ductal carcinoma in 
situ (DCIS), particularly of the comedo type, and in high-grade inflammatory breast cancer. In 
addition, HER2 expression is kept during progression to invasive cancer, nodal metastasis and distant 
metastasis. HER2 amplification/over-expression and aneuploidy are considered downstream 
mechanisms of p53 dysfunction. Therefore, HER2 overexpressing cells have significantly prolonged 
activation of downstream MAPK and c-jun following stimulation with EGFR or HER3 ligands compared 
with low HER2 cells (reviewed in Moasser, 2007). Furthermore, HER2 is also involved in metastasis 
through the cross-talk between HER2 and CXCR4 signalling pathways. CXCR4 contributes to 
invasiveness through increasing migration and adhesion activity (Freudenberg et al., 2009). Moreover, 
several studies correlate HER2 gene amplification or protein over-expression with poor prognosis and 
positive clinical results receiving systemic chemotherapy treatment (Dai et al., 2009). These 
amplification/over-expression events occur in 13% to 20% of invasive ductal breast cancer and around 
55% of this subtype is ER negative (ER -ve) and PgR negative (PgR -ve). HER2 tumours are negative for 
HR and overexpress HER2 protein, which is highly associated with gene HER2/neu amplification.  
 Basal-like tumours are mainly characterised by the absence of ER, PgR and HER2 expression 
(triple negative tumours), and constitutes a heterogeneous group of tumours expressing distinct basal 
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markers. Within the triple-negative subtype a novel subgroup has been described, which was 
designated claudin-low and is characterised by comparatively high expression of mesenchymal 
markers, such as vimentin, and low expression of epithelial markers, notably claudins and E-cadherin 
(Sørlie et al., 2003; Herschkowitz, et al., 2007; Prat et al., 2010).  The interferon-rich subtype was 
recognised from triple negative tumours, which is characterised by the over-expression of interferon-
regulated genes (Teschendorff et al., 2007). Within these interferon-regulated genes, STAT1 and 
SP110 are the most important and help differentiate tumours of this subtype. STAT1 is the 
transcription factor mediating interferon-regulated gene expression and SP110 is associated with 
prognosis (Dai et al., 2016). Additionally, metaplastic breast cancers (MPBC) with a triple-negative 
profile and overexpression of programmed death (PD)-ligand 1 (PD-L1) are rare and very aggressive 
tumours comprising ~1% of all breast cancers. MPBC prognosis is worse than the other triple 
negative cancers due to a low response to systemic therapy, and a median survival of 8 months 
after growth of metastases (Weigelt et al., 2014). Recently, besides ER, PgR and HER2, androgen 
receptor (AR) has also been used in molecular classifications.  AR is expressed in 90% of the ER positive 
(ER +ve) and in 55% of the ER negative tumours (Hu et al., 2011).  AR was considered a potential 
prognostic marker and therapeutic target in breast cancer playing a similar role as HER2. Studies 
conducted by Lakis et al., (2014) have classified ER-ve/PgR-ve tumours into ER -ve/ PgR -ve/ AR +ve 
(molecular apocrine, called MAC) and HR-ve tumours. MAC accounts for 13.2% of all the breast cancer 
cases and is commonly characterised by Ki67 expression.  
 These different subtypes result in different clinical outcomes and can respond differently to 
the same treatment; triple negative tumours have the worst prognosis, with luminal A tumours having 
the best (Simpson et al., 2005; Sørlie et al., 2006) (Table 1.1). 
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Table 1.1. Molecular and histological types of breast cancer (reviewed in Day et al., 2016). 
Molecular 
Subtype 
Biomarker status Grade Outcome Common histological type % 
Luminal A ER+; PgR+; HER2-; Ki67- 1/2 Good 
IDC; Lobular; Tubular; Mucinous; 
Neuroendocrine; Cribiform 
23.7% 
Luminal B 
ER+; PgR+; HER2-; Ki67+ 
ER+; PgR+; HER2+; Ki67+ 
2/3 
Intermediate 
Poor 
IDC; Micropapillary 
38.8% 
14% 
HER2 
overexpression 
ER-; PgR-; HER2+ 2/3 Poor 
IDC; Apocrine; Micropapillary; 
Pleomorphic lobular 
11.2% 
TNBC - Basal 
ER-; PgR-; HER2-; basal 
marker+ 
3 Poor 
IDC; Medullary; Metaplastic; 
Adenoid cystic; Secretory 
10-25% 
TNBC - Claudin-
low 
ER-; PgR-; HER2-; EMT 
marker+; stem cell marker+; 
claudin- 
3 Poor IDC; Medullary; Metapladtic 7-14% 
TNBC – 
Metaplastic 
breast cancer 
ER-; PgR-; HER2-; EMT 
marker+; stem cell marker+; 
PD-L1 
3 Poor  1% 
TNBC – 
Interferon-rich 
ER-; PgR-; HER2-; interferon 
regulated genes+ 
3 Intermediate IDC; Medullary; Metaplatic ~10% 
 
1.2.3. Breast Cancer Histological Subtypes 
Breast cancers can be categorised into biologically and clinically subgroups according to 
histological grade (Elston and Ellis, 1991) and histological type (Ellis et al., 1992). Grade is an evaluation 
of the degree of differentiation (tubule formation and nuclear pleomorphism) and proliferative 
activity (mitotic changes) of a tumour. Grade is therefore related to tumour aggressiveness and 
identifies prognostic subgroups (Elston and Ellis, 1991, Mallotra et al., 2010). Tumours present a wide 
histological diversity with specific morphological and cytological patterns that can be associated with 
individual clinical characteristics and outcomes, such patterns are called ‘histological types’. Breast 
cancer can be broadly categorised into in situ carcinoma and invasive (infiltrating) carcinoma 
(Malhotra et al., 2010). Carcinoma in situ is further sub-classified into ductal carcinoma in situ (DCIS) 
or lobular carcinoma in situ (LCIS). DCIS was primarily sub-classified based on the architectural features 
of the tumour into: comedo, cribiform, micropapillary, papillary and solid white. The main invasive 
tumour types include invasive ductal, invasive lobular, ductal/lobular, mucinous (colloid), tubular, 
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medullary and papillary carcinomas. Of these, invasive ductal carcinoma is the most frequent subtype 
accounting for 70–80% of all invasive lesions. Invasive ductal carcinomas are further sub-classified as 
well-differentiated (grade 1), moderately differentiated (grade 2) or poorly differentiated (grade 3) 
(Ellis et al., 2003). Moreover, a recent histological classification has been created with a new subgroup 
of breast cancer special types. These special types represent around 25% of all breast cancers and the 
latest edition of the World Health Organisation classification recognises the existence of at least 17 
distinct histological special types (Ellis et al., 2003.) Within these histological special types of breast 
cancer, some are preferentially estrogen receptor positive: tubular carcinoma, cribriform carcinoma, 
classic invasive lobular carcinoma, pleomorphic invasive lobular carcinoma, mucinous carcinoma, 
neuroendocrine carcinoma, micropapillary carcinoma, papillary carcinoma and low grade invasive 
ductal carcinoma with osteoclast-like giant cells. In addition, the other histological special types of 
breast cancer preferentially estrogen receptor negative: adenoid cystic carcinoma, secretory 
carcinoma, acinic-cell carcinoma, apocrine carcinoma, medullary carcinoma, metaplastic carcinoma 
with heterogenous elements, metaplastic carcinoma with squamous metaplasia, metaplastic spindle 
cell carcinoma, metaplastic matrix-producing carcinoma (Weigelt et al., 2010). 
 
1.3. Estrogens, Estrogen Receptor and Endocrine Therapies in Breast Cancer 
1.3.1. Estrogens and Estrogen Receptor 
The hormone estrogen works as a chemical messenger in the body. It is essential for normal 
sexual development and function of female organs (ovaries, uterus, breasts) that are important for 
childbearing (Yager and Davidson, 2006). The three maim estrogens in women are estrone, estradiol 
and estriol.  The release of estrogen from the ovaries causes a systemic effect that is mediated by the 
ER (Tsai and O'Malley, 1994). ER is a ligand-dependent nuclear transcription factor, which regulates 
downstream gene expression and transcription when activated by ligand binding (Bocchinfuso & 
Korach, 1997). 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
19 
 
Since Jensen et al., described the ER, in 1960, two different isoforms have been found, ER 
alpha (ERα) and beta (ERβ) cloned in 1986 (Green et al., 1986) and 1996 (Kuiper et al., 1996), 
respectively. Although ERα and ERβ are encoded by two different genes, ESR1 and ESR2 (DeLisle et al., 
2001), and the codified proteins have different sizes (595 and 530 amino acids), these have high overall 
sequence homology in the ligand binding domain (59%) and in the DNA binding domain (97%) (Kuiper 
et al., 1996). The ERα and ERβ genes encode 66 kDa and 59 kDa proteins, respectively (Kumar et al., 
1987; Kumar et al., 1986). ERα is expressed exclusively in the cells of the luminal breast epithelium 
(15-30 %), which invariably also express PgR (Clarke et al., 1997; Petersen et al., 1987). On the other 
hand, ERβ is expressed in both luminal and myoepithelial mammary cells as well as in fibroblasts and 
other stromal cells (Speirs et al., 2002). In fact, the two receptors have similar, but distinct tissue 
distribution patterns (Lu et al., 1998). ERα is expressed in brain, bone, cardiovascular system, uterus, 
liver and breast cells. Tissues with predominant expression of ERβ are apparent in the lower urogenital 
tract, the gastrointestinal tract and some brain areas (Gustafsson, 1999). 
The biological effects of estrogen are primarily mediated by these both estrogen receptors. In 
estrogen signalling, the binding of estrogen to the ER causes receptor dimerisation and binding to 
estrogen responsive elements (EREs) in the promoter and/or enhancer regions of estrogen-responsive 
genes. Estrogen binding alters the three-dimensional structure of ER to facilitate the recruitment of 
coactivator complexes, thereby activating the transcription of genes that induce estrogen production 
(Ao et al., 2011; Kocanova et al., 2010). Potentially, the proliferation of HR negative cells, which cannot 
respond directly to hormonal signals, is “mediated by a paracrine signal released from HR positive cells 
to which they are often adjacent” (Brisken et al., 1998). Mice with targeted removal of one or both ER 
genes have determined that ERα is the key regulator of mammary gland development.  It has been 
reported that an ERα homozygous knockout (-/-) mouse model showed no development of the 
mammary gland beyond the formation of the rudimentary ductal tree formed during embryogenesis. 
However, when the ERα -/- cells were mixed with wild type steroid receptor positive cells, before being 
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engrafted into the cleared fat pad of a recipient mouse, they were able to proliferate and contribute 
to the normal mammary development (Mallepell et al., 2006). These conclusions support the theory 
that a paracrine signal is released from the non-dividing HR positive cells, in response to hormonal 
signalling, causing proliferation of the HR negative cells. 
1.3.2. Estrogens, Estrogen Receptor and Breast Cancer 
Estrogens play a crucial role in the development of the mammary gland and are central to the 
aetiology of breast cancer (McDonnell & Norris, 2002). This hormone can act as a “mitogen” by 
stimulating breast tissue proliferation and increasing cell divisions (mitosis) this can result in cancer 
due to DNA errors acquired during replication (gene mutation). Moreover, certain estrogen 
metabolites can act as carcinogens or genotoxins, by directly inducing DNA damage, facilitating cancer 
cells to form (Yager and Davidson, 2006). The resultant transcriptional changes induced by estrogen 
promote: cell proliferation, survival, angiogenesis, and tumour metastasis (Ao et al., 2011; Kocanova 
et al., 2010).  
ERα is a key transcriptional regulator in breast cancer and is responsible for many effects of 
estrogen on cancerous breast tissue. Mutations within the ER gene are observed in roughly 1% of 
primary breast tumours yet it is unclear how these contribute to the regulation of ER expression 
(Fuqua et al.,2000, Herynk and Fuqua, 2004; Roodi et al., 1995). The majority of breast cancers are 
ERα-positive (75%) and depend on estrogen for growth (Ao et al., 2011). 
In contrast to the increased ERα-positivity in the transition from normal to malignant tissue, 
ERβ expression was shown to be downregulated in tumours such as atypical ductal hyperplasia and 
DCIS (Roger et al., 2001). ERβ synthesis was also correlated with lower proliferation and grade. The 
ratio of ERα to ERβ synthesis increase with increasing proliferation and risk of breast cancer in 
premalignant lesions (Roger et al., 2001).  Thus, it has been suggested that ERβ might negatively 
regulate ERα signalling and may play a role in suppression of tumour progression (Kocanova et al., 
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2010). Importantly, patients whose tumours express ERα tend to have a better prognosis, that is 
longer periods without recurrence and overall survival rates, than those with tumours that lack ERα 
expression (Knight et al., 1980).  
1.3.3. Endocrine Therapy Resistance 
The fact that ERα expression (ER expression) is associated with tumour formation has led to 
the development of anti-hormone therapies that could suppress the estrogen signalling. Thus, ER 
positive breast tumours are treated with targeted anti-estrogen therapy, including selective estrogen 
receptor modulators (SERMs), such as tamoxifen and raloxifene (Herynk & Fuqua, 2007; Osborne et 
al., 2000), and selective estrogen receptor down-regulators (SERDs), such as fulvestrant (Faslodex, ICI 
182,780) (Osborne et al., 2004; Vesuna et al., 2012; Ao et al., 2011).  Furthermore, synthetic 
compounds that either act as estrogen-antagonists or block the function of aromatase (the enzyme 
that catalyses the last step of estrogen biosynthesis), have been also produced – aromatase inhibitors 
(Kocanova et al., 2010). 
However, ER positive breast tumours frequently become hormone resistant through various 
molecular mechanisms and patients usually relapse within five years after the diagnosis (Herynk & 
Fuqua, 2007). Endocrine resistance can compromise the effective treatment and the potential cure of 
up to 25% of all of breast cancers, therefore finding the mechanisms of endocrine resistance has been 
a major research focus (Sutherland, 2011) (Figure 1.4). A study revealed that 33% of the women 
treated with tamoxifen for 5 years have recurrence after 15 years and die from their breast cancer 
disease (Figure 1.4). This poor result after tamoxifen treatment shows that is imperative to improve 
anti-endocrine therapies in breast cancer patients (Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG), Lancet, 2011). 
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Figure 1.4. Breast cancer recurrence after treatment with tamoxifen (adapted from Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG), Lancet, 2011). 
 
 
Activation of classical signalling pathways, including the ones induced by HER2 and Epidermal 
Growth Factor Receptor (EGFR) (Herynk and Fuqua, 2007), MAPK (Oh et al., 2001), and PI3K/AKT 
(Campbell et al., 2001) have already been implicated in hormone resistance. Additionally, the absence 
or low expression of ER in breast cancer stem cells (bCSCs) might be relevant to understand endocrine 
resistance. These cells are likely to be endocrine resistant and respond to treatment only by virtue of 
paracrine influences of neighbouring, differentiated ER +ve tumour cells (O’Brien et al., 2009). 
Exposure of breast cancer cells to estrogen was shown to cause expansion of the bCSCs compartment, 
presumably in response to a paracrine signal released from the ER positive tumour cells to the ER -ve 
bCSCs. This was shown to occur through a combination of pathways including, but possibly not limited 
to, EGFR and Notch (Harrison et al., 2013). There is evidence for an ER -ve/low status of bCSCs in ER 
+ve cell lines and in patient derived samples. CSC amount and activity increases in response to 
estrogen stimulation and, as in the normal breast, this outcome is partly mediated by EGFR signalling 
pathway (Harrison et al., 2013). 
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 A better understanding of the molecular changes associated with the endocrine resistant 
growth is urgently needed in order to find targeted therapies for resistant tumour cells, or treatments 
that can inhibit or delay the emergence of resistance (Frogne et al., 2008).  
1.3.3.1. Tamoxifen 
Tamoxifen is a tripheyllenthylene and needs to be metabolised into 4-hydroxytamoxifen (4-
OHT) to bind to ER and hence block breast cancer cell growth, by stopping ER +ve cancer cells in cell 
cycle G1 (Kocanova et al., 2010). In 1977, tamoxifen was approved by the Food and Drug 
Administration (FDA) for breast cancer treatment and in 1985, as a therapy in conjunction with 
chemotherapy in postmenopausal women showing node-positive breast cancer. In 1998, tamoxifen 
administration in pre- and postmenopausal healthy women at high risk of developing the disease was 
also approved by the FDA (United States).  
It has been shown an effect of anti-estrogens on expression and/or intracellular distribution 
of factors that control cell cycle progression. However, the administration of tamoxifen in 
postmenopausal women has several side effects such as increased risk of both thromboembolic 
disease and endometrial cancer (Fisher et al., 1998). 
Tamoxifen competitively inhibits the binding of estrogen to its target ER resulting in a receptor 
conformational change blocking AF-2 function. This inhibits proliferation of ER +ve breast cancer cells, 
being effective in ~60% of ER +ve patients (Gee et al., 2005). De novo resistance to tamoxifen in ER 
+ve tumours has been described.  In vitro experiments have shown different genetic alterations that 
confer a constitutive activation of ER and a loss of response to tamoxifen, such as duplication of exons 
6 and 7 (Pink et al., 1997) and a tyrosine-to asparagine substitution at residue 537 (Y537N) (Zhang et 
al., 1997). ER mutations can affect hormone therapy response, but this is estimated to be present in 
only 1% of breast tumours (Roodi et al., 1995). Although downregulation of ERα expression can 
contribute to de novo anti-estrogen resistance, loss of the receptor during the acquisition of tamoxifen 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
24 
 
resistance is not commonly observed in clinical samples (Clarke et al., 2001). However, breast tumours 
that respond to hormones constantly develop resistance to tamoxifen, despite the continued 
expression of wild-type ER in most cases (Encarnacion et al., 1993). Various signalling networks that 
control cell proliferation or survival have been implicated in acquired resistance to tamoxifen. In vivo 
studies reported that during the development of tamoxifen resistance, tumours may become able to 
grow in a tamoxifen-stimulated manner (Gottardis and Jordan, 1988). Studies have demonstrated the 
capacity of tamoxifen to function as an agonist or antagonist dependent on whether it recruits co-
activators or co-repressors to the ERα transcription complex. One of these co-regulators is the AIB1 
protein and its over-expression is correlated with agonistic activity of tamoxifen, especially in the 
presence of HER2 (Osbourne et al., 2003). In addition to HER2 signalling, the growth factor receptor 
(IGFR1) and fibroblast growth factor receptor 1 (FGFR1) can activate MAPK and PI3K pathways, which 
are unresponsive to treatment in breast cancer (Zhang et al., 2011). Differences in ER concentration 
also leads to tamoxifen resistance. Hypermethylation of DNA sequences containing CpG islands and 
histone deacetylase activity in the ESR1 promoter are similar to genomic deletion of ER because these 
can inactivate gene expression, therefore associated with a lower expression of ER (Sharma et al., 
2005).  Resistance to tamoxifen may also be associated to a dysregulated metabolism of the drug. 
Cytochrome P450 enzymes, which converts tamoxifen into metabolites, which are associated with a 
worse clinical prognosis after tamoxifen treatment (Desta et al., 2004). 
 Agents targeting EGFR/HER2 pathways in tamoxifen-resistant breast cancers are in clinical 
trials. The acquisition of enhanced EGFR/HER2 pathway signalling in ER+ breast cancer with tamoxifen 
resistance potentially results from selection of cells with a more stem-like phenotype. Expression of 
EGFR has already been demonstrated in stem cells of the normal mammary gland in both mice and 
humans (Asselin-Labat et al., 2000). In tamoxifen resistant tumours that overexpress HER2, anti-
apoptotic molecules, such as Bcl-2 and Bcl-xL are upregulated (Kumar et al., 1996) and EGFR can 
promote cell survival by acting together with c-Src and Cas proteins (Riggins et al., 2006). Furthermore, 
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in tamoxifen resistant cells, the binding of tamoxifen to cytoplasmic ER can activate EGFR and HER2 
signalling pathways leading to ER and ER co-factors phosphorylation (Shou et al., 2004). 
Overexpression of constitutively active AKT in breast cancer cell lines can induce estrogen 
independence and resistance to tamoxifen (Campbell et al., 2001; Faridi et al., 2003). 
Despite this growing understanding of the molecular mechanisms underlying both de novo 
and acquired tamoxifen resistance, there is no approved targeted therapy to improve outcomes of 
tamoxifen- resistant breast cancers (Lee et al., 2012).  
1.3.3.2. Fulvestrant 
Since it is believed that the transcription of ER has an important role in acquired resistance 
process, second-line endocrine therapies, have been developed to alternatively inhibit ER (McDonnell, 
2006). One of these, the pure steroidal antiestrogen fulvestrant (Faslodex, ICI 182,780, Astra Zeneca 
Corp., London, UK), entirely represses ER activity, inactivating both ERα-mediated genomic and non-
genomic signalling. It was recently used in postmenopausal women who showed no improvement 
after antiestrogen therapy (tamoxifen or aromatase inhibitors). Fulvestrant binds to ER with a higher 
affinity, suppresses ER regulated genes more powerfully and is stronger than tamoxifen in inhibiting 
cell growth mediated by ER (Frogne et al., 2009). However, despite its potent anti-tumour effects, 
fulvestrant does not avoid the development of anti-endocrine resistance. Acquired resistance to 
fulvestrant is an ER-independent mechanism, associated with constitutive activation of autocrine-
regulated growth-stimulatory pathways, ultimately dissociating breast cancer cells from growth 
controlled by ER. However, the mechanism(s) of upregulation of these mitogenic pathways are not 
clear (Rao et al., 2011).  Experiments in MCF-7 cells demonstrated that the obstruction of cell growth 
with fulvestrant was correlated with a lower expression of ER protein resulting in decreased 
transcriptional activity, demonstrated by lower PgR mRNA and cyclin D1 protein expression levels.  
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These findings show fulvestrant as a powerful agent anti-ER activity (Hutcheson et al., 2011). 
It is crucial to study fulvestrant treatment and elucidade ER-ve state. Lack of ER expression is an 
important clinical feature in breast cancer, consisting of 30% of tumours on presentation and in some 
ER-ve tumours when relapse to tamoxifen occurs (Gee et al. 2005). In the clinic lack of ER expression 
is associated with poor prognosis, impeding response to all types of anti-hormones.  These ER -ve 
tumours are more aggressive and have a higher proliferative rate, featuring fulvestrant-resistant cells 
(Nicholson et al., 2004). 
1.3.3.3. Aromatase Inhibitors 
The aromatase inhibitors (AIs), suppress estrogen synthesis through the aromatase pathway, 
blocking the synthesis of estrogen from androgens in the peripheral tissues, such as adipose tissue 
and muscle (Miller, 2003). AIs decrease systemic estrogen levels and therefore avoid growth of 
estrogen-dependent ERα positive tumours. In MCF-7 human breast cancer cells, estradiol stimulates 
proliferation and growth through the induction of G1- to S-phase transition (Lewis-Wambi and Jordan, 
2009), protective cells against apoptosis (Song and Santen, 2003). Accordingly, estrogen deprivation 
inhibits cell proliferation and induces apoptosis in this breast cancer model (Kyprianou et al., 1991). 
The AIs, letrozole and anastrozole, inhibit proliferation of breast cancer cells by inducing cell cycle 
arrest in G0/G1 phase and cell death by apoptosis (Sasano et al., 1999; Thiantanawat et al., 2003; Itoh 
et al., 2005). 
Cross-talk between the PI3K, the most frequently mutated pathway in breast cancer, and ER 
has been reported to be involved in endocrine resistance to anti-estrogen therapies (Musgrove and 
Sutherland, 2009). Experimental and clinical studies suggest that hyperactivation of the PI3K pathway 
leads to resistance to anti-estrogen drugs. In breast cancer cells, PI3K is usually activated by growth 
factor receptor (tyrosine kinases) and G-protein-coupled receptors in the breast cancer cells. A 
requirement for PI3K overexpression in the estrogen-independent growth of long-term estrogen-
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deprived ER +ve breast cancer cells seems to mirror the clinical resistance to AIs (Sabnis et al., 2007; 
Crowder et al., 2009; Miller et al., 2010; Fox et al., 2012).  
Additionally, high-dose of fulvestrant provides a longer period to cancer progression 
compared to the AI anastrozole as first-line treatment for advanced breast cancer (Robertson et al., 
2009). In other studies, ~35% of patients who progressed on an AI responded to second-line 
fulvestrant treatment (Ingle et al., 2006; Perey et al., 2007). Therefore, in some clinical conditions, 
downregulation of ER could be higher to aromatase inhibitor therapy (Robertson et al., 2009). ER holds 
transcriptional activity in estrogen deprived cells and primary human breast tumours (following AI 
therapy), driving their estrogen-independent growth (Miller et al., 2011, Fox et al., 2012). Thus, it is 
reasonable to hypothesise that estrogen (ligand)-independent ER activity potentially promotes 
resistance to AI therapy. Having similar side effects, AI treatment increases the risk of bone fractures 
and joint disorders more so than fulvestrant (Howell et al., 2002; Howell and Sapunar, 2011). 
Some studies have recently shown that the use of AIs (letrozole) in breast cancer therapy can 
increase the proportion of cells with CSCs features. Protein and gene expression of markers of the 
mesenchymal phenotype are increased within tumours after chemotherapy and endocrine therapy 
(Creighton et al., 2009). Therefore, the future challenge will be to combine conventional therapies 
with therapies that target cells with CSC/mesenchymal features to overcome any intrinsic resistance 
to therapy. 
1.4. Breast Cancer Stem Cells 
In 1994, the first cancer stem cell (CSC), the leukaemia stem cell, was identified in samples 
from patients with acute myeloid leukaemia and it was proposed that blocked proliferation was 
responsible for CSC differentiation and tumour growth (Lapidot, 1994). As well as being able to 
differentiate, these cells manifested self-renewal capacity, since the disease could be transferred into 
recipient mice (Bonnet & Dick, 1997).  
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The concept of CSCs is consistent with observations made by scientists over many years that 
there exists a robust similarity between normal development and the development of cancer (Al-Hajj 
et al., 2003). In tumours, the CSC model proposes a cellular hierarchy in which CSCs are the only cells 
capable of unlimited cell divisions and, as a consequence of their ability to propagate differentiated 
progeny by asymmetric division, generate the full heterogeneity inherent within all tumours (Reya et 
al., 2001). These CSCs or ‘cancer-initiating cells’ divide slowly and asymmetrically, whereas the 
resulting progenitor cells divide rapidly, progressively lose proliferative potential and undergo limited 
differentiation to form the heterogeneous populations of cells within the tumours. The verification of 
the existence of CSCs remains controversial but experimental evidence has gained prominence in the 
past 10 years and has contributed much to our understanding of tumour biology and the clinical 
relevance of this tumour subpopulation. The first report of the presence of CSCs in a solid tumour was 
in breast cancer by Al-Hajj et al., (2003) where it was identified as a CD24/low/CD44þ population, with 
a higher capacity to initiate tumour growth when transplanted into immunocompromised mice. It has 
been reported other markers, such as aldehyde dehydrogenase 1 (ALDH1), CD133, Sox2, CK5, alpha-6 
integrin/CD49f, beta-1 integrin/CD29 or lack of ER. Cells exhibiting these phenotypes are also present 
in breast cancer cell lines and may mark cells with higher tumour initiation capability (Ginestier et al., 
2007; Fillmore and Kuperwasser, 2008; Wright et al., 2008; Charafe-Jauffret et al., 2009; Lawson et al., 
2009). Moreover, distinct mesenchymal-like bCSCs are characterised by the CD44high /CD24low 
phenotype, and the epithelial-like bCSCs are characterised by the ALDH1 +ve phenotype (Mani et al., 
2008). The mesenchymal-like bCSCs are primarily quiescent and frequently localised at the tumours 
invasive margins whereas the epithelial-like bCSCs are proliferative and positioned more centrally 
within the tumour (Mani et al., 2008). A study has shown that fractionating stem-like 
CD44high/CD24low cells by FACS from human mammary epithelial cells shows that the mesenchymal-
like bCSCs exhibit phenotypes similar to cells that have undergone an EMT (Mani et al., 2008).  
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Advances in cell culture techniques have been important in the identification and study of 
both murine MaCSCs and human bCSCs (Dontu et al., 2003). The in vitro study of MaSCs was 
developed from a methodology in the neuronal field in which a cell culture assay, known as the 
neurosphere assay, was used to identify neural stem cells (Dontu et al., 2003; Ponti et al., 2005). 
Plating normal human mammary epithelial cells in non-adherent, serum-free conditions with a specific 
set of growth factors resulted in the formation of spherical colonies termed mammospheres (Dontu 
et al., 2003). These culture conditions mimic those which cells must survive in vivo to metastasise and 
these mammosphere colonies were shown to be enriched for cells that have functional characteristics 
of stem/progenitor cells, such as multipotency and self-renewal and tumour initiation (Dontu et al., 
2004; Tao et al., 2011). Currently, the mammosphere-forming assay is routinely used to identify key 
features of stem cell behaviour and maintenance in vitro (Shaw et al., 2012). 
Investigation of known bCSCs markers demonstrated that individual markers are not always 
expressed in an individual cancer, or co-expressed in the same cells. Currently, it is not possible to 
identify specific CSC sub-populations in all cell lines (Liu et al., 2014). Some commonly used bCSCs 
markers correlate with certain clinical and biological characteristics. For example, CD44- +ve/CD24-ve 
breast cancer cells, which are enriched for stem cells, have a higher ability to form mammospheres 
and/or tumours when injected into immunocompromised mice than CD44-ve/CD24-ve cells (Farnie et 
al., 2007). Moreover, only a small percentage of primary tumours and two-thirds of breast cancer cell 
lines have any ALDH1+ cells, and a distinct sub-population is seen in only 25% of breast cancer cell 
lines (Christgen et al., 2007; Tan et al., 2013). A recent study summarised that none of the markers 
employed can be considered as a universal marker applicable to the identification of a CSC population 
in breast cancer cell lines or metastatic breast cancer (Liu et al., 2014). 
Low survival rates, therapeutic resistance and premature recurrence are associated with 
residual breast cancer stem cells at the time of surgery after chemotherapy. Second-line therapies are 
not able to improve prognosis of breast cancer patients and little research exists related to which 
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pathways should be targeted in patients with residual disease (Visvader et al., 2012; Mitra et al., 2015; 
Singh and Settleman, 2010). However, while invasive bCSCs are established drivers of metastasis and 
recurrence, targeting bCSCs may only be effective at eliminating pre-existing bCSCs, failing to prevent 
non-CSCs from acquiring CSC-like features in response to the tumour microenvironment and therapy 
(reviewed in Doherti et al., 2016). 
1.4.1. Breast Cancer Stem Cells and Therapy Resistance 
The role of bCSCs in therapy resistance has had minimal study but some evidence does exist 
that these cells have a decreased sensitivity to treatment therefore being therapy resistant (Reya et 
al., 2001). Therapy-resistant CSCs are able to survive after current therapies as they are able to 
regenerate recurrent disease through their tumour-initiation properties. In order to overcome 
therapy resistance, CSCs should be targeted in combination with standard treatments (Reya et al., 
2001). Importantly, using chemotherapy to eliminate CSCs drives quiescent CSCs into activity to 
stimulate tumour development (Moore and Lyle S., 2010). Furthermore, the quiescent CSCs may 
acquire several DNA repair mechanisms, which gives protection against treatment. Therefore, both 
active and quiescent CSC populations should be targeted but quiescent cells are problematic to 
identify, isolate and study.  Ffrench et al., proposed that an alternative for future treatments is a 
‘Proliferate to Kill’ strategy, which proposes to stimulate the quiescent CSCs, making them re-enter 
the cell cycle causing vulnerability to standard therapeutics (Ffrench et al., 2014). Overall, CSC therapy-
resistance mechanisms involve five components: Quiescence; Detoxification/Multi-Drug Resistance 
(MDR); Repair of damaged DNA; Survival and Adaptation (reviewed in Gasch et al., 2017).  
CSCs have MDR mechanisms that function to detoxify the cell in response to chemotherapy. 
MDR refers to the efflux mechanisms that allow chemotherapy drugs to be pumped out of the cell 
before DNA damage can occur (Shen et al., 2012). The most well-known MDR proteins are the 
members of the ‘ABC (ATP-Binding Cassette) transporter’ family, found in bacterial antibiotic 
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resistance (Michalet and Dijoux-Franca, 2009). ABC transporters have been described to be related 
with chemo-resistance of CSCs in several cancer subtypes, including ovarian, breast, colon, and non-
small cell lung cancers (Zhang et al., 2015; Sun et al., 2015; To et al., 2015; Hashida et al., 2015). 
Therefore, MDR is considered the second CSC therapy-resistance mechanism. To date, efforts to 
create clinical-targeting of MDR mechanisms have not been successful (Yu et al., 2013), as targeting 
specific ABC transporters results in activation of redundant ABC transports to continue the MDR 
mechanism (McGrogan et al., 2008).  
Another mechanism by which CSCs resist therapy is by detecting and repairing DNA damage, 
allowing them to survive by resistance to DNA damage, induced by cancer therapies. Chemotherapies 
using platinum consist by forcing the formation of intra- and inter-strand DNA crosslinks upon the 
rapidly-dividing cancer cell. These cross-links break chromatin structure, and a resultant stall of the 
replication fork and activation of several DNA damage response (DDR) pathways. In sensitive cells, 
multiple cross-link formations are more than cells can repair. As a result, unrepaired DNA lesions cause 
cell-cycle arrest through apoptosis, either directly, or following DNA replication during the S phase of 
the cell cycle (Jung and Lippard, 2007). Pathways that have been shown to be involved in platinum-
induced DNA damage include the Nuclear Excision Repair (recognition and excision of single-strand 
DNA damage) and the FA/BRCA pathway (repair of DNA crosslinks, UV-induced dimers, and double-
strand breaks). There are similar DDR mechanisms that cause resistance to DNA-damage induced by 
radiotherapy. In contrast, taxane-based chemotherapies (for example Paclitaxel and Docetaxel) target 
microtubule dynamics during mitosis. Cells cannot repair these targeted microtubules, which results 
in apoptosis through the G2/M checkpoint. Taxane-resistance is due to mutations in the tubulin sub-
units that contain microtubules rather than therapy-resistance mechanisms (McGrogan et al., 2008). 
 The accumulation of significant DNA damage drives the activation of apoptotic mechanisms, 
which must be targeted to kill therapy-resistant cells. Anti-apoptotic mechanisms aid therapy-
resistance; directly by inhibiting cell death, and indirectly by creating delays so enhanced DDR 
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mechanisms can repair therapy-induced DNA damage. These anti-apoptotic strategies comprise the 
extrinsic and intrinsic pathways, and the tumour suppressor protein p53. The extrinsic apoptotic 
pathway involves the detection of death signals by ‘Death Receptors’, which belong to the superfamily 
of tumour necrosis factor receptors (TNF-R) that are activated by TNF family ligands.  Cancer cells have 
developed several mechanisms to resist drug-induced cell death via the extrinsic pathway (discussed 
in Section 1.5) (Safa et al., 2008; Piggott et al., 2011; reviewed in Gasch et al., 2017) 
The intrinsic apoptotic pathway drives apoptosis by interfering with mitochondrial 
permeability, leading to the release of cytochrome C to activate caspases. This pathway is mainly 
regulated by members of the BCL-2 family (Fulda et al., 2013). This family includes the pro-survival 
protein BCL-2, which binds to the pro-apoptotic BCL2-associated-X-protein (BAX) and BCL-2 
homologous antagonist killer (BAK), which decreases release of cytochrome C from the mitochondria. 
BCL-2 family members are overexpressed in many solid tumours and have been linked to cancer 
development, cell survival and chemo-resistance (Kirkin et al., 2007). An experiment has shown that 
BCL-2 overexpression is also related to CSC chemoresistance. For example, Madjd et al. (2009) showed 
that CD44+/CD24-/low breast CSCs express very high levels of BCL-2. To date, this mechanism is 
uncertain but it is proposed that these proteins can affect chemo-resistance through induction, by 
other signalling pathways required for CSC survival. For example, Ma et al. (2008) demonstrated that 
BCL-2 induction by AKT1 may be a mechanism by which CSCs can mediate chemo-resistance. 
Moreover, Liu et al., (2014) performed repeated treatments on cell lines to enrich for a 
therapy-resistant sub-population (Phillips et al., 2006; Kabos et al., 2011). They found that the two cell 
lines investigated display distinctive changes in CSC marker expression according to the precise 
therapy. The only consistent finding across therapeutic agents was an expansion of ER -ve cells after 
exposure of the luminal cancer cell line, supporting previous findings that a lack of ER in individual 
cells within ER +ve breast cancer is a marker of a therapy-resistant population of CSCs (Kabos et al., 
2011) and could account for the recurrence of ER -ve phenotypes observed in clinical practice 
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(Thompson et al., 2010; Moussa et al., 2012). Additionally, it has been established that cells positive 
for the CSC marker ALDH isolated from lung cancer cells lines, demonstrated a high resistance to 
multiple chemotherapeutic agents (Cisplatin, Gemcitabine, Vinorelbine, Docetaxel, Doxorubicin and 
Daunorubicin) when compared to ALDH -ve cells (Jiang et al. 2009). This data indicates that tumours 
have some CSCs that are resistant, or sensitive to therapies. After first treatments, sensitive CSCs are 
eliminated, resulting in a recurrent tumour and ‘CSC hierarchy with increased levels of therapy-
resistant CSCs’. Also, surgical resection of the tumour may awake quiescent CSCs to synergistically 
increase the production of the therapy-resistant recurrent malignancy. This may clarify why initial pre-
clinical experiments are successful but such success have not largely translated to the clinic (reviewed 
in Gasch et al., 2017). It is therefore crucial to identify, study and target the specific CSCs that are 
responsible for specific types of resistance to treatments within specific cancers. 
SCs and CSCs function is regulated by several signalling pathways such as: Wnt, Notch, 
Hedgehog and the mTOR signalling hub, which are frequently dysregulated in therapy-resistant CSCs 
(Ffrench et al., 2014). SCs and CSCs belonging to the same type of tissue share some self-renewal and 
differentiation regulatory mechanisms, which challenges to target CSCs without harming normal cells 
(Pardal et al., 2005). For example, the blockage of the Wnt signalling pathway to treat cancer had 
detrimental effects on normal development that is regulates by the Wnt signalling in pre-and clinical 
studies (patients with bone-side effects). The primary side effects in targeting the Wnt/β-catenin 
pathway in anti-cancer treatments are myelo- and gastro-intestinal suppression, this is due to the 
side-effects effects of anti-Wnt treatments on proliferation of hematopoetic and intestinal stem cells, 
and also due to progenitor cells in other organs. However, it is important to find the right tool by 
designing specific agents to target the Wnt/FZD sub-pathways activated in certain cancer, rather than 
blocking the Wnt/β-catenin signalling altogether which prevents damage to normal tissue (reviewed 
in Blagodatski et al., 2014). 
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Thus, it is reasonable to say that these stemness signalling pathways may simplify coordinated 
CSC therapy-resistance mechanisms such as quiescence, detoxification (MDR), repair (DDR), survival 
(anti-apoptosis) and adaptation (reviewed in Gasch et al., 2015). 
Additionally, extracellular vesicles (EVs) are believed to have an important role in breast 
cancer growth and metastasis and could be potential anti-cancer therapies. Cancer cells secrete high 
volumes of EVs, including exosomes and microvesiculess, into the local microenvironment and 
premetastatic niche. These EVs released by tumour cells deliver procancerous transcripts and 
proteins, to both other cancer cells and nontransformed cells (reviewed in Green et al., 2015). 
Suetsugu et al., was able to visualise the transfer of exosomes from cancer cells and colonisation of 
these into lung cells. This study also demonstrates that breast cancer EVs can transfer nucleic acids 
and proteins to autologous and heterologous cells within the tumour microenvironment, culminating 
in the acquisition of the cancer phenotypes, tumour progression, immune evasion, and metastasis 
(Suetsugu et al., 2013). Furthermore, many mechanisms have been described for breast cancer EV-
mediated transfer of drug resistance to promote tumour growth and progression. One such 
mechanism includes the transfer of the P-glyoprotein (P-gp), which is linked to resistance. For 
example, one study showed that doxorubicin- or docetaxel-resistant breast cancer cells produce MVs 
into target endothelial or drug-sensitive cancer cells. Additionally, EVs act as tumour modulators 
within the tumour niche and are capable to succeed in the acidic, hypoxic environments common to 
tumours in order to confer prometastatic phenotypes such as inflammation, migration, and invasion. 
Cancer cells can use several methods to avoid immune system recognition through EVs, such as 
secretion of immunosuppressive proteins, inhibition of NK cell proliferation, or a decrease in CD8+ T-
cell cytotoxicity. Importantly, it is possible to take advantage of the drug delivery capabilities of 
exosomes for breast cancer therapy. One study has shown that Doxorubicin, fused into exosomes 
from immature dendritic cells and taken up by both MDA-MB-231 and MCF-7 cells, led to an 
impairement of cell proliferation in vitro and tumour growth in vivo. Several proteins have been 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
35 
 
recognised within breast cancer EVs that can be used as prognostic marker and could be used in 
combination with other analytical methods. Currently, some targeted breast cancer therapies have 
been studied using exosomes as a vehicle for drug delivery, but due to the complex nature of EV-cell 
interactions, more studies are needed to EVs be used as a  therapeutic strategy (reviewed in Green et 
al., 2015).  
 
1.4.2. Breast Cancer Stem Cells and Metastasis 
Metastasis is the main cause of death leading to >90% of mortality from cancer (Gupta and 
Massagué, 2006; Steeg, 2006). Tumour removal by surgery and adjuvant therapy can treat well-
confined primary tumours. However, metastatic disease is incurable because of its systemic nature 
and the resistance of disseminated tumour cells to current treatments. Moreover, the ability to treat 
cancer efficiently is mainly dependent on the capacity to inhibit or to reverse the process of 
metastasis. The metastasis generated by carcinomas are formed following the completion of a 
complex succession of cell-biological events – collectively termed the invasion-metastasis cascade – 
whereby epithelial cells in primary tumours (1) invade locally through surrounding extracellular matrix 
(ECM) and stromal cell layers, (2) intravasate into the lumina of blood vessels, (3) survive the hurdles 
of transport through the vasculature, (4) arrest at distant organ sites, (5) extravasate into the 
parenchyma of distant tissues, (6) initially survive in these foreign microenvironments in order to form 
micrometastases, and (7) re-initiate their proliferative programs at metastatic sites, thereby 
generating macroscopic, clinically detectable neoplastic growths (termed “metastatic colonisation”) 
(Fidler, 2003) (Figure 1.5). Many of these complex cell-biological events are coordinated by cell-
intrinsic molecular pathways within cancer cells. Additionally, non-autonomous cell interactions 
between cancer cells and normal stromal cells have crucial roles throughout the invasion during the 
metastasis cascade. Deregulation of these intrinsic and extrinsic signalling cascades, allow metastatic 
breast cancer cells to generate high-grade malignancies (reviewed in Valastyan and Weinberg, 2011).  
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A number of cellular properties required for metastasis to occur are shared by CSCs.  One such cell-
intrinsic property is EMT.  
1.4.3. Epithelial-Mesenchymal Transition (EMT) 
During the EMT process, the epithelial cells lose their epithelial characteristics and acquire 
more mesenchymal properties by cytoskeleton rearrangements and alterations in adhesion, cellular 
structure and morphology. In fact, cell surface proteins, such as E-cadherin (CDH1) or integrins are 
replaced by mesenchymal markers, such as N-cadherin, vimentin or fibronectin. As a result, epithelial 
cells are detached from the basal membrane and are therefore more capable of migrating to other 
sites or becoming more invasive and entering the blood and lymphatic systems (Britton et al., 2011). 
Thus, EMT-like changes correlate with a more aggressive phenotype. High levels of Matrix 
Metalloproteinases (MMPs) in the tumour microenvironment can directly induce EMT in epithelial 
cells. During EMT, cells can then produce more MMPs facilitating cell invasion and EMT can generate 
activated stromal-like cells that cause cancer progression via further MMP production (Kadisky and 
Kadisky 2010). The molecular mechanisms involved in metastasis are not clearly understood, but it 
has been suggested that there is deregulation of the signalling pathways that control normal EMT. 
One of the most prominent EMT molecules is E-cadherin, whose expression is increased in more than 
50% of metastatic tissues in breast ductal carcinoma (Chao et al., 2012).  
A recent study attempted to characterize an EMT signature in circulating tumour cells from 
breast cancer patients (Yu et al., 2013). They investigated seven pooled epithelial transcripts 
(cytokeratins 5, 7, 8, 18, and 19; EpCAM [epithelial cellular adhesion molecule] and E-cadherin) and 
three mesenchymal transcripts (fibronectin, N-cadherin, and SERPINE1/PAI1 [serpin peptidase 
inhibitor, clade E]) in 11 human breast cancer samples. They found it was rare to find cells expressing 
both mesenchymal and epithelial markers but mesenchymal markers were enriched in these 
circulating tumour cells. Interestingly, they demonstrated that expression of the mesenchymal 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
37 
 
markers was more likely to be associated with clusters of circulating tumour cells rather than a single 
set of migratory cells. These experiments provide evidence that a single cell may be undergoing EMT 
into cluster cells, or a pre-existing cluster undergo mesenchymal transformation in the bloodstream 
which would demonstrate evidence of EMT occurring in relation to blood-borne dissemination of 
human breast cancer (Yu et al., 2013). Additionally, circulating tumour cells from patients with 
advanced prostate and breast cancer expressed both epithelial and mesenchymal markers, indicating 
a possible switch or transition was happening between those states. Similar studies also detected EMT 
markers such as pan-cytokeratin, Twist, and Vimentin in circulating tumour cells from early and 
metastatic breast cancer patients (Papadaki et al., 2014).   
 Elucidating the molecular mechanisms responsible for EMT-mediated drug resistance and 
tumour metastasis is crucial to discovering strategies to prevent EMT, and restore the sensitivity of 
cancer cells to therapeutic treatment. It has been shown that the transcriptional factors Snail, Slug, 
Twist and zinc-figure E-box-binding homeobox (ZEB1 and ZEB2) are classified as EMT inducers. These 
can induce EMT via different cell signalling pathways. TGF-β, Wnt (wingless-type MMTV [mouse 
mammary tumour virus])/β-catenin, and Notch (a family of transmembrane proteins) pathways have 
been highly associated in inducing EMT in breast cancer epithelial cells. 
Interestingly all of these signalling pathways are implicated in CSC biology, and consequently 
there have been numerous studies describing an association between CSCs and EMT (Mani et al., 
2008; Morel et al., 2008; Scheel et al., 2011; Yang et al., 2012; Wang et al., 2014).  The effects of TGF-
β are not restricted to embryogenesis, but are also observed during cancer progression and has 
tumour promoting effects in almost all types of cancer. In addition, TGF-β has a direct effect on EMT 
by down-regulating epithelial markers and by up-regulating mesenchymal markers.  TGF-β can induce 
the CSC phenotype and can cause EMT in vitro by up-regulation of Oct-4, Nanog, N-cadherin, 
Vimentin, Slug and Snail, and down-regulation of E-cadherin and Ck18 (Wang et al., 2014). Knock-
down of Oct-4 and Nanog inhibited the TGF-β-induced EMT (Micalizzi et al., 2010, Wang et al., 2014).  
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TGF-β can also regulate EMT via the activation of additional molecules, such as MAPK, PI3K or GTPases 
belonging to the Rho family of proteins (Moustakas et al., 2007). 
Additionally, ERK2 activity results in nuclear accumulation of Snail1 with no cytosolic 
proteasomal degradation. This mechanism, which increases in tumour fibrosis, can prolong activation 
of CAFs to endure tumour fibrosis and to promote tumour metastasis through the regulation of Snail1 
protein level and activity (Zhang et al., 2016). Twist-induced EMT in breast cancer cells was followed 
by increased cell invasion, migration and CSC-like properties under hypoxic conditions. Twist activated 
PAR1 and PAR3 gene expressions, which are G-protein-coupled receptors that are “high-gain sensors” 
of extracellular protease concentrations, permiting cells to respond to a proteolytic microenvironmet 
(Wang et al., 2016). 
BCSCs can shift between epithelial-like and mesenchymal-like states (Gupta et al., 2011; Yang et 
al., 2012; Liu et al., 2014). It is becoming more important to understand how cellular plasticity modifies 
tumour biology and affects therapeutic response.  In addition, the plasticity of bCSCs that allows them 
to undergo these reversible transitions regulated by the tumour, may be necessary for successful 
metastatic colonisation (Liu et al., 2014). An additional subtype of breast cancer, termed basal 
B/claudin-low, has recently been highlighted and found to display EMT- and CSC-associated gene 
signatures. However, it is important to know whether claudin-low tumours reflect altered 
myoepithelial differentiation or, rather, de-differentiation. Is has been shown that EMT induction in 
an immunocompromised-mouse-derived epithelial cell line leads to a claudin-low gene expression 
profile with acquisition of several stem-like features, including the ability to form mammospheres, an 
increased tumourigenic potential, and activation of signalling pathways previously associated with 
cancer stem cells (for example TGFβ, Notch, Wnt and Hedgehog signalling pathways) (Asiedu, et al., 
2011; Takebe et al., 2011). This further supports the hypothesis of EMT-promoted cell de-
differentiation rather than altered myoepithelial differentiation. Corroborating this definition of 
plasticity, transgenic mouse models that combined expression of RAS and of the EMT inducer TWIST1 
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in luminal-committed cells induced the development of claudin-low breast tumours in vivo (Morel et 
al., 2012).  
Therapy-resistance has been associated with EMT in a study that has found up- regulation of 
P-glycoprotein 1 or multidrug resistance protein 1 (MDR1) in MCF-7 cells after Adriamicyin treatment 
(Li et al., 2009). These cells displayed enhanced invasion, and ablation of Twist1 expression in these 
cells, blocked EMT and partially reversed drug resistance, suggesting that EMT contributes to 
resistance to this drug (Li et al., 2013).  Several studies have shown an EMT- resistance phenotype 
after paclitaxel/docetaxel and 5-fluorouracil treatments and after treatments targeting hormone and 
epidermal growth factor receptors. MCF-7 cells become tamoxifen-resistant when they acquire an 
EMT-like morphology—growing as dispersedly grouped colonies with loss of cell-cell junctions and 
altered morphology.  These cells also express increased mRNA levels of Snail, Vimentin, and N-
cadherin and decreased levels of E-cadherin, which are considered hallmark EMT characteristics 
(Hiscox et al., 2006; Britton et al., 2011) (Table 1). 
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Figure 1.5 Process involved in the formation of metastases. Sequential steps of the breast cancer 
metastatic cascade (adapted from Wang and Wang, 2011 and Chang et al., 2014).  
 
Table 1.2. Plasticity Cell features involved in EMT during metastasis and drug resistance. EMT results 
in a transformation and transition of polarised epithelial cells toward mobile mesenchymal cells. The 
E-cadherin to N-cadherin switch indicates epithelial cells are progressing through EMT (reviewed in 
Wu et al., 2016). 
Epithelial-Mesenchymal Transition (EMT) 
Features Loss of cell polarity 
Cell migration 
Cell invasion 
Up-regulation  N-cadherin 
Vimentin 
Fibronectin 
Twist 
Snail 
Slug 
P-glycoprotein 1/MDR1 
Zeb1/Zeb2 
FOXC2 
Down-regulation E-cadherin 
EpCAM 
Ck18 
Signalling Pathways TGF-β (activates PIK3K/MAPK) 
Notch 
Wnt/β-catenin 
 
Epithelial Cells: 
E-cadherin 
Zo-1 
Desmoplakin 
Cytokeratins 
Cortical Actin 
Mesenchymal Cells: 
N-cadherin 
Vimentin 
Fibronectin 
Twist 
Snail/Slug 
Zeb1/Zeb2 
FOXC2 
Sox2 
Smooth Muscle 
MMPs 
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1.5. Breast Cancer and TRAIL / c-FLIP 
Therapeutic resistance and relapse are strongly associated with metastatic disease in breast 
cancer patients. Almost 30% of early breast cancer patients eventually develop metastatic disease and 
in 90% of these, a therapeutic resistance occurs and patients end-up dying from the disease (Grupta 
and Massangue, 2006).  Functional studies in a number of malignancies suggested that CSCs may lie 
at the heart of this therapy resistance in metastatic disease.  Tumours are treated with drugs based 
on their capability to cause regression of advanced tumours. These drugs are then given with adjuvant 
therapies after the primary tumour is removal. The CSC model, questions this strategy since regression 
of advanced tumours drastically affects the bulk tumour populations while growth of metastasis may 
be driven by CSCs. Only CSCs hold sufficient self-renewal ability to form metastases and since CSC and 
bulk tumour cells may be driven by different pathways, it will be crucial to use drugs that target the 
CSC regulatory pathways in the adjuvant setting (Korkaya and Wicha, 2013).  Given the complexity of 
the disease, new treatments for breast cancer need to be targeted at individual patient subgroups to 
ensure improved efficiency either as monotherapy treatments or in combination with standard of care 
(Mallini et al., 2013). A common feature of therapy resistance in metastatic disease is the inability to 
respond to pro-apoptotic stimuli. Cancer cells have developed several mechanisms to resist apoptosis 
induced using the extrinsic pathway. For example, therapy resistant ovarian tumours have been found 
with absent or downregulation of surface death receptors including platinum-resistant cancer and 
upregulation of FAS has been shown to reverse this platinum-resistance (Fan et al., 2015). FAS have a 
pro-apoptotic role in SCs but may drive survival in CSCs. Additionally, upregulation of the adaptor-
protein FADD has been shown to sensitise ovarian cancer cells to platinum treatment. CSC 
chemoresistance by evasion of apoptosis is not clarified but studies suggest that CSCs resist apoptosis 
via the extrinsic pathway. In mammalian cells, induction of apoptosis results into a perturbation of the 
mitochondria resulting in release of cytochrome C or factors that directly stimulate members of the 
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death receptor family (reviewed in Gasch et al., 2017). Therefore, there has been much interest in 
finding ways to re-sensitise cancer cells to pro-apoptotic stimuli. 
 
1.5.1. TNF-related Apoptosis Inducing Ligand (TRAIL) 
The tumour necrosis factor (TNF) superfamily of cytokines are key extracellular mediators of 
apoptosis (Ashkenazi, 2002). This family includes TNFα, FAS and TRAIL signalling pathways. Targeting 
TRAIL has become a good candidate for cancer therapy due to its well-recognised ability to induce 
apoptosis in cancer cells with limited toxicity to normal cells in vitro (Ashkenazi et al., 1999). Tumour 
necrosis factor-related apoptosis inducing ligand (TRAIL) or Apoptosis 2 ligand (APO-2L) was first 
identified due to its sequence homology to the extracellular domain of CD95 ligand (FasL) and tumour 
necrosis factor (Pitti et al., 1996; Wiley et al., 1995). The primary, but not exclusive, function of human 
TRAIL ligand is the induction of extrinsic apoptosis in target cells. It performs this function by binding 
to its cognitive receptors on the cell surface. TRAIL interacts with membrane-bound TRAIL receptors 
(TRAIL-R1/DR4 and/or TRAIL-R2/DR5) leading to receptor clustering and trimerisation. Intracellular 
adaptor protein FADD is recruited to the death domain of the TRAIL receptor. In the appropriate 
cellular context, the initiator caspase-8 is recruited to the complex, collectively known as the death-
inducing signalling complex (DISC) and interacts with FADD through its death effector domains. DISC 
activation of caspase-8 leads to caspase cascade activation where caspase-8 can either directly 
activate caspase-3 to induce apoptotic cell death (extrinsic pathway), or it can cleave the protein BID, 
leading to release of cytochrome-c from the mitochondria with subsequent apoptosome formation 
and activation of the caspase-9 (intrinsic pathway). Within the apoptosome caspase-9 is activated and 
cleaves caspase-3 to induce apoptotic cell death (Figure 1.6) (Crowder and Deiry, 2012). Activation of 
caspase-8 is inhibited by the intrinsic caspase-8 inhibitor, c-FLIP (Siegelin and Siegelin, 2011). C-FLIP 
plays an important role in moderating alternative downstream responses to TRAIL-inducing survival 
and proliferative activity. Endogenous TRAIL is expressed on natural killer cells, macrophages, T-cells 
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and dendritic cells and is believed to have an immune defence function destroying virus-infected and 
malignant cells (Duiker et al., 2006). Furthermore, the use of antibodies against the TRAIL receptor 
have been used to good effect in preclinical studies. For example, the TRAIL-R2 agonist lexatumumab 
is more effective than the TRAIL-R1 agonist mapatumumab at (1) initiating apoptosis in several 
metastatic, triple-negative cancer cell lines and (2) reducing lymph node and lung metastases in an 
orthotopic model of triple-negative breast cancer.  These findings provide robust preclinical evidence 
for targeting TRAIL-R2 in metastatic breast cancer. However, it also provides fundamental knowledge 
of the different TRAIL receptors’ roles in each breast cancer subtype (Malin et al., 2011). Moreover, a 
subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to 
benefit from TRAIL targeted therapy (Rahman et al., 2009). In regards to clinical trials, compounds 
such as:  soluble rhTRAIL (dulanermin), the TRAIL-R1 mAb agonist mapatumumab and TRAIL-R2 mAb 
agonists tigatuzumab, lexatumumab and Apomab have demonstrated low toxicity. However, their 
anti-cancer activity was poor with the majority of patients showing no improvement.  To date, the 
most promising monotherapy has been mapatumumab which entered a phase II clinical trial in 
patients with non-Hodgkin lymphoma with almost one-third of patients responding and one showing 
complete recovery (Hayes and Lewis-Wambi, 2015).  
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Figure 1.6. Extrinsic and intrinsic TRAIL signalling pathways. TRAIL ligation to a pro-apoptotic TRAIL 
receptor causes receptor trimerization and activation of initiator caspase-8 and effector caspase-3, 
leading to cell death. Alternatively, caspase-8 can cleave Bid. Truncated Bid triggers the release of 
cytochrome c and formation of the apoptosome. The apoptosome activates caspase-9 resulting in 
activation of caspase-3 and cell death (Goncharenko-Khaider et al., 2013) 
 
1.5.2. Cellular FLICE-Like Inhibitory Protein (c-FLIP) 
1.5.2.1. c-FLIP Structure and Function 
Cellular FLICE-Like Inhibitory Protein (c-FLIP) was first identified in 1997, as a cellular 
homologue to viral FLIPs (Thome et al., 1997; Irmler et al., 1997; Hu et al., 1997). A number of c-FLIP 
mRNA splice variants exist but at present only three proteins have been isolated, c-FLIP short (c-FLIPS), 
long (c-FLIPL) and Raji (c-FLIPR). C-FLIPS is a truncated version of procaspase-8, containing tandem 
DEDs only, whereas c-FLIPL closely resembles full-length procaspase-8 but lacks the active site 
catalytic cysteine residue and proteolytic activity. C-FLIPS inhibits DR-mediated apoptosis by blocking 
caspase-8 activation at the DISC (Krueger et al., 2001b and Scaffidi et al., 1999) (Figure 1.7). 
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Figure 1.7. c-FLIP isoforms. Three c-FLIP isoforms, c-FLIPL, c-FLIPs, and c-FLIPR, contain two death 
effector domains (DEDs) at their N-termini. In addition to two DEDs, c-FLIPL contains a large (p20) and 
a small (p12) caspase-like domain without catalytic activity. c-FLIPS and c-FLIPR consist of two DEDs 
and a small C-terminus (Safa and Pollok, 2011)  
 
 C-FLIPS might act purely as an antagonist of caspase-8 activity but c-FLIPL has a more 
controversial role, being either an activator or inhibitor of procaspase-8 (reviewed in Oztürk et al., 
2012). Both c-FLIPL and c-FLIPS have been implicated as regulating a number of signalling pathways 
involved in cell survival and apoptosis, whereas the functional role of the c-FLIPR isoform is not so well 
known. The c-FLIPL and c-FLIPS isoforms have been shown to be overexpressed in a number of cancer 
cells and their downregulation using siRNA or non-specific compounds can successfully render 
previously resistant tumours sensitive to treatment with apoptotic cytokines and chemotherapy. 
Numerous transcription factors transcriptionally regulate the c-FLIP gene such as: NF-κB, p53 tumour 
suppressor protein, p63, E2F1, c-myc, IRF5, c-Fos, nuclear factor of activated T cells (NFAT), 
heterogeneous nuclear ribonucleoprotein K (hnRNP k), the forkhead transcription factor FOXO3a, 
early growth response-1(EGR1), androgen receptor (AR), E2F, AP-1, and SP1 (Safa et al, 2008, Shirley 
et al., 2010). While NF-kB, p63, NFATc2, EGR1, hnRNP K, AR and SP1 are known to induce c-FLIP 
expression, c-myc, Foxo3a, c-Fos, IRF5, and SP3 suppress c-FLIP transcription (Safa et al., 2008, Shirley 
and Micheau, 2010). The c-FLIP isoforms, especially c-FLIPL, conform structurally to the pro-apoptotic 
caspases -8 and -10 and are also found in close proximity on the genome suggesting they may have 
evolved from gene duplication. C-FLIPL is a 55kDa protein made up of two death effector domains 
(DEDs) and a c-terminal caspase-like domain. The caspase-like domain is catalytically inactive as a 
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result of various amino acid substitutions, especially the critical cysteine residue found in the catalytic 
domain which has been substituted by a tyrosine residue. All three isoforms are capable of interacting 
with the adaptor protein FADD through their DED at the DISC. Although c-FLIP has been implicated in 
development, cell proliferation and drug resistance, the primary function of the c-FLIP protein is as an 
apoptosis regulator. The precise mechanism by which c- FLIP regulates apoptosis still remains 
unknown yet it is reasonable to say that regulatory roles differ between the distinct isoforms )Figure 
1.7). For example, it has been demonstrated that c-FLIP directly inhibits TRAIL-induced DISC formation 
by interaction with the adaptor molecule FADD preventing the activation of caspase-8 (Kataoka et al. 
2000; Safa et al. 2008; Shirley and Micheau, 2010; Safa and Pollok, 2011). Thus, the variable ways in 
which c-FLIP isoforms regulate apoptosis in different cell types suggests that its’ apoptosis regulatory 
mechanism is cell dependent. However, a clarification as to how c-FLIP modulates procaspase-8 
activation/activity to produce diverse signalling outcomes has been elucidated by a recent study.  A 
study conducted by Hughes et al. (2016) has revealed that c-FLIP L/S isoforms are recruited to the DISC 
and differentially regulate caspase-8 activation to control cell fate. In their model, using structure-
guided DED mutants of full-length FADD, procaspase-8, and c-FLIP L/S, it was shown that contrary to 
what is known, c-FLIP isoforms do not directly compete with procaspase-8 by binding to FADD. When 
procaspase-8 is recruited to FADD it recruits and heterodimerises with c-FLIP L/S via a co-operative 
and hierarchical binding process. The composition of this procaspase-8:c-FLIP heterodimer then 
constitutes the important decision step, which determines procaspase-8 activation and further cell 
fate. Heterodimer composition is critically regulated by the ratio of unbound c-FLIP L/S to 
procaspoase-8. Therefore, at physiological concentrations, the procaspase-8:c-FLIPL heterodimer 
forms the first active protease at the DISC, exhibits localised activity, and is an activator that promotes 
procaspase-8 oligomer assembly cell death. In contrast, high levels of c-FLIP preclude procaspase-8 
oligomer assembly, restricting caspase-8:c-FLIPL heterodimer activity inhibiting cell death. C-FLIPS 
does not readily form DED oligomers; thus, high levels of c-FLIP disrupt procaspase-8 oligomer 
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assembly resulting in a catalytically inactive pro-caspase-8:c-FLIPS heterodimer and inhibition of cell 
death (Figure 1.8). Significantly, this alternative mechanism for c-FLIP L/S recruitment to the DISC and 
regulation of DED:DED interactions critically determines procaspase-8 function. This then explains the 
dual function of c-FLIP where the ratio of c-FLIP isoforms to procaspase-8 differentially control cell 
survival or apoptosis.  Additionally, c-FLIP regulation of caspase-8 is required in T cells where different 
concentrations of c-FLIP isoforms control cell fate during development of the immune response 
(Hughes et al., 2006). 
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Figure 1.8. c-FLIP mechanisms in controlling apoptosis. The composition of this procaspase-8:c-FLIP 
heterodimer constitutes a key decision step, which determines procaspase-8 activation and further 
cell fate. Heterodimer composition is critically regulated by the ratio of unbound c-FLIP L/S to 
procaspoase-8. Therefore, at physiological concentrations, procaspase-8:c-FLIPL heterodimer forms 
the first active protease at the DISC, acts as an activator, promoting procaspase-8 oligomer assembly 
cell death. In contrast, high levels of c-FLIP preclude procaspoase-8 oligomer assembly, restricting 
caspase-8:c-FLIPL heterodimer activity and inhibiting cell death. C-FLIPS does not readily form DED 
oligomers; thus, high levels of c-FLIP disrupt procaspase-8 oligomer assembly resulting in a caticaticaly 
inactive pro-caspase-8:c-FLIPS heterodimer and inhibition of cell death (Hudghes et al., 2016).  
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1.5.2.2. c-FLIP and Cancer 
Several in vitro studies have demonstrated the importance of the role of c-FLIP in resistance 
to apoptosis induced by death receptors and chemotherapy (Safa et al., 2008; Kruyt, 2008; Yang, 2008; 
Piggott et al., 2011). Increased expression of c-FLIP is identified in many malignant cancers such as: 
breast, pancreatic, colorectal, bladder urothelial, cervical, gastric, hepatocellular, Burkitt’s lymphoma, 
non-Hodgkin’s lymphoma, head and neck squamous cell carcinoma. It also plays an important role in 
lymph node metastasis, which ultimately contributes to tumour progression (reviewed in Safa, 2011). 
Importantly c-FLIP expression  and is  highly associated with a poor prognosis (Safa et al., 2008). C-FLIP 
has therefore been proposed a potential therapeutic target to overcome this drug resistance, by 
lowering the threshold of cancer cell apoptosis (Safa, 2008). Interestingly, reduction of c-FLIP has been 
demonstrated to induce cell death without the need of extra therapy. Specifically, it was found that 
siRNA knockdown of c-FLIP induced a DR5, FADD, caspase-8 and caspase-9 dependant cell death in 
MCF-7 cells (Day et al., 2008). In vivo results corroborated with these results demonstrating that 
injection of liposomal c-FLIP-specific siRNA into MCF-7 xenografts destroyed neoplastic cells with no 
effect on the normal stromal and fibroblastic cells (Day et al., 2009). The in vivo results seen from 
these RNAi-based therapeutic interventions of c-FLIP are crucial to further preclinical development. 
However, siRNA design, delivery and stability are still difficulties that must be overcome before RNAi-
based therapies are truly feasible as a clinical intervention. Besides inhibiting c-FLIP gene expression 
directly, alternative methods, including degradation and transcriptional regulation of c-FLIP, may also 
have potential for c-FLIP intervention. For example, a small molecule inhibitor of c-FLIP, 4-(4-Chloro-
2-methylphenoxy)-N-hydroxybutanamide (CMH) or droxinostat has been identified, which 
downregulates c-FLIPL and c-FLIPS mRNA and protein levels, decreases cell survival and induces 
apoptosis (Safa and Pollok, 2011). Furthermore, cancer cell pre-treatment with chemotherapy has 
proven to be a successful method of sensitisation to extrinsic cell death ligands. It has been 
demonstrated that the HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA, vorinostat) inhibit 
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transcription/translation of a large variety of gene targets, including c-FLIP (Bijangi-Vishehsaraei et al. 
2010; Shankar et al. 2009; Yerbes and Lopez-Rivas 2010). Despite being clinically approved, vorinostat 
exhibits some side effects in patients and limited efficacy as a monotherapy for breast cancer (Luu et 
al., 2008). However, studies in transgenic mouse models indicate that targeted loss of c-FLIP activity 
in mammary tissues is not detrimental to normal mammary development (Piggott et al., 2011) and c-
FLIP remains an attractive therapeutic target (Kruyt, 2008; Yang, 2008; Piggott et al., 2011). It has also 
been found that c-FLIPL is a potential target in TRAIL treatment in HER2 +ve breast cancer because it 
has been found to be upregulated in these types of tumours. Moreover, cell studies have shown that 
downregulation of c-FLIPL sensitised a HER2+ cells line (SKBR3) to TRAIL-induced apoptosis, in a dose- 
and time-dependent manner. Furthermore, c-FLIPL inhibition enhanced cleavage and activation of 
caspase-8 and caspase-3, which may cause an attenuation to TRAIL resistance in HER2+ breast cancer 
(Zang et al., 2014).   
A previous study from our laboratory showed that CSC-like activity was selectively abrogated 
following c-FLIP inhibition and TRAIL treatment, while the in vivo tumour-forming ability of these cells 
following treatment was reduced by more than 95% (Piggott et al., 2011). It has also been shown that 
c-FLIP upregulates Wnt signalling pathway (one of the pathways associated with cancer stem cells 
proliferation and survival) (Katayama et al., 2010) and affects Gsk3β activity, p27 and caspase-3 levels 
(Quintavalle et al., 2010).  These findings highlight cFLIP as a promising target to improve prognosis in 
breast cancer but as these studies were exclusively performed in cell lines this efficiency still has to be 
establish in primary breast cancer tissues.   
 
1.6. Breast Cancer and the Tumour Microenviromnent 
The tumour-stroma communication has been reported as a hallmark of cancer. The tumour 
microenvironment is composed of local fibroblasts, endothelial cells, pericytes, leukocytes, and an 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
51 
 
extra-cellular matrix. It is well known that the tumour stroma plays an important role in cancer 
initiation, growth and progression (Pietras and Ostman, 2010). Importantly, the quantity of tumour 
stroma has been reported as an independent prognostic factor in the clinic. Higher proportion of 
stroma within the tumour has been correlated with three times increased for risk of recurrence (Kruijf 
et al., 2011). 
Cancer associated fibroblasts (CAFs) form an integral component of the tumour 
microenvironment, and are one of the major components of breast tumours (Orimo et al., 2006). 
These cells have been shown to originate from a variety of sources such as bone-marrow 
mesenchymal stem cells, local fibroblasts and from cancer cells that have undergone an EMT process 
(Spaeth et al., 2013).  
CAFs can either control normal or cancer development. Fibroblasts can hamper neoplastic 
growth in normal tissues, but can also potentiate invasion and tumour growth in cancer progression 
(Kuperwasser et al., 2004; Schauer et al.,2011). The origin of CAFs is uncertain but a previous study 
recognised two potential pathways: local fibroblasts may be converted into CAFs through stimulation 
by cytokines, including transforming growth factor-beta (TGF-β) and stromal cell-derived factor-1 
(SDF-1). Alternatively, epithelial or endothelial cells may transform into CAFs via epithelial-
mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndMT), which are also 
mediated by cytokines, including fibroblast growth factor (FGF), osteopontin (9), TGF-β and SDF-1 
(Schauer et al., 2011). 
 Genetic alterations of tumour suppressors in cancer stroma or cross-signalling that upregulates 
key paracrine pathways (which stimulate cell growth) successful for tumour initiation probably 
depend on proximal stroma activation (Schauer et al.,2011). Other studies have shown that fibroblasts 
directly modulate tumour growth by secreting factors with oncogenic and mitogenic functions capable 
of increasing tumour cell proliferation and protecting from apoptosis (Pietras and Ostman, 2010). 
Additionally, CAFs are able to, indirectly, secrete chemotactic factors to recruit other stromal cell types 
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into the tumour compartment and also secrete pro-angiogenic molecules resulting in increased 
angiogenesis. In fact, CAFs release large levels of pro-angiogenic factors including VEGF, CXCL12, FGF, 
IL-8/CXCL8 and PDGF-C in the ECM to recruit other stromal cell types, such as endothelial cells and 
their precursors, in order to stimulate tumour angiogenesis and vasculogenesis (Schauer et al., 2011). 
Moreover, co-culture of fibroblasts/CAFs increased the proliferation of lung, pancreas and breast 
cancer cells. Additionally, co-cultures induced expression of different soluble factors dependent of the 
cancer type. EGF was mainly secreted by co-cultures of pancreatic and breast cancer cells, HGF was 
highly secreted by lung cancer cells and fibroblasts, and IL-6 was mainly secreted by the breast cancer 
co-cultures indicating a cancer-specific pattern in cytokine secretion. Therapies with blocking 
antibodies against some factors or their receptors inhibited the cancer cell proliferation in the co-
cultures.  Specifically, blocking IL-6 led to a significant decrease in the survival of BT20 cells that were 
co-cultured with fibroblasts, demonstrating that the increase in cell proliferation was mediated by IL-
6 (Majety et al., 2015). Furthermore, PI3K/Akt and MAPK/Erk pathways may be the common key 
pathways by which both normal and cancer fibroblasts regulate cancer cell proliferation. High 
secretion of one or more cytokines by CAFs (IL-6, IL-8, VEGF, CCL2 (RANTES) and CCL5 (MCP-1)) may 
potentially mediate the activation of these pathways to induce cancer cell proliferation (Subramaniam 
et al., 2013). In addition, co-culturing the MDA-MB-231 breast cancer cell line with human CAFs, in 
vitro, resulted in an increased proliferation rate, with a great proportion of tumour cells in S phase 
compared to tumour cells co-cultured with normal fibroblasts (Peng et al., 2013).  
CAFs can also promote EMT, invasion and metastasis (Bhowmick et al., 2004, Straussman et al., 
2012). The mesenchymal-like state is associated with the expression of mesenchymal markers, relative 
quiescence, and high invasive capacity, whereas the epithelial-like state is associated with expression 
of epithelial markers, establishment of cell polarity, and extensive proliferation (Moreno-Bueno et al., 
2008, Liu et al., 2014). IL-8, a known EMT marker is able reduce the expression of epithelial E-cadherin 
and increased fibronectin expression in MCF-7 and T47D luminal breast cancer cells (Palena et al., 
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2012). In addition, activation of EMT could induce the generation of the CSC population (Wellner et 
al., 2009). In prostate cancer, CAFs can stimulate EMT and increase the stemness properties of cancer 
cells through the secretion of MMPs (Giannoni at al., 2010). Furthermore, CAFs can promote EMT in 
breast cancer cells through the secretion of stromal-derived factor 1 (SDF-1) and TGF-β1 providing 
additional support, suggesting that CAFs may promote cancer stemness (Soon et al., 2013). Several 
genes expressed in the cell population defined as stem-like (for example ZEB1, VIM, and DCN) have 
been shown previously to contribute to the EMT signature. The deregulated balance of these EMT 
markers might therefore reflect the reversibility of EMT and the influence of microenvironmental 
changes (Taube et al., 2010).  In order to accommodate the potential plasticity of these tumour-
microenvironmental changes, a combination approach targeting the CSC and non-CSC like populations 
may present the best strategy for therapy to treat aggressive breast cancers. Accordingly, a number 
of CSC-targeting agents are now entering clinical trials (Pinto et al., 2014).  
 
1.7. Experimental Models of Breast Cancer 
1.7.1. Breast Cancer Cell lines and Primary Culture  
In general, cell lines mirror both the genomic heterogeneity and the recurrent genome copy 
number abnormalities found in primary tumours with high fidelity. The evolution of a normal somatic 
epithelial cell into an immortalised, metastatic cell requires deregulation of multiple cellular processes 
including genome stability, proliferation, apoptosis, motility, and angiogenesis (Albertson et al., 2003; 
Hanahan and Weinberg, 2000). Considering the fact that many of the cell lines have been cultured for 
long periods of time, this indicates that they have not accumulated substantial new recurrent 
aberrations during extended culture and is supported that stable genomic and expression patterns in 
the cell lines are kept over multiple passages. Important genome mutations like the high-level 
amplifications associated with poor prognosis in primary tumours are well represented. Furthermore, 
cell lines also group into basal-like and luminal expression subsets in a similar manner to primary 
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tumours and show heterogeneous responses to targeted therapeutics mirroring observations in the 
clinic (Neve et al., 2006). Clearly there are distinct advantages for the use of cell lines. However, their 
relevance in disease is questionable due to the lack of a surrounding microenvironment ( for example 
stroma and vasculature) that, as discussed above, plays a major role in the development and 
progression of human disease notwithstanding any additional acquired mutations during the 
transformation process (Place et al., 2011). In addition, another disadvantage in using established cell 
lines is the fact that most breast cancer cell lines are derived from metastatic lesions such as pleural 
effusions, and may not reflect important features of the biology of the primary tumour (Drews-Elger 
et al., 2014). Thus, the primary tumour heterogeneity and consequently the early stages of breast 
tumourigenesis are more appropriately modelled by patient-derived primary, short-term cultures 
from dissociation of specimens from breast tumours. These ex vivo models, therefore better mirror 
the characteristics features of primary breast cancer. Knowledge of breast cancer subtypes, 
correlation with clinico-pathological features and response to current treatments by means of 
genomic studies and profiling have significantly increased our understanding of the relevant 
properties of primary breast cancer cultures (Perou et al., 2000; Prat et al., 2010). Studies have shown 
that the tumourigenic primary cultures retain important markers in breast cancer biology (EGFR and 
HER2) in both the in vitro and in vivo settings, and shows significant gene expression similarities to 
their correspondent primary tumour.  
Moreover, it is becoming increasingly clear that cells from the tumour microenvironment 
including immune cells, pericytes, cancer-associated fibroblasts (CAFs), adipocytes, and endothelial 
cells play a vital role in tumour progression and metastasis (Mueler et al., 2004; Hanahan and 
Weinberg, 2011).  Therefore, using cellular models of CAFs in the context of breast cancer biology may 
lead to the better understanding of crucial interactions within primary breast tumours. In addition, it 
has been shown that primary cultures consist of two groups of cellular models; one comprising 
tumourigenic and metastatic breast cancer cells and another group formed by CAFs. These primaries 
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cultures provide important models for the study of breast cancer pathogenesis including metastatic 
disease, in vivo assessment of drug sensitivities, and discovery of new therapeutics (Drews-Elger et al., 
2014). 
Recently, primary 3D organoid culture of tumours has become a promising strategy for studies 
of solid, epithelial tumours. Organoids comprise all components of the original tissue, including cancer 
epithelial cells, endothelial cells, leukocytes, and fibroblasts. 3D organoid cultures recapitulate in vivo 
tissue structural organisation, functional differentiation, chemical and mechanical signals, and 
therefore, may be more physiologically relevant than 2D cultures of primary or immortalised cells 
(reviewed in Walsh et al. 2016).  
Hans Clevers and colleagues developed 3D culture conditions where single epithelial stem 
cells grow to form the physiological architecture of the organ. They have seen that single Lgr5 positive 
stem cells were able to form organoids with the appropriate crypt-villus structure with all of the 
component cell types, including stem cells, goblet cells, transiently amplifying cells, and villus cells. 
Because these 3D epithelial structures repeat the histology and differentiation of the intestinal 
epithelium in vivo, they were named “organoids”. Organoid has been defined as containing several 
cell types that develop from stem cells or progenitors and self-organise through cell sorting and 
spatially-restricted lineage commitment, which occurs in vivo (Clevers, 2016). Organoid conditions 
that allow propagation of multiple benign or cancer epithelial lineages can be used as an  in 
vitro patient-derived cancer model. In regards to the mammary epithelium, Sokol and collegues 
generated an hydrogel scaffold that contained both the protein (collagen, laminins, and fibronectin) 
and carbohydrate components (hyaluronan) of human breast tissue. Primary mammary epithelial cells 
isolated from patient breast tissues were cultured into these hydrogels and were able to self-organise, 
expand, and differentiate to form mature mammary tissues. They found  stem cells at the TEBs (Sox9 
and slug staining) and it is consistent with findings in the human breast. Culture of hormone-
responsive human breast tissues in hydrogels with defined components will allow deeper 
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investigations of the human mammary gland development and biology, giving a btter knowledge of 
breast cancer biology  (Sokol et al., 2016). Moreover, one disadvantage of organoid protocols involve 
immediate processing of fresh tissue into organoids, however, it has been recently shown that 
organoids can be grown and are viable when generated from flash-frozen and DMSO-frozen tissues. 
Importantly, the drug responses of organoids derived from frozen tissues correlates with that of 
organoids derived from fresh tissue (Walsh et al., 2016). Additionally, Clevers group has created a 
living biobank comprising over one hundred breast cancer organoids where they mimic the breast 
cancer histology: ductal tumours generate  solid organoids and lobular generate discohesive 
organoids. These breast cancer organoids have the advantage of allowing extraction of genetic data 
from pure tumour epithelium. The lack of contamination with normal cells generates a cleaner DNA 
profiles and easier detection of somatic mutations. Organoids should be created from breast cancer 
biopsies and treated in parallel to the respective patients in defined clinical trial and could help to 
identify possible treatment strategies and resistances for individual patients (Sachs et al., 2018). 
 
1.7.2. Mouse Models of Breast Cancer - Patient-derived Xenografts 
Mouse models can provide an excellent resource to study human disease and the 
development of cancer mouse models has provided important insight into the development of breast 
cancer. However, it is essential to ensure the chosen models accurately replicate genetic alterations 
and overall phenotypes observed in human tumours. Moreover, these models serve as preclinical 
platforms to verify efficacy of potential drug therapies. In some of the early models, mammary lesions 
were induced by external factors such as the mouse mammary tumour virus (MMTV) and chemical 
carcinogens. Progress in transgenic technology had provided the development of a new generation of 
models where tumour suppressors can be knocked out, or oncogenes overexpressed, genetically 
(Allred and Medina, 2008). In addition to making clear the role of specific genes in breast 
carcinogenesis or progression, these models have also been useful in elucidating molecular pathways. 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
57 
 
Despite advances in controlling transgene expression specifically in the mammary compartment, there 
are still limitations to constitutively active promoters especially when a transgene of interest has no 
desirable effects throughout development. This problem has been addressed with the use of inducible 
transgenic systems, such as the tetracycline-controlled system. This has also proved useful in revealing 
mechanisms such as oncogene addiction. This is feasible with conditional systems because gene 
expression can be switched on or off in the presence or absence of its inducer (Allred and Medina, 
2008). Another approach to mouse modelling breast cancer has been the use of xeno-transplantation 
where human cancer cells are transplanted into immunocompromised mice (Vargo-Gogola and Rosen 
2007). It has been hypothesised that tumour xenografts produce tumours that are more closely 
related to breast cancers observed in humans in the clinic. However, the use of immunocompromised 
mice to establish xenografts lacks the contribution of certain components of the immune system to 
tumour progression. In general, using established transformed cancer cell lines for transplantation 
omits certain aspects related to tumour initiation. Therefore, hetero-transplantation of primary 
tumour biopsies from patients into immune-deficient mice – patient derived xenografts (PDXs) - has 
many advantages over xenografts using cancer cell lines, for example they also carry human stroma. 
The hetero-transplant tumours can be directly compared to the original patient tumour biopsies, and 
to annotated information on patient features, family history, patient outcome, etc. (Marsden et al., 
2012). With the improvement of mouse clinical trials, it is possible to achieve and to predict important 
clinical treatments and to optimise new therapeutics more rapidly. However, the individual PDX 
created based on similarity between patient and PDX responses is challenged by low engraftment 
rates, time (several months) required to establish a PDX model and high costs in animal maintenance 
(Whittle et al. 2015). Given the current clinical challenge of eliminating metastatic disease, there is an 
emerging need for models that better predict metastatic behaviour (Whittle et al., 2015). It was shown 
that in studies using a large cohort of  breast cancer subtypes: (i)  grafts maintain key features of the 
original tumours, including histopathology, clinical markers, gene expression profiles, copy number 
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variants and estrogen dependence and/or responsiveness; (ii) the grafts spontaneously metastasise 
to many of the same organs that were affected in the subjects that were studied; and (iv) tumour 
engraftment is a prognostic factor for survival time, even in individuals with newly diagnosed breast 
cancer without known metastatic disease. Not only does this suggest a potential functional assay for 
assessing tumour aggressiveness, but it also supports the notion that tumour grafts accurately model 
the cancers from which they are derived (DeRose et al., 2012). 
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1.8. Aims and Objectives 
Several compounds targeting TRAIL receptors have shown to be efficient at targeting selected 
tumour subtypes in preclinical studies but have failed to translate similar potency in clinical trials 
(reviewed in De Miguel et al., 2016).  These compounds were intended to be used as a monotherapy 
and to date have largely been undertaken on patients with advanced solid tumours. These compounds 
demonstrated a low toxicity, however, their anti-cancer activity was poor with the majority of patients 
showing no improvement (reviewed in Hayes and Lewis-Wambi, 2015). Therefore, there is a 
contradiction between TRAIL efficiency in preclinical studies compared to clinical trials.  It is important 
to note that none of these trials pre-selected patients on the basis of degree of TRAIL sensitivity nor 
correlated with tumour molecular/histological subtype. Based on in vitro evidence of TRAIL sensitivity 
in mesenchymal-like breast cancer cell lines, we hypothesised that stratification of breast cancers may 
reveal sub-types that preferentially respond to TRAIL treatment besides mesenchymal cell lines 
(Rhaman et al., 2009). Additionally, acquirement of tamoxifen resistance has been associated with a 
mesenchymal phenotype, which led us to hypothetise that these endocrine resistant cells might be 
sensitive to TRAIL. Moreover, there are several studies demonstrating the effect of c-FLIP suppression 
at sensitising bCSCs to the apoptotic mechanisms of TRAIL (Kruyt, 2008; Yang, 2008; Piggott et al., 
2011). Therefore, we hypothetise that Tamoxifen-resistant cells will be sensitive to TRAIL and 
suppression of c-FLIP will sensitise resistant breast cancer cells to the apoptotic mecanisms of TRAIL.  
As there is no work testing this hypothesis in primary breast tissues, TRAIL and c-FLIP 
suppression will be tested in primary breast tissue directly from patients. 
 
Thus, this part of the project had three key objectives: 
(1) To perform TRAIL treatment as a monotherapy in primary breast tissues to identify a particular 
cohort of patients that might benefit most from TRAIL therapy. Cells will be treated with TRAIL in 
adherent and non-adhrent conditions. 
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(2) To combine TRAIL and c-FLIP-inhibition in primary breast tissues to investigate whether c-FLIP 
suppression can sensitise TRAIL-resistant tumours to TRAIL. c-FLIP would be ideally suppressed by viral 
transduction of primary cells with lentiviral shRNA targeting c-FLIP. As an alternative c-FLIP would be 
suppressed via a transient knockdown using siRNA. In addition, c-FLIP would be suppressed using 
OH14, a compound developed in our laboratory that is a competitive inhibitor of c-FLIP. OH14 binds 
to the c-FLIP DED domains not allowing c-FLIP binding to the DISC.   
(3) To combine TRAIL and c-FLIP-inhibition in human mammary epithelial primary cells (HMECs) 
to evaluate any toxicity to normal cells.  
 
The tumour microenvironment has been suggested to promote metastatic disease and the 
maintenance of a cancer stem-like cell phenotype. We hypothesise therefore that cancer associated 
fibroblasts, may sensitise tumour cells to TRAIL by promoting a more mesenchymal/stem cell-like 
phenotype. Furthermore, identification of the types of cancer associated fibroblasts that can confer 
this sensitisation to TRAIL, could be applied as a biomarker for TRAIL sensitivity.  For this purpose, we 
tested: 
(4) TRAIL treatment of a human breast cancer cell line and primary breast cancer lines in co-
culture with a panel of CAFs or treated with CAF-conditioned medium. 
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CHAPTER 2                        
Materials and Methods 
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2. Materials and Methods 
 
2.1.  Cell Lines and Cell Culture 
2.1.1. MCF-7 Cell Line 
The human immortalised MCF-7 breast cancer cell line was a gift from Dr. Julia Gee, Cardiff 
University These cells originate from invasive breast ductal carcinoma and are estrogen and 
progesterone receptor positive but do not over-express HER2 receptor (Neve et al., 2006). Cells were 
cultured in RPMI 1690 medium (Invitrogen) supplemented with L-glutamine mix (Invitrogen); 10% 
foetal bovine serum (FBS) (Gibco) and Penicillin (100 U/ml)/Streptomycin (100 U/ml) (Invitrogen). Cells 
were cultured in T25 (25 cm2) or T75 (75 cm2) cell culture flask (Nunc, Fisher) and maintained at 37° C 
in 5% CO2.   
Cells were split when 80-100% confluent every 3-4 days. The medium was removed from the 
tissue culture flask and replaced with trypsin-EDTA (Invitrogen) and incubated at 37° C for 5 minutes. 
Cell detachment was confirmed by microscopy. Trypsin was inactivated by the addition of cell culture 
medium containing FBS (Invitrogen). Cells were split at a ratio of 1:10 and the remaining cells were 
used for cell-based assays. 
 
2.1.2. Primary Patient-derived Samples 
2.1.2.1. Human Mammary Epithelial Cells 
Human primary mammary epithelial cells (HMECs) were purchased from Lonza (Walkersville, 
MD, USA). Single-cell suspensions of HMECs were obtained by mechanical and enzymatic dissociation 
from reduction mammoplasties. Cells arrived to the host laboratory in single cells suspensions in a T75 
(75 cm2) at passage 7 and were maintained under culture for a maximum of 15 passages. After 
centrifugation, cells were cultured in MEBM media (Lonza) supplemented with SingleQuots™ Kit: 
Gentamicin; Hydrocortisone; Bovine Pituitary Extract; Insulin and Epidermal growth factor (Lonza). 
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Cells were split at 60-80% of confluency. Medium was aspirated and replaced by 5 ml of room 
temperature HEPES-BSS (Lonza) prior to trypsin-EDTA because the medium contains complex proteins 
and calcium that neutralise the trypsin. HEPES-BSS was then removed and replaced with 2ml of trypsin 
for 6 minutes until 90% of cells were rounded up. After cell detachment, the trypsin was neutralised 
with 4 ml of trypsin neutralising solution (TNS) (Lonza). The mix was collected into a 15 ml falcon and 
centrifuged at 200 x g for 5 minutes to pellet cells. Cells were cultured in a T25 (25 cm2) or T75 (75 
cm2) cell culture flask (Corning, Costar) and maintained at 37° C in 5% CO2. 
 
2.1.2.2. Primary Culture of Breast Metastatic Samples (n=9) 
Primary culture breast metastatic samples were a gift from Dr Robert Clarke, at the University 
of Manchester. Cells from nine different pleural effusion ascites were collected from patients at The 
Christie NHS Foundation Trust. All patients were fully informed and gave their consent in accordance 
with local research ethics committee guidelines (study numbers: 05/Q1402/25 and 05/Q1403/159). 
Clinico-pathological details and treatments of the samples are summarised in Table 2.1. Single cells 
were extracted by Clarke’s laboratory. Cells were centrifuged at 1,000 × g for 10 min at 4°C. The cell 
pellets were diluted in PBS. Erythrocytes and leucocytes were removed using Lymphoprep (Axis-
Shield) and CD45-negative magnetic sorting (Miltenyi Biotec), respectively. Single cells Cells were 
cultured in adherence for 7–9 days in DMEM/F-12 medium, GlutaMAX (GIBCO) with 10% fetal bovine 
serum (FBS; GIBCO), 10 μg/ml insulin (Sigma-Aldrich), 10 μg/ml hydrocortisone (Sigma-Aldrich), and 5 
ng/ml epidermal growth factor (EGF; Sigma-Aldrich). Cells were then trypsined and single cells were 
frozen – 80° C. Vials were shipped to our laboratory and cells were thawed and cultured using the 
same media. Cells were split at 80-100 % confluence every 3 days. Medium was removed from the 
tissue culture flask and replaced with trypsin-EDTA (Invitrogen) and incubated at 37° C for 5-10 
minutes. Cell detachment was confirmed by microscopy. Trypsin was inactivated by addition of cell 
culture medium containing FBS (Invitrogen). The mix was collected into a 15 ml falcon and centrifuged 
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at 200 x g for 5 minutes to pellet cells. Cells were cultured in T25 (25 cm2) or T75 (75 cm2) cell culture 
flask (Nunc, Fisher) and maintained at 37° C in 5% CO2, 5% O2.  
 
Table 2.1. Characteristics of nine metastatic endocrine therapy‐treated, and patient‐derived 
tumours.  IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma: #: unknown; 5-FU:%-
Fluoroucil; FEC: 5‐FU, Epirubicin and Cyclophosphamide; ECF: Epirubicin, Cisplatin, 5-FU; EOX: 
Epirubicin, Oxaliplatin, Capecitabine. 
Sample 
name 
Type Grade ER PgR HER2 Chemotherapy Hormonal 
Therapy 
Target 
Therapy 
BB3RC29 IDC 2 + + - FEC 
Paclitaxel 
Epirubicin 
Anastrazole, 
Exemestane 
Fulvestrant, 
Letrozole 
- 
BB3RC59 ILC 2 + + - EOX 
Capecitabine 
Paclitaxel 
Letrozole, 
Tamoxifen, 
Exemestane, 
Fulvestrant, 
- 
BB3RC68 IDC 2 + # - EFC Tamoxifen, 
Letrozole,  
Anastrozole, 
Fulvestrant, 
- 
BB3RC71 IDC 3 + + + FEC 
Capecitabine 
Vinorelbine 
Docetaxel 
 
Tamoxifen, 
Anastrozole, 
Fulvestrant, 
Exemestane 
Herceptin 
Lapatinib 
BB3RC79 IDC 3 - - - FEC 
Capecitabine 
Docetaxel 
Epirubicin 
Gemcitabine 
Carboplatin 
- - 
BB3RC81 IDC 2 + + - FEC Tamoxifen, 
Anastrazole 
 
BB3RC90 # # + + - - - - 
BB3RC94 # # + + - - - - 
BB3RC96 # # - - + FEC 
Paclitaxel 
Trastuzumab 
Capecitabine 
- Lapitinib 
 
 
2.1.2.3. Breast Diagnostic Biopsies and Surgical Samples 
Primary human breast diagnostic biopsies (n=149; 145 females and 2 males) and post-surgical 
core biopsies (n=90; 89 females and 1 male) were obtained following consent from the Cardiff and 
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Vale Breast Cancer Centre at Llandough Hospital under NISCHR ethical approval (12/WA/0252). 
Clinico-pathological details of the samples used to generate data for the drug treatment result 
chapters are summarised in Table 2.2.  
Cells were processed, maintained and stored according to the Human Tissue Act, 2004 with 
local (Cardiff University) research ethics approval. Samples were collected in storage solution (Miltenyi 
Biotec) and washed in RPMI (Gibco). These samples were placed onto white discs and chopped using 
a McIlwain Chopper. When an homogeneous mash was visible, the aggregates were transferred into 
a 15 ml falcon containing RPMI with no additives and an enzyme mix from  the Human Tumour 
Dissociation Kit (Miltenyi Biotec): 200 µl of enzyme 1; 100 µl of enzyme 2 and 25 µl of enzyme 3.  The 
15 ml falcon tube was then placed on the Gentle MACS Dissociator (Miltenyi Biotec) using the program 
“h_tumour_01” (36 seconds). Samples were then incubated  for minutes at 37 °C under continuous 
rotation using the MACSmix Tube Rotator (Miltenyi Biotec). The previous two steps were repeated 
twice before the digested tissue was filtered through 70 μm cell strainers and then centrifuged at 1200 
rpm for 7 minutes. Cells were cultured in non-adherence conditions in DMEM/F12 media containing 
1× B-27 serum-free supplement (Invitrogen), 0.4% bovine serum albumin (BSA)(Sigma), 20 ng/ml 
epidermal growth factor (EGF) (Sigma), 10 ng/ml basic fibroblast growth factor (bFGF) (Sigma), 4 µg/ml 
insulin, human recombinant (Sigma) and Penicillin (100 U/ml)/Streptomycin (100 U/ml). Primary cells 
were maintained in 5% CO2, 5% O2 at 37°C and were cultured in low-attachment plates for 10-14 days 
to allow tumoursphere formation. 
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Table 2.2. Characteristics of biopsies and surgical samples and their therapies.  IDC: invasive ductal 
carcinoma; ILC: invasive lobular carcinoma: DCIS – Ductal carcinoma in situ; #: unknown. B – core 
diagnostic breast biopsy; SS – Surgical sample – post-surgical core breast biopsy; PDX – Patient-derived 
xenografts - tumour obtained after engrafment of a core biopsy or surgical sample.  
Sample 
number 
 
 Type Grade ER HER2 Chemotherapy Hormonal 
Therapy 
Target 
Therapy 
194 SS IDC 2 + + - - - 
149 B IDC 3 + - - - - 
61 PDX ILC 2 + - - - - 
209 SS IDC + DCIS+ ILCS 3 + - - - - 
202 SS IDC + High Grade 
DCIS 
2 + + - - - 
195 B IDC 3 - + - - - 
180 SS IDC + Mucinous 3 + - - - - 
123 B IDC + High Grade 
DCIS 
3 + - - - - 
165 SS IDC 3 + - - - - 
220  Papillary proliferation 2 + - - - - 
72 PDX IDC 3 - - - - - 
236 SS IDC + DCIS 2 + - - - - 
229 SS IDC + DCIS 2 + - - - - 
206 SS ILC 2 + - - - - 
215 SS IDC + ILC 2 + - - - - 
164 SS IDC 3 + + - - - 
217 SS IDC + DCIS 2 + - - - - 
207 SS IDC + DCIS 3 + - - - - 
188 SS IDC + DCIS 3 - + FEC 
Docetaxel 
 
Tamoxifen - 
139 SS IDC 3 + + - - - 
127 B IDC 3 + - - Tamoxifen - 
120 B High grade comedo 
DCIS 
3 - # - - - 
253 SS IDC + DCIS 2 + + FEC Tamoxifen 
Letrozole 
 
77 B IDC + DCIS 2 + - - - - 
261 SS IDC + DCIS 3 - +    
248 SS IDC + Mucinous 2 + + Vinorelbine 
 
- Rituximab 
242 SS IDC + DCIS 2 + + - - - 
243 SS IDC + DCIS 3 + - - - - 
218 B IDC 2 + - - - - 
170 SS IDC 3 - - - - - 
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2.1.3. Fibroblasts Isolation and Culture  
After breast samples dissociation (either breast diagnostic biopsies or surgical samples), cells 
were resuspended in 1ml of DMEM-F12 with 10% FBS and cultured in a 12 well-plate. Fibroblasts are 
fast growing cells and will rapidly adhere to the surface of the plate. One hour after culture, fibroblasts 
have already adhered to the plate and then the supernatant was collected and fresh media was added 
to the top of the fibroblast monolayer. Fibroblast monolayer purity was confirmed using a microscope. 
These primary fibroblasts were maintained under culture in 5% CO2, 5% O2 at 37°C until passage 
number 10. Cell morphology was analysed under the microscope to confirm the purity of the 
fibroblasts cultures.  
2.1.4. Co-culture of Fibroblasts with MCF-7 and Fibroblasts Conditioned 
Medium 
On day 1, 160000 cancer-associated fibroblasts (CAFs) from five surgical samples (148, 168, 
207, 209 and 253) were plated in 6 well-plates. On day 4, the medium was removed and wells were 
washed with PBS. Then, 80000 or 160000 of MCF-7 cells expressing GFP were seeded on top of the 
confluent monolayer of fibroblasts. Co-cultures were fed with 1 ml of medium to mimic the 
experiments with conditioned medium. After 24 hours, cells were treated with 20 ng/ml of TRAIL for 
18 hours. To quantify the percentage of MCF-7 cells expressing GFP, cells were analysed by flow 
cytometry using BD Accuri. Results were analysed using FlowJo software.  
Fibroblasts from either normal breast samples (98) benign breast conditions (213 and 214) or 
breast cancer (isolated from the diagnostic samples and surgical samples; 61, 89, 105, 148, 153, 168, 
206, 207, 209 and 253) were used to generate conditioned medium. Confluent fibroblasts (90 - 100%) 
were incubated with fresh medium for 24 hours to generate fibroblasts-conditioned medium (CM).  
After 24 hours, medium was filtered through a 70 µM strainer and either used directly fresh the CM 
experiments or frozen at - 80°C. For the CM experiments, the immortalised breast cancer cell line  
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MCF-7 and the metastatic breast cancer cells from pleural effusions BB3RC29, BB3RC81 and BB3RC90 
were incubated with 100 µl of 100% CM during 24 hours when at 60-70% of confluency in a 96 well-
plate.  
 
2.2. Cell Seeding and Long-term Storage of Cell Lines 
MCF-7, HMECs and cells from pleural effusions of patients with advanced breast cancer were 
detached with trypsin and cells were collected in a 15 ml falcon tube (see previous section for 
individual protocols used for each sample). Cells were centrifuged at 1200 rpm. Medium containing 
trypsin was removed and the cells were diluted in medium. Cells were counted using Fast Read Slides 
(Immune Systems, UK). Cells were then seeded at optimal concentrations into appropriate culture 
plates (Costar, Sigma, UK), depending on the assay being performed and number of days left for 
culture (Table 2.3).  When  all the primary cells used for this study were no longer needed for culture, 
cells were frozen and cryo-stored in liquid nitrogen at the lowest passage possible. Cells were 
resuspended in a solution containing 10% v/v dimethyl sulfoxide (DMSO) and 90% FBS and 1ml 
aliquots were placed in 1.5 ml cryo-tubes (Nunc, Leics, UK). These aliquots were then placed in 
isopropanol for a slower freezing process at - 80°C in a freezer. On the next day, cells were moved to 
liquid nitrogen at -180°C. To defrost cells, cells were quickly thawed in a 37°C waterbath and re-
suspended in 10 ml of complete media, centrifuged for 5 minutes at 1200 rpm, the supernatant was 
then removed and the pellet re-suspended in 7 ml of complete media in a T25 flask.  
Table 2.3. Plates surface area, media volume and number of cells used for cell culture. 
Plate Surface Area (cm2) Volume (ml) Number of cells 
96-well 0.2 0.1 5000 - 15000 
24-well 1 0.5 50000 
12-well 205 1 100000 
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2.3. Animal Experiments - Patient-derived Xenografts 
All animal xenograft procedures were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 and approved by the UK Home Office (PPL 30/2849). Samples (see Table 3.3) 
were transplanted into 8-10 week old NOD/SCID/IL-2γ-receptor null (NSG) mice, commercially 
obtained from Charles River Laboratories (Wilmington, US). Mice were maintained in individually 
ventilated cages (Allentown Inc, US) in the Animal House, at the Heath Hospital, Cardiff. Mice were 
fed with Teklad global 19% protein extruded rodent diet (Harlan Laboratories) and water. Before 
transplantation tumour/cells were washed with RPMI 1640 medium with no additives. Several 
methods of sample transplantation were tested such as: chunks, tumourspheres, single cells and 
aggregates. Chunck refers to a approximately 2 mm segment of the core biopsy or surgical samples. 
Aggregates refer to the homogeneous mash generated after mechanical disaggregation with the 
McIlwain Chopper. Single cells refer to the last step of the mechanical and enzymatic digestion of the 
samples and tumourspheres are obtained 10 days after single cell culture into non-adherent 
conditions. Chunk and aggregates from biopsies were transplanted directly into the abdominal 
mammary fat pad of anaesthetised animals in the presence and absence of 100 µl of Matrigel (BD 
Biosystems) depending on the experiment. Tumourspheres and single cells (either from the diagnostic 
biopsies or MCF-7 expressing GFP) were diluted with 50% of Matrigel. Mice were supplemented with 
estrogen and palpated weekly to check possible tumour growth.  
 
2.3.1. TRAIL Treatment in vivo and Tumour monitoring 
Mice were treated with four daily doses of vehicle or with 16 mg/kg of TRAIL via intraperitoneal 
injection.  Mice were monitored at least twice per week via palpation and measurements were taken 
with digital calipers (Fisher Scientific, UK). The size of tumours was calculated as volume in mm3 using 
the formula: Volume = (Length x (Width2))/2.  
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2.4. c-FLIP Genetic Suppression using Small Interfering RNA  
Small interfering RNA (siRNA) targeting c-FLIP, or a non-specific scrambled control were both 
custom designed and used in either fast-reverse transfection (ON-target plus SMART pool GE 
Dharmacon, L-003772-00-0005, UK) or reverse transfections (Stealth siRNA, Invitrogen Life 
Technologies Ltd, UK). Two different constructs of siRNA for c-FLIP were used: (A) targets long and 
short form of c-FLIP and (B) is a smartpool siRNA that targets four siRNA duplexes all designed to target 
distinct sites within the specific gene of interest which target both long and short forms of c-FLIP (Table 
2.5).  
Cells were transfected using lipofectamine RNAimax (Invitrogen) according to manufacturer’s 
instructions. Mastermixes were prepared by diluting siRNA to a final concentration of 10 or 20 nM in 
serum-free OptiMEM (Invitrogen) containing lipofectamine as these molarities have proven to be 
efficient at transfecting cells. 
For the reverse transfection, cells were plated and the transfection performed on the same 
day. Mastermixes were incubated in wells of culture plate at room temperature for 20 minutes prior 
to cell seeding. Then, 5000 to 10000 cells were trypsinised and seeded into 96 well-plates containing 
20 μl of 10 nM siRNA in serum free OptiMEM in a volume of 100 μl per well, together with 0.3 μl of 
Lipofectamine.  
For the fast-forward transfection, cells were plated 24 hours prior to transfection. 20 nM of 
siRNA was prepared in 10 μl serum-free OptiMEM (Invitrogen) before the addition of 0.1 μl of 
lipofectamine. This solution was mixed and kept at room temperature for 5min before 10 μl being 
added to cells in the 96 well-plates containing 90 μl of medium (Table 2.4).  Cells were cultured in the 
presence of siRNA for 48 or 72 hours prior to subsequent assay.  
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Table 2.4. Volumes and concentrations for siRNA transfections.  
96-well 
Culture Plates 
Volume of plating 
media (μl) 
Volume of OptiMEM 
medium (μl) 
Volume 
Lipofectamine 
RNAiMAX (μl) 
Final siRNA 
concentration 
(nM) 
Fast-forward 
Transfection 
80 20 0.3 10 
Reverse 
Transfection 
90 10 0.1 20 
 
Table 2.5. siRNA sequences for fast and reverse transfection. 
Target Sequence 
c-FLIP 1 Sense: GGAUAAAUCUGAUGUGUCCUCAUUA 
Anti-sense: UAAUGAGGACACAUCAGAUUUAUCC) 
c-FLIP 2 (smartpool) Sense: GUGCCGGGAUGUUGCUAUACAAGCAGUCUGUUCAAGGA 
Anti-sense: CAUGGUAUAUCCCAGAUUCCCUAGGAAUCUGCCUGAUA 
Scrambled Sense: GGACUAAUAGUUGUGCUCCAAUUUA 
Anti-sense: UAAAUUGGAGCACAACUAUUAGUCC 
 
2.5. Drug Treatments 
2.5.1. TRAIL and Caspase Inhibitor Treatments  
TRAIL was obtained from Enzo technologies (Human SuperKillerTRAIL trade), diluted 1:4 in 
TRAIL buffer and stored at -80°C.  Cells were treated with 20 -100 ng/ml of TRAIL for 18 hours. Prior 
to TRAIL treatment cells were cultured with the caspase inhibitor Z-VAD-FMK (R&D Systems) for 1 
hour at a concentration of 20 ng/ml.  
 
2.5.2. OH14 Treatment  
OH14 was developed by the Clarkson group, Cardiff University (Figure 2.1). OH14 is a small 
molecule compound selected as part of an in silico screen on the surface of c-FLIP DED1 for compounds 
which interfere with the interaction between c-FLIP DED1 and DED of FADD in order to prevent its 
competitive inhibition of caspase-8 activity. OH14 was diluted from DMSO stock at 100 mM and then 
diluted in medium to give concentrations of 100 µM and 10 µM of OH14. Cells were treated with 100 
µM/10 µM of OH14 and 0.1% and 0.01% of DMSO in the control wells 1 hour before TRAIL treatment. 
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For assays using OH14, caspase inhibitor and TRAIL, cells were first treated with OH14 before, then 45 
minutes between caspase inhibitor and TRAIL.  
 
2.6. Stem Cell Culture and Sphere Assay 
The sphere assay is an assay designed to isolate normal stem cells (mammosphere assay) and 
cancer stem cells (tumoursphere assay) by their ability to survive in anoikis conditions (Dontu et al., 
2003). A very low concentration of cells is plated into ultralow attachment plates (Corning). These 
plates are covered with a covanlently bound hydrophilic, non-ionic, neutrally charged hydrogel, which 
induce anoikis in the bulk population meaning only stem cells are able to survive and form spheroids.  
MCF-7 cells were plated at a density of 5000 cells/ml in serum-free epithelial growth medium 
(MEBM, Lonza), supplemented with growth supplement B27 (Invitrogen), 20 ng/ml EGF (Sigma), 
Insulin (Sigma), and hydrocortisone (Sigma).  
Metastatic cells were plated at a density of 20,000 viable cells/ml in primary culture (exception 
for BB3RC29, which was at a density of 10000 cell/ml). Diagnostic biopsies and post-surgical samples 
were plated using the entire number of single cells harvested after tumour dissociation. These cells 
were seeded in DMEM/F-12 medium, GlutaMAX (Gibco) supplemented with B27 and 0.4% bovine 
serum albumin, 4 μg/ml insulin (Sigma), 20 ng/ml EGF (Sigma), 10 ng/ml bFGF (BD Biosciences), and 
Penicillin (100 U/ml)/Streptomycin (100 U/ml). Alternatively, these cells were cultured in 
MammoCult™ medium with supplements commercially bought from STEMCELL Technologies in ultra-
low attachment plates (Costar, Corning). 
HMECs were seeded at a density of 20000 cells/ml and grown in a serum-free mammary 
epithelial growth medium (MEGM, Lonza), supplemented with B27 (Invitrogen), 20 ng/mL EGF and 20 
ng/mL basic fibroblast growth factor (bFGF) (BD Biosciences), and 4 μg/mL heparin (Sigma). Bovine 
pituitary extract was excluded.  
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For a second passage to test self-renewal, spheres were collected by gentle centrifugation (800 
rpm) after 7–10 days and dissociated enzymatically (10 min in 0.05% trypsin-0.25% EDTA, Invitrogen) 
and mechanically, using a 200 µl pipette. The cells obtained from dissociation were analysed 
microscopically for single-cellularity. Cells were counted under the microscope and it was only 
considered spheroids bigger than 50 μM of diameter. 
 
2.7. Lentiviral Transduction 
MCF-7 cells were transduced using a lentivirus carrying GFP as a fluorescent marker to 
investigate how transduction efficiency could be recapitulated into tumoursphere cultured. The 
lentivirus carrying GFP was a gift from Dr Matt Smalley’s group and it was ready to use. 75000 single 
cells were resuspended in 100 µl of lentivirus and plated under adherent conditions with antibiotic-
free media and 6 – 10 µl of Polybrene ( neutralises charge repulsions between the virus and the cells 
and greatly enhances transduction efficiency).  The medium was changed after 72 hours and GFP 
positive cells were analysed when cells were confluent. 
  To test the efficiency of lentiral transduction in vivo, 80 GFP positive MCF-7 spehres 
resuspended in 100 µl of PBS and 100 µl of Matrigel and then transplanted into the mammary fatpad 
of an immunocompromised mouse, which generated primary tumours over a 7 week period. Palpable 
tumours were excised and viewed under fluorescence microscope along with excised lungs. Primary 
tumours were dissociated using the same protocol used for the patient-derived samples.  
To investigate the transduction efficiency of MCF-7 cells versus primary cells, the metastatic 
cell line BB3RC81 was transduced using the same protocol.  
Additionally, an inducible lentivirus carrying shRNA for c-FLIP was tested in MCF-7 cells. This 
ready-to-use lentivirus expressing GFP and RFP was commercially purchased from AMSBIO (AMS 
Biotechnology Europe Ltd, UK). The shRNA sequences (Table 2.6) were cloned into a lentiviral shRNA 
expression vector that also contains a marker GFP-Puromycin under Rsv promotor. The target is driven 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
74 
 
by a tetracycline CMV promoter. For inducible expression, a tetracycline protein must be present in 
advanced to inhibit the expression.  
35000 MCF-7 cells were cultured in a 24 well-plate  and 24 hours later at 50% confluence, cells 
were transduced with the tetracycline repressor (TetR) particles (AMSBIO) marked with blastomycin. 
The expression could be induced after the addition of tetracycline which removes TetR from the 
promoter. After 72 hours, medium was replaced with complete medium containing 10 μg/ml of 
Blastomycin to select the stably transduced cells. When cells reach confluency, cells were trypsinised 
and the number of RFP positive cells was assessed. RFP positive cells were sorted and plated into 24 
well-plated.  
MCF-7 cells were also transduced with the expression particles to test single transduction 
efficiencies. Cells were transduced at 50% confluency with the inducible expression particles. Medium 
was replaced 72h after with medium containing 10 μg/ml of puromycin.  
All cells were sorted using the BD Accuri and data was analysed using FlowJo software. 
Table 2.6. shRNA sequences for lentiviral transduction. 
shRNA Sense Anti-sense Titer (IFU/ml) 
Negative Control GTCTCCACGCGCAGTACATTT AAATGTACTCGCGTGGAGAC 1.33 x107 IFU/ml 
Sequence #2 AGATTGGTGAGGATTTGGATA TATCCAAATCCTCACCAATCT 1.02 x107 IFU/ml 
Sequence #3 GTGGTTGAGTTGGAGAAACTA TAGTTTCTCCAACTCAACCAC 1.15 x107 IFU/ml 
 
 
2.8. Gene Expression Analysis Using Quantitative Real-Time PCR 
2.8.1. RNA Analysis and Extraction 
Prior to working with RNA, all equipment and work surfaces were cleaned using RNAseZAP 
(Ambion) to prevent contamination from RNAses. Then total RNA was extracted using the RNeasy Plus 
Mini Kit (QIAGEN, 74104). The RNeasy procedure is a methodology for RNA isolation that combines 
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the selective binding properties of a silica-gel based membrane with the speed of microspin 
technology. Biological samples are lysed and homogeneised in the presence of a highly denaturing 
guianidine isothiocyanate containing buffer, which immediately inactivates RNases. Ethanol is added 
to provide appropriate binding conditions, and the samples are then applied to an RNeasy mini column 
where the total RNA binds to the membrane, contaminants are washed away, and RNA is eluted in 
RNase-free water.  
RNA extraction and analysis were performed for HMECs, MCF-7 cells or Metastatic breast 
samples. Culture medium was removed from well-plates, washed with PBS and replaced with 350 μl 
RLT buffer for 5min. After cell lysis cells were mixed 1:1 with 70% ethanol and RNA extraction was 
performed using the RNeasy Plus Mini Kit. After addition of 70% ethanol (350 μl), each samples was 
applied to an RNeasy minicolumn placed in a 2 ml collection tube and centrifuged for 15 seconds at 
8000 xg. The flow-through was discarded and 700 μl of washing RW1 buffer was added to the columns 
and centrifuged for 15 seconds at 8000 x g. The columns were then washed using 500 μl of RPE buffer 
and centrifuged for 15 seconds at 8000 x g and flow-through was discarded. The columns were washed 
again with RPE buffer at the same centrifugation speed but for 2 minutes. To dry the silica-gel 
membrane, columns were centrifuged again for 1 minute at 13200 x g. Finally, the RNA was diluted by 
adding 30 μl pf RNase-free water directly onto the silic-gel membrane and centrifuging the columns 
for 1 minute at 13200 xg. The concentration and purity of RNA preparations were determined by the 
spectrophotometric measurement of the absorvances of the samples at 260 nm and 280 nm using the  
Nanodrop 3000 spectrophotometer (Thermo Scientific). RNA samples were stored at -80°C. 
 
2.8.2. c-DNA Synthesis 
Reverse transcription of 100 ng of RNA was performed with the High-Capacity c-DNA Reverse 
Transcription Kit (ThermoFisher, 4368814). Samples were treated with a mastermix containing: 2µ 10X 
RT Buffer; 0.8 µl 10X dNTP Mix (100 nm); 2 µl 10X RT Random Primers, 1 µl MultiScribeTM Reverse 
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Transcriptase and 4.2 µl of Nuclase-free water giving a total volume of 10 µl. Then, the RNA was added 
giving a final volume of 20 µl reaction.  Samples were incubated on a thermal cycler (BioRad) for 10 
minutes at 25°C, 120 minutes at 37°C and 5 minutes at 85°C. c-DNA was stored at -20°C until future 
use. 
 
2.8.3. qRT-PCR Analysis  
2.8.3.1. Primer Design 
  All primers were commercially bought from ThermoFisher Scientific. Each primer was 
designed to express a FAM-reporter dye with the exception of β-actin controls (ACTB) which was 
designed to carry a VIC-reporter dye so multiplex PCR reactions could be performed (Table 2.7). 
 
Table 2.7. qPCR primers. 
Target Assay ID (Taqman probes) 
β-Actin Hs99999903_m1 
c-FLIP Hs.00390736_m1 
E-cadherin Hs01023894_m1 
N-cadherin Hs00983056_m1 
Vimentin Hs00958111_m1 
Snail Hs00161904_m1 
Slug Hs00161904_m1 
IL-6 Hs00985639_m1 
IL-8 Hs00174103_m1 
 
2.8.3.2. qRT-PCR Reaction and Analysis 
Quantitative real-time PCR reactions were designed to include primers targeting the gene of 
interest and the house-keeping control gene β-actin (ACTB) together in the same well. This method 
gives a more accurate reading of gene expression because it is possible to normalise target 
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amplification specific to the amount of cDNA in each sample.  Experiments were set up in triplicate for 
each biological triplicate. 96 well-plates or 384-well plates and performed on the QuantStudio 7 Flex 
PCR machine (Applied Biosystems) using TaqMan® Universal PCR Master Mix (Applied Biosystems). 1 
µl of c-DNA was added to the well and then 9 µl of a mastermix containing: 5 µl TaqMan Universal 
Master Mix II; 0.5 µl of target primer; 0.5 µl of ACTB primer and 3 µl of RNAse free water. 
The plate was sealed with Micro AMP optical adhesive films (Applied Biosystems) and shortly 
centrifuged to remove any drops from the lid. Plates were then run on a QuantStudio 7 Real-Time PCR 
machine (Applied Biosystems). Conditions used for amplification of cDNA fragments were as follows: 
95°C for 10 minutes, 40 cycles of amplification at 95⁰C for 15 seconds (denaturation), 60⁰C for 1 
minute (annealing/elongation). 
 The expression levels were calculated using the ΔΔCt method and normalised to the 
housekeeping gene β-actin in Excel Office 2013. In these calculations, Ct values were subtracted from 
ACTB control Ct values for individual wells to create a ΔCt, which was then averaged from triplicate 
wells for each sample. To calculate difference in gene expression between samples, ΔCt of treated 
samples was subtracted the to the ΔCt of the untreated control resulting in a ΔΔCt value. This value 
was then calculated as -2 ΔΔCt to give the relative fold change, which was then transformed on a log10 
scale.  
 
2.9. Cell Viability Assay   
Cell viability was assessed by CellTiter blue assay (Promega, UK). This assay measures cell 
viability by measuring their ability to convert the blue dye reasurin into the fluorescent product 
resofurin. Non-viable cells do not have the metabolic capacity to convert this subtract and do not 
produce a fluorescent signal. Cells were washed with PBS and fresh medium was added to the plates. 
Then the appropriate amount of cell titre blue reagent (kept at -20°C and thawed at room 
temperature) was added to the medium (eg. 20 µl of reagent in 100 µl of media). Plates were 
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incubated for 1-4 hours at 37 °C 5% CO2 5% O2. Fluorescence was assessed using a ClarioStar plate 
reader (BMG Labtech).  
 
2.10. Live/dead Assay 
  Live/Dead Assay (Invitrogen) was performed to access the number of dead cells using a the 
far-red fluorescent reactive label. Cells were trypsined and washed in PBS. Red dye was diluted in PBS 
at a ratio 1:20. Cells were centrifuged and resuspended in 10 µl of dye/PBS. Samples were incubated 
at 4C for 15 minutes and then resuspended in 100 µl PBS. Flow cytometry was performed using Accuri 
Flow Cytometer (BD Biosciences) for analysed using FlowJo software.  
2.11. Aldefluor Assay  
Identification of stem cells with high activity of aldehyde dehydrogenase (ALDH) was assessed 
usng the Aldefluor assay (Stemcell Technologies). The amount of fluorescence released by the product 
is directly proportional to the ALDH activity in cells. Dissociated single cells were suspended in 
Aldefluor assay buffer containing an ALDH substrate, bodipyaminoacetaldehyde (BAAA) at 1.5 mM, 
and incubated for 45 minutes at 37ºC. To distinguish between ALDH-positive and -negative cells, cells 
were incubated under identical conditions in the presence of a 2-fold molar excess of the ALDH 
inhibitor, diethylaminobenzaldehyde (DEAB) previous the incubation. Cells were centrifuged at 12000 
rpm and resuspended in 100 µl of PBS. Data was acquired on a flow cytometer, Accuri Flow Cytometer 
(BD Biosciences) and analysed using the FlowJo™ software. 
2.12. Immunofluorescense of Fixed Cells 
MCF-7 cells were seeded onto sterile glass coverslips previously place into 24 well-plates at a 
density of 10000 cells/ml. On the day of analysis, cells were rinsed with PBS to remove any dead cells. 
Cells were fixed with 4% formalin for 15 minutes followed by 3 x 5minute washes in PBS. Non-specific 
epitopes were then blocked with 10% normal goat serum (Dako) in PBS with 0.5% triton-X (Sigma) for 
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1 hour. Cells were incubated with primary antibody overnight at 4°C (Table 2.8). A negative control 
without primary antibody was used for every sample. After another 3 x 5 minute wash with PBS, cells 
were incubated in fluorescence-conjugated secondary antibodies (Invitrogen) diluted in 10% normal 
goat serum (Dako) and containing DAPI nuclear stain at a ratio of 1:1000 (Invitrogen) for 1 hour. Cells 
were then washed for 3 x 5 minute in PBS and mounted in Mowiol solution (Sigma). Cells were 
visualised on a confocal microscope from Leica. 
 
 Table 2.8. Antibodies used for immunofluorescence. 
 
 
 
2.13. Statistical Analysis 
Independent experiments were performed in triplicate and data are represented as mean +/- 
standard deviation (SD) or standard of mean (SEM) as stated in respective legends.  Statistical analysis 
was used using Graphpad Prism version 6.0. Unpaired paired data set were parametrically tested using 
Student’s t test. A value of probability (p) equal or inferior to 0.05 was considered to be statiscally 
significant.  
Pearson’s correlation coefficient (r) was calculated to statiscally investigate whether two sets of 
groups were linearly associated. The correlation coefficient ‘r’ was calculated using Excel 2016 
software. Results were considered significant if the calculated value of r was greater than or equal to 
the tabulated value at the 5% significance level for n – 2 degrees of freedom.   
The waterfall plots were used to help and visualisation and interpretation of the TRAIL treatment 
on all the samples used in this study. Graphs were ploted from the sample with the least response to 
the sample that had the best response to TRAIL treatment.  
Primary Antibody (Dilution) Secondary Antibody (Dilution) Species Company 
E-cadherin (1:100) Goat Anti- Mouse (1:200) Mouse Abcam 
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2.14. Workflow Chart 
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CHAPTER 3                     
Optimising Cell Culture Conditions and 
Lentiviral Transduction for Primary 
Human Breast Biopsies 
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3. Optimising Cell Culture Conditions and Lentiviral Transduction for Primary Human 
Breast Biopsies 
 
3.1. Introduction 
Primary tumour heterogeneity and early stages of breast tumourigenesis are more 
appropriately modelled by cultures from dissociated primary breast tumours than by established 
transformed cell lines. These ex vivo models, better mimic the characteristic features of primary breast 
cancer (Perou et al., 2000). Assays utilising primary cultures provide important models for the study 
of breast cancer pathogenesis including metastatic disease, in vivo assessment of drug sensitivities 
and discovery of new therapeutics (Drews-Elger et al., 2014). Furthermore, hetero-transplantation of 
primary tumour biopsies from patients into immune-deficient mice, patient-derived xenografts 
(PDXs), has many advantages over xenografts using cancer cell lines. Histologically, PDX models are 
able to retain the architecture and stromal components of the original tumour potentially 
representing the complex biochemical and physical interactions between the cancer cells and their 
microenvironment, not observed in cell lines (Tentler et al., 2012). At the cellular level, PDXs preserve 
the inter-tumoural and intra-tumoural heterogeneity, as well as the phenotypic and molecular 
characteristics of the original tumour, including chromosomal copy number variants, single-nucleotide 
polymorphisms and gene expression profiles (reviewed by Choi et al., 2014.) Thus, the tumours from 
these transplants can be more directly compared to the original patient tumour biopsies (Marsden et 
al., 2012). Moreover, given the current clinical challenge of eradicating metastatic disease, there is a 
pressing need for models that better predict metastatic behaviour.  
There is robust evidence supporting a potent effect of c-FLIP suppression and TRAIL treatment 
on bCSCs in cell lines (Piggott et al., 2011).  As these studies have so far only been performed on breast 
cancer cell lines, the key question still remains whether these findings have direct clinical relevance 
for breast cancer patients.  As such, this study will test the hypothesis that c-FLIP suppression 
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combined with TRAIL reduces cell viability of primary breast cancer cells (bCSCs) including bCSCs ex 
vivo.  To achieve this aim, breast cancer samples were collected from the clinic and maintained in 
different culture conditions supporting bCSC growth. These cells were then to be used to investigate 
breast cancer cell response to TRAIL alone and in combination with c-FLIP suppression. A range of 
tumour types were tested to determine if this strategy is most effective in a specific cohort of patients 
or if this approach may be effective across a broad spectrum of breast cancer subtypes as 
demonstrated in cells lines (Piggott et al., 2011). Moreover, we wished to investigate as to whether 
serial passaging of patient-derived xenografts altered their phenotype or morphology in order to 
determine the translational relevance of these models. 
 
3.2. Results 
3.2.1. Different tumour samples have different sphere forming efficiency   
During the course of this three year study, 239 samples have been processed and cultured ex 
vivo. Due to the different parameters that affects quality and quantity of the samples, such as: 
differing proportions of tumour versus normal tissue; heterogeneity of relative epithelial, adipose, 
connective tissue, haematopoeitic cells and non-tumour content within tumours; and the variability 
associated with mechanical and enzymatic digestion of bulk tissues; the efficiency of recovery of 
epithelial cells from primary biopsies were subject to substantial variation. Of the 239 tumour samples 
collected: 6.3% (n=15) were subsequently characterised as normal breast samples including 
microcalcifications and cysts that naturally occur within the breast due to the aging process; 18.8% 
(n=47; female + male) were benign breast conditions such as: fibroadenomas; sclerotic tissue and 
hyperplasia; and 74.0% (n=177; diagnostic biopsies + surgical samples; female + male) were found to 
contain bone fide tumour. In regards to grade: 8.0% (n=14) of the tumour samples were grade 1; 43.0% 
(n=76; female + male) were grade 2 and 36.9% (n=65) were grade 3 (Table 3.1). Additionally, 37.9% 
were pre-menopausal; 64.8% post-menopausal and 2.1% were peri-menopausal.  
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Table 3.1. Statistical analysis of the samples received. 
 
 
 
 
 
 
 
 
 
 
 
Samples (n=239) 
Characteristics Female (n=236) Male (n=4) 
Age (Range) 22-95 45-85 
Normal breast samples 15 (6.3%) 0 
Benign condition samples 45 (18.8%) 2 (0.8%) 
Diagnostic biopsy tumour samples 87 (36.4%) 0 
Surgical biopsy samples 89 (37.2%) 1 (0.4%) 
Family history 5 (2.8%)  - 
Grade 
Grade 1 14 (8.0%) 0 
Grade 2 75 (42.6%) 1 (0.4%) 
Grade 3 65 (36.9%) 0 
Previous therapies 
Chemotherapy 7 (4.0%) - 
Radiotherapy 5 (2.8%) - 
Endocrine 13 (7.4%) - 
Surgery 3 (1.7%) - 
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The initial proportion of viable samples growing under culture was very low and to overcome 
this issue the protocol to process these samples has been optimised. Firstly, we adopted a method 
used by Marsden et al., 2012: a mechanical dissociation with a scalpel and enzymatic dissociation with 
collagenase and hyaluronidase. 15 samples were dissociated using this method and only 3 samples 
have grown spheres under culture (20%). Further optimisation was introduced to improve enzymatic 
dissociation of samples. For enzymatic dissociation, a collagenase and trypsin mix was replaced by the 
Miltenyi Biotec “tumour dissociation kit” which was introduced to alleviate undue stress on the cells 
imparted during long enzymatic digestion, thus increasing cell viability. To improve mechanical 
dissociation of samples a scalpel was also replaced by a McIlwain mechanical chopper. This was 
consistent with a study conducted by Turin et al. 2014, where two different approaches to obtain 
viable cells from surgical samples were performed:  the use of mechanical disaggregation with a cell 
scraper and a Gentle MACS Dissociator. Here, it was shown that primary culture was considered 
effective if they met the following requisites: presence of a pure line of tumour cells confirmed by 
morphological and immunological experiments; sufficient cell number to perform the previous 
experiments and cell survival when cells are frozen and subsequently thawed. They found that the 
disaggregation using the GentleMACS improved the capacity to establish the tumour cell lines with a 
successful rate of 50% and resulted in 100% efficiency when generating primary cultures from pleural 
effusions (Turin et al., 2014).  
After dissociation, cells were originally washed with RPMI and passed through a 40 µM 
strainer, however, cells were found to be retained in the strainer due the presence of the adipose and 
connective tissue resulting in a reduced cell recovery. Thus, a 70 µM strainer was found to be more 
suitable for the protocol, increasing the number of cells collected for plating and substantially 
decreasing the probably of cell-clogging whilst still providing single cell isolates. Furthermore, before 
cell culture, the number of cells counted and the number of cells extracted did not correlate nor 
predict the sphere forming efficiency. This might be explained by the heterogeneity of the tissue 
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processed. Within the isolated cells, red blood cells, adipose cells, fibroblasts, etc., are also present 
with the tumour cells. Consequently, prior to culture, a red blood cells lysis buffer was used to 
eliminate red blood cells. To increase the purity of epithelial cells, cells were incubated in adherent 
conditions for 1 hour in DMEM to allow the fibroblasts to attach to the plate surface leaving a 
suspension of purer epithelial cell population that could be collected (Smalley et al., 2007).  
After fibroblast removal, the medium was removed and cells were centrifuged and 
resuspended in tumoursphere medium. Initially, cells were cultured in the tumoursphere medium 
optimised for use in cell lines. To increase the sphere forming efficiency, the cell line tumoursphere 
media was replaced by medium detailed in the Marsden et al. 2012 protocol, which includes the 
addition of fresh growth factors (EGF and bFGF) prior to every tumoursphere culture. However, as the 
number of spheres did not substantially increase with these medium changes, another tumoursphere 
medium, Mammocult™ (Stem Cell Technologies, Canada), was used in attempt to further improve the 
sphere forming efficiency.  Mammocult™ significantly increased the number of spheres in four out of 
seven samples. However, the increase was relatively small. Despite of existing a trend towards the 
Mammocult medium, this increase in the number of spheres was not much higher than the other 
medium (Figure 3.1 A).  
Analysing all the samples, were able to calculate: the percentage of viable samples (samples 
that formed any number of spheres under culture) and successcul samples (samples that formed more 
than 20 spheres in three wells used for control). Therefore, within normal or breast benign conditions, 
48.8% (n=29) of the samples were viable, while out of all the diagnostic biopsies, only 36.7% were able 
to grow spheres under culture (Table 3.2). In regards to the percentage of successful samples within 
the viable samples: 75% (n=32) of the normal and benign conditions and 28.9% (n=39) of the 
diagnostic samples were able to successfully  form more than 20 spheres (Table 3.2).  
Spheres formed from biopsies may not be derived purely from tumour cells as, despite the 
isolation step, it is possible that benign (or normal) stem/progenitors could be plated among the 
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tumour cells. To overcome this problem, core tumour tissues have been extracted from surgically 
resected tumour samples where nearly the entire sample processed is tumour tissue. However, 
despite this enrichment for tumour cells, the total number of cells extracted did not increased 
compared to diagnostic biopsies (Figure 3.1 B) and the percetange of viable samples only increased 
8%. However, the efficiency of these tumour-rich samples to successfully form spheres increased by 
47.6% (Table 3.2). This leads us to believe that the efficiency of successfully growing spheres is not 
related to the number of cells extracted but rather to the type (number of tumour cells) and 
proportion of stem-like progenitors within the samples and that cell number cannot predict the 
number of spheres that can be generated in culture.  
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Figure 3.1 Number of cells and of spheres in breast samples| | A. Number of spheres in 7 samples 
(A-G) cultured with Marsden and Mammocult™ media. | B. Number of cells extracted from benign, 
diagnostic and surgical breast samples. | Bars represent mean +/- SD; *(p) < 0.05; t-test. 
Table 3.2. Statistical analysis of cell number and spheres formed under culture of the breast samples 
received from the clinic. “Viable” samples refers to samples that have formed any number of spheres 
under culture. “Successful” refers to the samples within the viable samples that formed more than 20 
spheres. 
Breast samples (n=239) 
 Normal + Benign samples Diagnostic biopsy 
tumour samples 
Surgical 
samples 
Number of processed samples 
(total %) 
62 (25.9%) 87 (36.4%) 90 (37.7%) 
Total number of cells 
extracted (Mean) 
375000 
(178869) 
 
525000 
(95571) 
 
425000 
(109704) 
 
Average number of spheres 51 37 57 
% “Viable” Samples 48.8% 36.7% 44.5% 
% “Sucessful” Samples  75.0% 28.9% 76.5% 
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The short-term survival of primary cells under adherent conditions and poor propagation 
during passages unable to achieve our objective of subjecting cells to shRNA and siRNA for c-FLIP, prior 
to tumoursphere culture, as although a mean of 500,000 cells would be sufficient for knockdown 
protocols. Also, attempts to increase cell number by passaging the spheres in non-adherent culture 
were unsuccessful since the cell numbers remained stable over several passages and ultimately 
declined.  However, we were able to test the effect of TRAIL treatment alone, through administration 
of the peptide to the culture medium.  Furthermore, we adopted a pharmacological inhibitor of c-FLIP, 
OH14, for use in sphere conditions.  
Using these small molecules we set out to correlate histological and molecular subtypes of the 
samples with tumoursphere forming capacity, and ultimately (Chapter 5) their susceptibility to TRAIL 
stimulation and/or c-FLIP suppression.  
The most common histological subtype was Ductal (50% of the tumour samples), including 
Invasive Ductal and/or DCIS with the lobular subtype being the second most common (8%). We have 
received additional histological subtypes such as: high grade comedo; Invasive Mucinous; Phylloides; 
Pappilary; Micropapillary and Cribiform DCIS. However, very few of these samples could be cultured 
in sphere conditions such that no statistically robust data could be generated.  The Invasive 
Ductolobular subtype had the highest sphere forming capacity, with an average of 78 spheres 
although only two samples of this kind were collected. The Ductal subtype had an average of 73 
spheres and Lobular 18 (Figure 3.2. D) demonstrating that ductal subtype might have a higher capacity 
than lobular at generating spheres. In addition, to histological grade and molecular subtype 
comparisons, receptor expression was believed to be another potential predictive marker of sphere 
forming capacity. Estrogen Receptor (ER) – positive (+ve) samples and ER- negative (-ve) samples 
generated an average of 58 and 53 spheres, respectively (Figure 3.2. E). The molecular subtype luminal 
B (ER +ve and HER2 +ve) generated an average of 64 spheres; luminal A (ER +ve HER2-ve) an average 
of 59 spheres; HER2 (ER -ve HER2 +ve) generated 30 spheres and the triple negative, basal-like (ER -
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ve HER2 -ve) counted with 54 spheres (Figure 3.2 F). This may suggest  that HER2 may possibly play an 
important role in stem cell survival in mammosphere conditions.  This is consistent with previous 
reports of the role of HER2 in CSC-like activity in vitro (Farnie et al., 2007; Korkaya et al., 2008).   
Hitherto, 14 samples of grade 1 have been collected, however, none were capable of 
generating spheres.  Grade 2 samples and grade 3 samples generated an average of 62 and 79 spheres, 
respectively (Figure 3.2 C), highlighting the importance in grade for sphere forming capacity.  
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Figure 3.2 Sphere forming efficiency of the breast samples. Y axes represents number os spheres 
formed from normal/benign brest condtions, diagnoastic biopsies and surgical samples. | A. Number 
of spheres in benign and tumour samples. | B.  Number of spheres in diagnostic and surgical samples 
| C. Number of spheres in grade 2 and grade 3. | D. Number of spheres in ductal, lobular and 
ductolobular breast samples | E. Number of spheres in estrogen receptor positive and estrogen 
receptor negative tumours. | F. Number of spheres for ER and HER2 receptors: luminal B (ER +ve HER2 
+) luminal A (ER +ve HER2 -ve); and triple negative (ER -ve and HER2 -ve). | Bars represent mean +/- 
SD.  
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3.2.2. Patient-derived xenografts increase the number of cells for in vitro 
studies 
Due to the number of cells not being sufficient to successfully address the aforementioned 
aims, we investigated another methodology using patient-derived xenografts (PDXs) to address this. 
The rationale for this was that PDX tumours would provide a larger, more homogeneous tumour tissue 
sample for processing.  For this purpose, chunks, aggregates, single cells and spheres from the 
biopsies/surgical samples were orthotopically xenografted into immune-compromised NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. These are immunodeficient mice, which lack B- and T-cell function 
but retain innate cellular immunity (including natural killer cells, macrophages). 
Overall, ER negative tumours achieved a more successful engraftment rate than ER-positive 
tumours (45% and 7%, respectively; Table 3.3). The efficiency of transplanting aggregates and single 
cells was 0% (Table 3.3).  Transplanting 30 spheres generated from ex vivo culture samples 120 and 
123 were able to generate metastases in the lungs but no primary tumour, whereas 10 spheres from 
sample 7, and 89 spheres from the surgical sample 202 were not able to form tumours in the primary 
site or metastasise. Interestingly, transplantation of 244 spheres from a tumour harvested from the 
PDX 151 model (this PDX was previously established by transplanting a 2mm chunk) was able to 
generate a primary tumour and lung metastases (Table 3.3). Transplantation of tumour chunks proved 
to be the most successful mechanism for establishing tumours in NSG mice where transplanting 2 mm 
tumour chunks prepared directly from the biopsy resulted in approximately 29% of xenografts 
generating primary tumours and metastases (Table 3.3). Additionally, ER -ve tumours (2/4 – 50%) have 
a higher engraftment rate than ER +ve tumours (2/10 – 20%), however, this did not correlate with 
histological subtype (Table 3.3). 
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Table 3.3. Patient-derived xenogratfs characteristics vs Transplantation Methods and Primary tumour 
Metastasis forming efficiency. (1) – unknown (2) Sample is still growing in vivo. 
 
Transplantation 
Method 
Sample characteristics Primary 
tumour 
Metastasis 
No Type Grade ER HER2 
Chunk 
 
11 Invasive Ductal 2 + - ✗ ✗ 
12 Invasive Ductal 1 + (1) ✗ ✗ 
61 Invasive Lobular  2 + + ✓ ✗ 
72 Invasive Ductal 3 - - ✓ (1) 
110 Invasive Ductal 2 + - ✗ ✗ 
151 Invasive Ductal 3 - - ✓ Lung 
160 Invasive Ductal  3 + - ✗ ✗ 
188 Invasive Ductal + DCIS 3 - + ✗ ✗ 
190 Lobular pleomorphic 3 + - ✗ Kidney 
191 Invasive Ductal + DCIS + 
LCIS 
3 + - ✗ Lung 
204 Invasive Ductal 3 + - ✗ Lung 
218 Invasive Ductal 2 + - ✗ ✗ 
227 Invasive Ductal 3 - - ✗ ✗ 
231 Invasive Ductal 3 + + ✓ (2) 
232 Invasive Ductal 3 - - ✗ ✗ 
253 Invasive Ductal + DCIS 2 + + ✗ ✗ 
255 Invasive Ductal + DCIS (1) + - (2) (2) 
262 Invasive adenocarcinoma 3 - - ✓ (1) 
262 Invasive adenocarcinoma 3 - - ✓ (1) 
Single Cell 60 Invasive Carcinoma (1) - - ✗ ✗ 
Aggregates 
 
62 Invasive Ductal 2 + - ✗ ✗ 
Spheres 7 DCIS (1) (1) (1) ✗ ✗ 
120 High grade comedo + 
cribiform DCIS 
(1) - (1) ✗ Lung 
123 Invasive Ductal + High 
grade DCIS 
3 + + ✗ Lung 
151 Invasive Ductal 3 - - ✓ Lung 
202 Invasive Ductal + High 
grade DCIS 
2 + + ✗ ✗ 
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Moreover, the number of cells extracted from PDXs was significantly higher than from biopsies 
and surgical samples (Figure 3.3 A). The number of spheres generated from the tumour harvested 
from the PDX was higher than the original biopsies A, B and C. Samples A, B and C tissues were cut 
into 2 mm chunk for orthotopic transplantation into mammary fat pad and processed for in vivo 
studies and the rest of the tissue for in vitro culture. The tissues plated in sphere conditions generated 
a low number of spheres (Table 3.4). However, 7 weeks after xenograft a primary tumour in the 
mammary gland was palpable and the tumours were dissected and dissociated using the same 
protocol used for biopsies. The single cells were plated under non-adherent conditions and samples 
A, B and C generated 61, 49 and 357 spheres, respectively indicating xenografts may be a suitable 
model to increase cell number and culture efficiency (% of viable and successful samples). This higher 
number of cells and spheres was probably due to the much larger tumour size that could be acquired 
from PDX tumours compared to biopsies (Figure 3.3 D and E). For example, a 2 mm chunk of the 
sample A was able to generate an 8mm diameter tumour after 8 weeks in vivo (data not shown) which 
could be successfully dissociated to generate a high number of spheres.   
Furthermore, serial passaging of established PDX models was investigated to determine 
whether the key characteristics (ER and HER2 status) remained stable through further tumour 
generations. To date, PDX 151 has been passaged 4 times and has maintained a stable phenotype with 
identical ER and HER2 status throughout passages. This phenotype was analysed by Dr Fauad Alchami, 
a histopathologist at The Heath Hospital in Cardiff and receptor status was analysed using 
immunohistochemistry by Dr. Julia Gee in School of Pharmacy, Cardiff University (data not shown). 
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Table 3.4. Number of cells extracted and tumouspheres formed from original tumours vs PDXs. 
Number of cells and spheres formed from three original tumour (A, B and C) and respective PDXs. 
PDXs were generated by transplanting 2mm chunks into mice and a palpable primary tumour was 
grown in 7 weeks.  
Sample 
Original tumour PDX 
No. cells extracted No. spheres formed No. cells extracted 
No. spheres 
formed 
A Invasive Lobular 
G2 ER+ HER2+ 
Undetermined 0 30000 61 
B Invasive Ductal 
G3 ER- HER2+ 
Undetermined 3 Undetermined 49 
C Invasive Ductal 
G3 ER- HER2+ 
2500 19 1250000 357 
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Figure 3.3 A. PDX tumours. | A. Number of cells extracted from diagnostic biopsies, surgical samples 
and PDXs Bars stood for mean +/- SD. *(p)<0.05; t-test.  | B. A 2mm chuck from  an Invasive Ductal G3 
ER- HER+ biopsy was transplanted into the mammary fat pad (PDX B). 7 weeks after, the primary 
tumour was dissected and dissociated into single cells. | C. Tumourspheres formed after 5 days under 
non-adherent culture from the PDX B. | D. Surgical samples ready to be mechanically dissociated. | E. 
Primary tumours generated from a PDX.  
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3.2.3. MCF-7 cells are efficiently transduced with a lentivirus carrying GFP 
compared to primary cells 
Luminal-like breast tumour cell lines, which represent 60-70% of the breast cancer population 
are resistant to TRAIL killing but can be sensitised to TRAIL through suppression of c-FLIP (Safa et al., 
2008; Piggott et al., 2011). In order to determine if this is also true for primary tumours, we proposed 
to suppress c-FLIP in primary breast cancers using: 1) an inducible lentivirus carrying shRNA to inhibit 
c-FLIP gene expression and 2) OH14, a pharmacological compound that binds to c-FLIP DED domain 
inhibiting c-FLIP binding to FADD in the disc complex.  
 Since the aim was to use an inducible lentivirus for tumoursphere culture of breast primary 
tissues, it was important to optimise conditions first in an immortalised breast cancer cell line with 
known tumoursphere characteristics. Therefore, transduction efficiency of a constitutive lentiviral 
vector carrying GFP into MCF-7 cells was investigated and how this efficiency could be recapitulated 
into tumoursphere culture. These cells were transduced under adherent conditions and GFP positive 
cells was assessed by flow cytometry, which showed 87.9% of MCF-7 cells expressing GFP (Figure 3.4 
B). Cells were sorted and 100% GFP positive cells were plated into non-adherent conditions to 
propagate tumourspheres (Figure 3.4 C). On second passage, tumourspheres were dissociated and 
cells were analysed by flow cytometry which showed 99% of the MCF-7 population expressing GFP 
(Figure 3.4 D). Thus, MCF-7 CSCs can be transduced in adherent culture and with high efficiency by 
lentivirus to stably express GFP in subsequent progenitor cells. Furthermore, 80 GFP positive MCF-7 
spheres were transplanted into the mammary fatpads of recipient immunocompromised mice, which 
generated primary tumours over a 7 week period. Palpable tumours were excised and viewed under 
fluorescence microscope along with excised lungs. Primary tumour exhibited strong fluorescence, 
indicating that a high proportion of cells retained GFP expression while small foci of fluorescence were 
seen within the lung tissue, indicating the presence of metastatic tumours (Figure 3.4 E). Primary 
tumour was dissociated and single cells were plated in sphere conditions. Seven days later, spheres 
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were dissociated and single cells from these cultures were assessed by FACS. Cell analysis showed that 
94.5% of the cells were expressing GFP (Figure 3.4 F). These data confirm the stable expression of GFP 
in stem/progenitors and their progeny. 
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Figure 3.4. MCF-7 expressing GFP. | Pre- transplantation. A. Adherent culture 7 days post-infection with a 
lentivirus carrying GFP.| B. MCF-7 GFP +ve cells were analysed by flow cytometry which showed 87.9% GFP +ve 
cells. | C. Cells were sorted and plated under sphere condition. | D.  After second passage, spheres were 
dissociated and 99% were expressing GFP (FACS plot showing representative percentage of MCF-7 expressing 
GFP (blue) compared to the control after GFP-cell sorting (red). | Post-transplantation. E. 80 GFP positive MCF-
7 spheres were transplanted into the mammary fatpads of recipient immunocompromised mice, which 
generated primary tumours after 7 weeks. Then, primary tumour (left side) and lungs (right side) were harvested 
and observed through a fluorescent microscope. White arrows show lung metastases. | F. Three primary 
tumours were harvested (5.1 mm; 4.4 mm and 3.1 mm) and one of the primary tumours was dissociated and 
cells were plated under sphere conditions (left side). One week after, spheres were disaggregated and cells were 
analysed by FACS. 94.5% of the MCF-7 cells were GFP +ve (right side). | Scale bars represent 200 µm.  
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Parallel to this transduction, we tested an inducible lentivirus acquired from AMSBIO (AMS 
Biotechnology Europe Ltd, UK), which expressed GFP and RFP (RFP for the lentiviral particles 
expressing the tetracycline regulator (TetR) and GFP for the lentivirus expressing short hairpin RNA 
(shRNA) to target c-FLIP expression). The efficiency and stability of the shRNA lentiviral construct was 
tested initially in MCF-7 cells.    
MCF-7 cells were transduced with different concentrations of TetR particles and different 
concentrations of two different shFLIP constructs (seq#2 and seq#3, Table 3.5).  Cells were treated 
with different concentrations of puromycin to select cells that were tranduced with TetR particles and 
blastomycin to select cells with shFLIP. A lentivirus lacking a sequence to target c-FLIP was used as a 
negative control. To enhance transduction efficiency, cells were treated with 8-12 µg/ml of polybrene. 
Cells were transduced according to the manufactures protocol (Section 2.7) where cells are firstly 
transduced with the TetR particles and transduced with the shFLIP construct 24 hours later. The 
ultimate objective was to work with an inducible dual transduction lentivirus but first the efficiency of 
single transductions was tested. Transduction with TetR particles was very low, only 19% of the cells 
expressed RFP using the highest titration of the virus (Table 3.5) Moreover, using different 
concentrations of the shFLIP vectors for sequence 2 (seq#2) and sequence 3 (seq#3) resulted in an 
equally low percentage of GFP positive cells, with the negative control giving the highest transduction 
efficiency (Table 3.6). Cells were sorted and 100% of GFP +ve cells were plated into adherent 
conditions to collect RNA for c-FLIP gene analysis by qPCR. qPCR analysis of c-FLIP gene expression 
showed that seq#3 was effective at knocking down c-FLIP gene by 80% using the lowest concentration 
of virus (#3_15) (Figure 3.5). However, after a few passages the number of GFP +ve cells was 
significantly lower showing that the lentivirus transduction was unstable (perhaps due to GFP 
silencing) and subsequent progenitor cells were not expressing GFP. Using the dual transduction, TetR 
particles plus shFLIP for the seq#3 showed an efficiency of 0.5% when cells were analysed by flow 
cytometry (data not shown). 
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Table 3.5. Efficiency of a lentivirus carrying RFP in MCF-7 cells. 35000 MCF-7 cells were plated in 24 
well-plates and 24h after cells were transfected at 50% confluency. Cells were treated with 
blastomycin for antibiotic selection and 8 µg/ml of polybrene. After cell growth, cells were analysed 
by flow cytometry to measure the percentage of cells expressing RFP.  
TetR (µl) (Titer- 5x10
7 
IFU/ml) 
% RFP+ cells 
10 3 
20 4.1 
30 5.5 
50 19 
 
Table 3.6. Efficiency of a lentivirus carrying shFLIP and GFP in MCF-7 cells. 35000 MCF-7 cells were 
plated in 24 well-plates and 24 after cells were transfected at 50% confluency. Cells were treated with 
puromycin for antibiotic selection and 8 g/ml of polybrene. After cell growth, cells were analysed by 
flow cytometry to measure the percentage of cells expressing GFP.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. c-FLIP expression after transduction with a lentivirus carrying shRNA for c-FLIP. Relative 
fold change in c-FLIP gene expression. Cells were transduced using three different concentrations of 
the sequence 3 (#3) as seen in table 5.2 and 15 days after RNA was extracted and c-FLIP expression 
was analysed using qPCR.   
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Subsequently, lentivirial transduction in primary cells was investigated. A simple lentiviral 
vector carrying only GFP was used to determine the efficiency of lentiviral transduction in primary 
cells. The lentivirus efficiency was investigated using metastatic primary cells obtained from a pleural 
effusion (BB3RC81). Using the same protocol as for the MCF-7 cells, the efficiency was very low; only 
4% of the total population was expressing GFP (Table 3.7). To improve this efficiency, the protocol was 
optimised by centrifuging the cells with the virus to increase the number of viral particles entering 
into the cells. In addition, cells were plated with 50% of concentrated virus plus 50% of media. 
However, this efficiency only improved to 14% of the total population expressing GFP (Table 3.8). 
During this optimisation, it was determined that the optimal number of cells (for the BB3RC81) for 
lentiviral transduction was 10,000 cells, below this number, cells did not form more than 10 spheres 
and higher numbers of cells (50000 and 100000) appeared to decrease the transduction efficiency 
(Table 3.6). Thus, the efficiency on transducing primary cells was very low compared to the 89.7% 
efficiency observed with the transformed MCF-7 cell line.  
Moreover, the lentiviral vector targeting c-FLIP was not stable in MCF-7 cells and it is reasonable 
to suggest that this efficiency would be even lower in primary cells. Yet, another primary cell line or 
another vector from another company could be optimised to extend the voracity of these results. 
Having no strategy to inhibit c-FLIP in a long and inducible manner, we opted to suppress c-FLIP using 
a transient knockdown (siFLIP) and using the in house made c-FLIP “inhibitor”, OH14. 
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Table 3.7. Lentiviral transduction efficiency in the surviving population in tumoursphere assay using 
primary cells. Primary cells were transduced with a lentivirus carrying GFP. Cells were resuspended in 
the virus and plated for 72h. Media was changed after 72h. Spheres were counted after 7 days, 
dissociated to single cells and sorted for cells expressing GFP. After sorting cells GFP +ve cells were 
plated under non-adherent conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.8. Lentiviral transduction efficiency in the surviving population in tumoursphere assay using 
primary cells. Primary cells were transduced with a lentivirus carrying GFP. Cells were resuspended in 
the virus, centrifuged and plated with a ratio 1:1 with media:virus. Media was changed after 72h. 
Spheres were counted after 7 days, dissociated to single cells and sorted for cells expressing GFP. After 
sorting cells GFP +ve cells were plated under non-adherent conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
BB3RC81 
Number of spheres 
GFP+ cells 
Number of cells % GFP+ cells Number GFP+ cells 
Control (4000) 11 0 0 
500 0 0 0 
4000 0 0 0 
10000 N/A  4 43 
BB3RC81 
Number of spheres 
GFP+ cells 
Number of cells % GFP+ cells Number GFP+ cells 
Control (4000) 15 0 0 
500 1 0 0 
4000 8 0.5 0 
10000 N/A  14 110 
50000 N/A  3.5 - 
100000 N/A  0 0 
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3.3. Discussion 
The aims for this project were straight forward: to generate a sufficient number of tumour 
cells from primary culture to enable shRNA transfection prior to propagation of tumourspheres.  There 
were a number of key technical hurdles to overcome related to tumour heterogeneity and cell viability 
in vitro. After biopsy collection, the core tumours were dissociated and primary cells cultured under 
non-adherent conditions. Due to the nature of some samples, the obstacle to culturing these cells was 
determined to be having a sufficient number of cells after harvest that will allow enough replicates to 
perform a statistically robust experiment.  Moreover, due to the large variety of breast tumour sub-
types it proved difficult to obtain sufficient sample numbers to reach statistical power when 
correlating the response to treatment with tumour subtype.  Furthermore, among the several biopsies 
that we received, we observed that in most cases it was the quality (high proportion of adipose tissue; 
red blood cells and non-tumour tissue) of the original tumour that determined yield and not the 
amount of the tissue. The efficacy in establishing and maintaining tumour cells in culture depends on 
the characteristics of the original sample, which in most cases could be rich in connective and adipose 
tissue, in some cases small fragments were obtained at the completion of the dissociation protocol 
and it was not possible to count the number of cells that were cultured. One study tried to establish 
primary cultures from surgical breast samples using mechanical and enzymatic dissociation and 
culture with feeder cells (Janik et al., 2016). This feeder layer has been associated with numerous 
technical issues, including incomplete inactivation of fibroblasts leading to overgrowth of feeder cells, 
and there is a risk that feeder cells will not be able to provide epithelial cancer cells with adequate 
support (Pourreyron et al., 2011).  Janik et al., 2016 found that using Geltrex coating had a similar 
efficiency to feeder layer, while being substantially less complicated and easier to validate. Also, 
commercial primary cell media demonstrated lower efficiency than tissue-specific ones. This strategy 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
105 
 
using feeder cells could be adopted for optimisation of our protocol in the future to improve primary 
cell growth in adherent conditions.   
During the 3 year project, 239 breast samples were processed from the clinic with two thirds 
being characterised as carcinomas, half derived from diagnostic biopsies and half from surgical 
resections. 
In our study, the majority being tumour samples, the non-cancer samples (normal and benign 
breast conditions) had a slightly higher percentage of viable cells than diagnostic biopsies and surgical 
samples (49%; 37% and 45%, respectively) (Table 3.2). 
Furthermore, the surgical samples had a higher rate of viable samples compared to the 
diagnostic samples, 44.5% and 36.7%, respectively. Additionally, surgical samples had a higher rate of 
successful samples compared to the diagnostic samples, 76.5% and 28.9%, respectively (Table 3.2). 
The size of the surgical resection material was similar to the diagnostic biopsies which may explain 
why the number of cells extracted and  number of spheres were similar between those samples (Figure 
3.1 B and 3.2 B). However, as surgical samples were more enriched with tumour cells, which explain 
the higher rate of successful samples compared to diagnostic biopsies.  
Moreover, tumourspheres generated from grade 3 breast cancers were found to form a 
greater number of spheres compared to grade 1 which is consistent with previous studies (Allan, 
2011). Previous studies have also detailed that grade 3 tumour samples generate a greater number of 
spheres when compared to the grade 2, suggesting that more aggressive samples have a higher sphere 
forming capacity (Farnie et al., 2007). However, in the data presented here, the number of spheres 
from grade 3 was not significantly higher than grade 2 (Figure 3.2 C). In conjunction with this 
hypothesis we would also expect the typically more aggressive ER -ve samples to also grow a higher 
number of spheres. However, Farnie et al. 2007 showed that ER-positive samples have a higher sphere 
forming efficiency (growing higher number of spheres) than ER-negative. In our study, the average 
number between the two groups was very similar although for the purpose of comparison only six 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
106 
 
samples that were ER-negative were propagated (Figure 3.2 E). This might be explained once again by 
the quality of the samples and we might have received better (more tumour-rich) samples from grade 
2 and ER +ve specimens. The majority of the samples collected were luminal A, ER +ve HER2 -ve. This 
is not surprising since 50 – 60 % of the breast cancer cases belong to this subtype (Carey, 2010). We 
hypothesised that tumour samples that express HER2 would have a better capacity to generate 
spheres as previous studies have shown HER2 plays an important role in regulating the CSC population 
in luminal breast cancers, increasing the frequency of spheres formation (Farnie et al., 2007; Korkaya 
et al., 2008). In this study, luminal B (ER +ve and HER 2 +ve) subtype had slightly higher sphere forming 
capacity than Luminal A, this might be because this subtype is more aggressive than luminal A and 
expresses HER2 (Creighton et al., 2012). In regards to HER2 and ER -ve samples, we have had only 
received two ER -ve and HER2 +ve samples and so we are not able to provide any significant conclusion 
(Figure 3.2 F).  
PDXs generated from fresh tumour recapitulate the heterogeneity of the disease and reflect 
histopathology, tumour behaviour, and the metastatic properties of the original tumour (Whittle et 
al., 2015). Improvement has been made in xenografts engraftment: implantation into the orthotopic 
site, estrogen supplementation, the use of more highly immunosuppressed mice; the addition of 
mesenchymal stem cells and/or Matrigel have all improved the successful establishment of PDX 
models (Whittle et al., 2015).  
We have demonstrated that sphere cultures can be enhanced if propagated from PDX samples 
rather than the primary tissue. To bulk up the number of cells for future studies, tumour samples are 
currently being xenografted into immunocompromised mice, with estrogen supplementation in the 
presence or absence Matrigel. Thus far, our results suggest that Matrigel does not have an impact in 
the engraftment rate which is consistent with other studies establishing breast cancer PDX models 
(Zhang and Lewis, 2013). Several methods of sample transplantation were tested such as: chunks, 
tumourspheres, single cells and aggregates. To date, transplanting chunks from biopsies seems to be 
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the best method to propagate a primary tumour formation when transplanted into the mammary fat 
pad (Table 3.3).  This higher transplantation efficiency might be because in chunks the cell contacts 
are maintained, may contain blood vessels, stroma, immune cells and extracellular matrix.  
Furthermore, when three biopsy samples were plated directly in vitro these did grow a low 
number of spheres but the dissociation of the tumour from the matched PDX tumour generated 
enough spheres for our experiments with TRAIL and OH14 ex vivo (Table 3.4; see Chapter 5). The use 
of these PDXs seems promising as a method to increase the number of spheres in order to perform 
larger more statistically robust studies ex vivo. Moreover, in order for PDXs to be translated to the 
clinic at the level of the individual patient and to incorporate drug efficiency, the engraftment rate 
(particularly of ER +ve and HER2 +ve) needs to be drastically increased, and the time required for 
engraftment needs to be reduced, without compromising biological fidelity relative to the original 
tumour. Early biopsy and engraftment of samples might enable determination of important changes 
in the tumour at the time when tumour resistance becomes clinically apparent (Whittle et al., 2015). 
 
It was our intention to use a lentivirus that could genetically suppress c-FLIP in an inducible 
and long-term manner (TetR particles that express RFP and shRNA for c-FLIP that expresses GFP). As 
the aim was to use the inducible lentivirus for tumoursphere culture it was important to test this 
method first in a cell line with known tumoursphere characteristics. Firstly, the lentivirus was tested 
in a breast cancer cell line prior to its use in primary cells to fully evaluate the lentiviral shRNA system. 
Secondly, it was tested in a primary cell line prior to the biopsies. In addition, lentiviral transduction 
efficiency could also be compromised on transducing tumourspheres because the lentivirus may not 
reach the cells in centre of the spheres. For the reasons outlined, a series of optimisation steps were 
used to address issues associated with handling small cell numbers and the nature of primary cells to 
transduce.  
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As a tumoursphere is the result of clonal expansion of a single CSC into a heterogeneous 
collection of cells, the fact that almost 100% of the cells in tumoursphere conditions were GFP positive 
indicates that: (1) all the viable CSCs in the cell population were transduced; (2) all progeny of the CSC 
was also positive suggesting stable GFP expression by the lentivirus. MCF-7 was infected with a 
lentivirus carrying GFP and after the second passage the efficiency still remained with 99% of the stem 
cell/stem progenitor tumoursphere cells expressing GFP (Figure 3.4 D). Additionally, the spheres 
generated from the PDX tumours kept 94.5% of GFP positivity, which means that GFP positivity is 
stable in vivo (Figure 3.4 F).  
Transduction efficiency in primary cells with the TetR particles was very low (Table 3.5). The 
optimal number for the metastatic cell line used for this experiment was 4000 cells. However, 
experiments were also run with 500 cells, to mimic the low number of cells extracted from the 
biopsies. Moreover, 10000, 50000 and 100000 primary cells were also transduced but such numbers 
are not suitable for a sphere assay due the generation of aggregates. However, even using a high 
number of cells, the transduction efficiency remains very low. These results, where a single 
transduction was used, lead to the conclusion that transducing the biopsy cells might not be feasible 
by this method. Parallelly to this, the efficiency of the shRNA construct used in the lentiviral 
transduction adequately supressed c-FLIP in MCF-7 cells with 80% of knockdown, yet, when cells were 
transduced with the TetR particles these efficiency was equally low, cells started to die and 
transduction was not stably maintained after passages (data not shown). This low efficiency could be: 
GFP and RFP silencing after passages or the promoter used was not suitable for the cells used in this 
study. 
The primary objective was to transduce the biopsies with an inducible lentivirus that required 
a double transduction. Since the experiments using a single vector had failed, it seems reasonable to 
conclude that using a double transduction would not be at all feasible in primary cells. Since a 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
109 
 
transduction with shRNA for c-FLIP was not possible with these samples, it was thought that cells could 
be treated with siRNA and OH14 to suppress c-FLIP in the short term. 
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Suppression in Human Primary Breast Cells 
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4. Investigating TRAIL Treatment and c-FLIP Supression in Human Primary Breast Cells 
 
4.1. Introduction 
  TRAIL has become a strong candidate for cancer therapy due to its well-recognised ability to 
induce apoptosis in cancer cells, with almost no toxicity to normal cells (Ashkenazi et al. 1999; Zhang 
et al., 2005). One study investigated TRAIL-mediated cytotoxicity in sixteen breast cell lines, including; 
six primary human mammary epithelial cells (HMECs), two immortalized non-tumourigenic breast 
epithelial cell lines (including MCF-10A), and eight breast cancer cell lines (Keane et al., 1999). This 
study demonstrated that MCF-10As and one breast cancer cell line were significantly sensitive to 
TRAIL-induced apoptosis. Additionally, the HMEC lines were relatively resistant to TRAIL-induced 
apoptosis, with 65–100% viability following treatment at 25 µg/ml and even 10-fold higher 
concentrations of TRAIL failed to induce a greater degree of apoptosis (Keane et al., 1999).  
There is currently no experimental data on the effects of c-FLIP suppression and TRAIL 
treatment on normal primary breast cells. This is key to determining the potential in situ toxicity of c-
FLIP inhibitors.  Here, we set out to establish the cytotoxicity of c-FLIP inhibition (with and without 
TRAIL stimulation) in primary breast epithelial cells ex vivo. 
Our laboratory has seen that using siRNA against both isoforms of c-FLIP (for siFLIPL and 
siFLIPS) with and without TRAIL does not affect bulk and stem cell viability in the non-tumourgenic 
breast cell line, MCF-10As (Piggott et al., 2011). This was confirmed using the novel c-FLIP inhibitor 
OH14 developed in our laboratory.  Up to 100 µM OH14 failed to affect bulk cell or stem-like cell 
viability in the MCF-10A cell line (L. Piggott, unpublished data).  In contrast, another study has shown 
that using siRNA against both forms of c-FLIP, with or without TRAIL increased the percentage of 
apoptotic cells in MCF-10A cells (Yerbes et al., 2011). These two contradictory outcomes may reflect 
differences in the specificity of the siRNA sequences for c-FLIP isoforms used in these experiments. 
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However, the relevance of the MCF-10A cell line has recently been challenged.  Liu et al., 
showed that MCF-10A cells exhibit a unique differentiated phenotype in 3D culture which may not 
exist or be rare in normal human breast tissue (Qu et al., 2014). This study questioned whether this 
immortalised cell line appropriately represented normal mammary cell biology.  
To overcome these limitations, we proposed to inhibit c-FLIP with pan-isoform siRNA and a 
pharmacological inhibitor in primary breast tissues. Thus, cytotoxicity assays were performed on bulk 
and stem cell cultures of HMECs and non-tumourigenic tissues from the clinic.  
 
4.2. Results 
4.2.1. TRAIL treatment has no effect on HMECs viability in adherent 
conditions 
Prior to combining c-FLIP suppression and TRAIL, we investigated the effect of TRAIL alone in 
HMECs. These normal primary breast cells were sourced from a commercial supplier (Lonza, 
Switzerland) and maintained under culture up to a maximum of 15 passages. HMECs were treated 
with different concentrations of TRAIL to investigate the optimal concentration where viability was 
not affected by TRAIL but still induced apoptosis in cancer cells.  HMECs were treated with 20-100 
ng/ml of TRAIL in adherent conditions, a dose range in which TRAIL-sensitive breast cancer cell lines 
have previously been shown to significantly respond (Piggott et al., 2011). After 18 hours, cell viability 
was assessed by the cell titre blue and Live/Dead assays. TRAIL treatment at 20 ng/ml, 60 ng/ml and 
100 ng/ml slightly decreased (2%; 5% and 7%, respectively) the viability of the cells compared to the 
untreated controls (Figure 4.1. A). Despite a statisticaly significant decrease of 7% for HMECs viability 
at 100 ng/ml TRAIL, 7% was a small percentage to be considered overly detrimental.  
 An analysis of the number of dead cells after treatment (Figure 4.1. B), demonstrated a non-
significant 2% increase in cell death using 20 ng/ml of TRAIL, correlating with cell-titre blue viability 
data. These results show that TRAIL has no significant effect on HMECs viability. 
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Figure 4.1. TRAIL treatment has no effect on HMECs viability in adherent conditions. | A. HMECs 
viability was assessed by fluorescence (cell titre blue assay) after +/- 20 ng/ml (n=4), 60 ng/ml (n=2) 
and 100 ng/ ml (n=5) of TRAIL treatment normalised to untreated control. Each biological replicate 
was performed with 3 internal replicates. Bars represent mean +/- SEM. | B. HMECs were incubated 
with +/- 20 ng/ml TRAIL and assessed by FACS for live/dead cells using Live/Dead assay. Treatment 
was normalised to the control. Two independent experiments with 3 internal replicates. Bars 
represent mean +/- SD.  ** (p) significant vs untreated control <0.005; t-test. 
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4.2.2. TRAIL does not affect mammary stem cells originating from HMECs or 
tissues from benign conditions 
The effect of TRAIL on normal mammary stem cells (MaSCs) was investigated using two 
methods: (1) by treating single cells, directly, when plated in non-adherent mammosphere conditions 
(3D); and (2) by pre-treating cells in adherent (2D) before plating in 3D for the mammosphere assay. 
These different treatment designs aimed to represent the effect of the drug in the whole tumour (bulk 
– adherent culture) and when breast cancer stem cells are circulating as a single cell in the blood 
stream (single cell in non-adherent culture). While, the 3D treatment method was recognised to be 
limited for MaSCs, as these are unlikely to be circulating in the blood stream as a single cell in vivo, 
this method was used here in lieu of future analysis of 3D cancer stem cell assays (tumoursphere 
assays) using primary breast cancer tissues.  
Cells were treated using a range of different concentrations from 0 to 100 ng/ml of TRAIL. Pre-
treating HMECs in adherent conditions with 20 ng/ml of TRAIL did not affect the number of spheres 
but 100 ng/ml decreased by 38% the mammosphere forming units (MFUs)(Figure 4.2 A, left side). To 
confirm the presence of stem cells, spheres were dissociated into single cell for a second passage, 
where only stem cells are able to self-renew and form new spheres. In passage 2 (P2), 100 ng/ml of 
TRAIL decreased 20% of the spheres, which was not statistically significant suggesting that TRAIL was 
primarily targeting the anchorage dependent transit-amplifying cell population and not self-renewing 
stem cells (Figure 4.2 A, right side).  
Treating cells directly when plated in non-adherent conditions up to a concentration of 60 
ng/ml with TRAIL does not affect the number of spheres (Figure 4.2 B). Concentrations of 20 ng/ml 
and 40 ng/ml slightly increased the number of spheres (4.81% and 4.05%, respectively) although not 
statistically significant. However, at concentrations of 70; 80 and 100 ng/ml of TRAIL the number of 
spheres decreased significantly by 44%; 53% and 72%, respectively (Figure 4.2. B and C).   
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Some biopsies collected from the clinic were histopathologically characterised as benign 
conditions, such as: fibroadenomas (solid benign tumours); cystic hyperplasia of the breast (fluid-filled 
sacs with overgrowth due to proliferation of cells) and sclerotic adenosis (extra growth of tissue within 
the breast lobules). These were treated with either 20 ng/ml or 100 ng/ml of TRAIL and did not, 
significantly, compromise sphere number in any of the samples tested (Figure 4.3 B).  
Overall, with six fibroadenomas tested with 20 ng/ml of TRAIL and five fibroadenomas tested 
with 100 ng/ml, there was a slightly decreased in the number of spheres by 13% and 12%, respectively, 
but not significantly (Figure 4.3 B). Therefore, 20-100 ng/ml TRAIL does not affect MaSCs in breast 
benign conditions.  
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Figure 4.2. High doses of TRAIL affect HMECs mammosphere forming units (MFU) in 3D. 
Mammosphere assay: Cells were either pre-treated with TRAIL (2D) and then passaged into spheres 
or cells were directly treated with TRAIL into non-adhrent conditions (3D). Cells were treated with 20-
100 ng/ml TRAIL for 18h. TRAIL was not removed from the cultures. The number of spheres were 
counted after 10 days of culture. To confirm stem cell self-renewal, spheres were dissociated and then 
plated again under 3D for passage 2 (P2).  |A. Relative change in MFUs after 20 ng/ml and 100 ng/ml 
of TRAIL after treatment in 2D. Treatments were normalised to the untreated control. P1: Bars stood 
for mean  +/-SEM. n=3 independent experiments with 5 internal replicates. P2: Bars stood for mean 
+/- SD represents one single experiment with 5 internal replicates. | B. Relative change in MFUs after 
20 ng/ml- 100 ng/ml of TRAIL treatment in 3D. Bars represent mean +/-SEM. n=3 independent 
experiments, except for 70 ng/ml, which is a single experiment. All with 5 internal replicates. | C. Light 
microscope images representing HMECS spheres after treatment in B (40x magnification). Scale bar = 
200 µM. *(p)<0.05; **(p)<0.005; t-test. 
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Figure 4.3. 20- and 100 ng/ml of TRAIL does not affect mammosphere forming units (MFUs) in breast 
tissue from benign conditions such as fibroadenomas; cyst hyperplasia and sclerotic breast tissues. 
| 13 breast samples were dissociated into single cells and plated under non-adherent conditions. Cell 
suspensions were treated with 20 ng/ml or 100 ng/ml TRAIL for 18 hours. Number of spheres were 
counted after 10 days. | A. TRAIL treatment in 13 samples represented in a waterfall plot based on 
TRAIL sensitivity at 20 ng/ml and 100 ng/ml normalised to each untreated control. | B. Representation 
of the three breast benign conditions grouped together for 20 ng/ml (8 samples) and 100 ng/ml of 
TRAIL (5 samples). | Bars represent mean +/- SD. n=1 for each sample performed in triplicate.  
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4.2.3. siFLIP and TRAIL decreases HMECs viability  
It was shown that TRAIL treatment has a minimal effect on bulk HMECs viability (Figure 4.1A 
and 4.1B). To explore the effects of c-FLIP suppression on normal mammary cells, HMECs were treated 
with a scrambled control (SC) and siRNA targeting both long and short form of c-FLIP (siFLIP). c-FLIP 
knockdown was confirmed by qPCR that showed 76% efficiency in the gene suppression (Figure 4.4 
B).  To further investigate the specificity of the knockdown for TRAIL mediated killing, cells were 
treated with a pan caspase inhibitor (iCAS), Z-VAD-FMK, at pre- and post-transfection. Cells were 
treated with SC and siFLIP, 10 ng/mL of iCAS for 48h and fresh iCAS added 1h prior 100 ng/ml of TRAIL. 
18h later the viability of the cells was checked by cell titre blue.   
siFLIP treatment alone decreased viability of HMECs by 24% (although this was not statistically 
significant) and the combined treatment siFLIP/TRAIL reduced viability by 48%. The overall sensitivity 
of the combined treatment was 30% (Figure 4.4 A, red asterisk). This provides evidence of sensitisation 
by c-FLIP inhibition for TRAIL mediated killing, as the loss of viability in combination was significantly 
more than the cumulative reduction in viability of either treatment alone. The caspase inhibitor was 
able to rescue the cell death caused by c-FLIP suppression demonstrating the participation of caspases 
in this process (Figure 4.4 A).  
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Figure 4.4. siFLIP and TRAIL decrease HMECs viability. Cells were treated with SC (scrambled control), 
siFLIP (transient knockdown using siRNA), 20 ng/mL of iCAS (pan caspase inhibitor, Z-VAD.FMK) for 48 
hours and fresh iCAS added 1 hour prior 100 ng/ml of TRAIL. 18 hours later the viability of the cells 
was assessed by cell titre blue. | A.  Representation of the HMECs viability after treatments  
normalised to scrambled untreated control (*p=0.0179; t-test). * - red asterisks highlight combination 
treatments (siFLIP + TRAIL) that are more than the sum of the respective individual treatments. Data 
represents 3 independent experiments with at least 3 internal replicates. | B. c-FLIP gene knockdown 
confirmed by qPCR after treatment in A.  (**p=0.0031; t-test). | Bars represent mean +/- SEM.  
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4.2.4. OH14 and TRAIL decreases HMECs viability 
After demonstrating that c-FLIP suppression +/- TRAIL affects HMECs viability in the bulk 
population, we want to investigate whether OH14 had a similar effect. To test drug specificity of 
inhibiting c-FLIP for sensitising to TRAIL, a pan caspase inhibitor (iCAS) was used before TRAIL 
treatment.  Cell viability was assessed by cell titre blue after 18 hours of 100 ng/ml of TRAIL treatment.   
Concentrations of 0.1% and 0.01% DMSO, the vehicle for OH14, had no significant effect on viability 
in HMECs (Figure 4.5 A).  To test OH14 in HMECs, 100 µM and 10 µM of OH14 were used because our 
group have seen that these concentrations display  cytotoxicity to breast cancer cells without harming 
MCF10-As cells (unpublished data). 100 µM of OH14 in 0.1% DMSO showed the most significant effect 
on cell viability by reducing cell viability by 42%, with 10 µM OH14 resulting in a reduction of 18%. This 
compared to a 24% reduction in cell viability following c-FLIP siRNA knockdown (Figure 4.4 A). 
The combination of OH14 and TRAIL led to a 59% and 30% reduction in viability at 100 µM and 
10 µM, respectively, which was partially rescued by the addition of the caspase inhibitor (Figure 4.5 
A) confirming that at least some of the loss in cell viability was mediated by caspases (Figure 4.5 A). 
This rescue by caspase inhibition was relatively more pronounced when cells were treated with 10 µM 
OH14 compared to 100 µM.  While inconclusive, one explanation for this was that an undefined non-
specific toxicity of OH14 was more pronounced at the higher concentration of OH14/TRAIL. 
Combined use of OH14 represented a 14% sensitisation to TRAIL at 100 µM OH14 and 10% 
sensitisation at 10 µM OH14, thus the primary cytotoxicity of OH14 occurred in the absence of TRAIL. 
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Figure 4.5. OH14 and TRAIL decreases HMECs viability. | A.  To investigate whether DMSO itself displays any toxicity to 
normal cells, these were treated with 0.1% and 0.01% of DMSO, which mirrors the same concentration of DMSO present in 
100 µM and 10 µM of OH14, respectively. Graph represents HMECs viability (cell titre blue assay) following TRAIL +/- 100 µM 
and 10 µM of OH14 treatment normalised to the control treated with DMSO. HMECs were treated with OH14 1h prior to 
100 ng/ml of TRAIL treatment for 18h. * - red asterisks highlight combination treatments (OH14 + TRAIL) that are more than 
the sum of the respective individual treatments. Data represents 3 independent experiments with at least 3 internal 
replicates. Bars represent mean +/- SEM. **(p)<0.005 and *** (p)<0.0005; t-test.| B. Light microscope images representing 
HMECS spheres after treatment in A (40x magnification). Scale bar =100µM.  
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4.2.5. OH14 sensitises mammary stem cells to TRAIL 
 We have demonstrated that OH14 reduced HMECs viability in a dose-dependent manner.  We 
also wished to address whether the pharmacological suppression of c-FLIP also affected MaSCs 
viability, and whether this led to a sensitisation of otherwise resistant CSCs to TRAIL. HMECs were pre-
treated in adherent conditions with OH14 and/or TRAIL (2D assay) and, also, treated directly in sphere 
conditions (3D assay). To avoid potential non-specific toxicity at higher concentrations of OH14, thus 
limiting toxicity in normal tissues, these experiments were performed at 10 µM OH14, with or without 
100 ng/ml of TRAIL.  
In pre-treated cells, under 2D conditions, TRAIL and OH14 alone did not significantly decrease 
the number of spheres, with a 13% reduction seen in both treatments. Combined treatment, however, 
reduced the number of spheres by 54% compared to the DMSO control. Therefore, OH14 resulted in 
an overall sensitisation of tumoursphere forming cells to TRAIL by 28%.  The second passage after the 
treatment in 2D showed a similar result to the first passage. TRAIL plus OH14 decreased the number 
of spheres and OH14 sensitised cells to TRAIL (Figure 4.6 C).  
 In cells treated in 3D, a different pattern of responses was observed.  TRAIL decreased the 
number of sphere by 44%, OH14 by 25% and OH14 with TRAIL by 44%. Therefore, OH14 did not 
sensitise the non-adherent sphere forming cells to TRAIL, with the major sensitivity being to TRAIL 
alone.   
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Figure 4.6. OH14 sensitises mammary stem cells  (MFUs) to TRAIL. Y axis represents Mammosphere 
Forming Units (MFUs) after TRAIL, OH14 and TRAIL/OH14 treatments normalised to the DMSO control. 
Mammosphere assay: Cells were treated with 10 µM of OH14 for 1hour prior a 18 hour treatment of 
100 ng/ml of TRAIL. Number of spheres were counted 10 days after passage 1 and after passage 2. | 
A. Left side: Cells were  pre-treated in adherent conditions (2D) and then cultured under non-adherent 
conditions (n= 5). Bars represent mean +/- SEM. Right side: Cells were treated directly into non-
adherent conditions (3D) (n=1). Bars represent mean +/- SD. | B. HMECs spheres after the treatments 
in 3D represented in  A. | C. Passage 2 after the treatment in A in 2D. Bars represent mean +/-SD (n=1). 
| *(p) <0.05; t-test. * - red asterisks highlight combination treatments (OH14 + TRAIL) that are more 
than the sum of the respective individual treatments. Scale bar = 200µM.  
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4.3. Discussion 
Following in vitro studies using cell lines, we and others have proposed that c-FLIP mediated 
sensitisation of breast cancer cells and breast cancer stem cells to TRAIL, may be an effective targeting 
therapy.  In order to substantiate this, it is crucial not only to demonstrate the efficacy of this approach 
in primary tumours, but also to investigate the cytotoxicity of TRAIL and c-FLIP inhibitors in normal 
primary breast cells. This will then help to establish the effective therapeutic window – the difference 
between the effective therapeutic dose for the cancer cells and the dose at which normal cells are 
compromised.  It is known that TRAIL preferentially induces apoptosis in cancer cells over normal cells, 
however, this has not been demonstrated for c-FLIP inhibition (LeBlanc and Ashkenazi, 2003; Daniels 
et al., 2005). TRAIL is expressed in several tissues and activates apoptosis through the death receptors 
DR4, DR5, DcR1 and DcR2. DcR1 and DcR2 receptors have an incomplete death domain and do not 
trigger apoptosis (Daniels et al., 2005). Therefore, these receptors function as 'decoys', competing for 
TRAIL's binding with the pro-apoptotic molecules, DR4 and DR5. Increased expression of these decoy 
receptors on normal cells explains why these cells have increased protection from TRAIL-induced 
apoptosis (LeBlanc and Ashkenazi, 2003; Daniels et al., 2005). It also has been reported that TRAIL 
does not induce toxicity in several animal models such as mice, cynomolgus monkeys, and 
chimpanzees  (reviewed in Rahman et al., 2013) 
To test TRAIL cytotoxicity, HMECs were treated with increasing concentrations of TRAIL in 
adherent and sphere conditions. In agreement with previous findings, we found TRAIL to have a 
minimal effect on bulk HMECs even at a concentration of 100 ng/ml (Figure 4.1 A and B). This minimal 
cell death response was demonstrated in a study by Keane et al., which investigated TRAIL-mediated 
cytotoxicity in six primary HMECs and two immortalised non-transformed breast epithelial cell lines 
(including MCF-10A). They observed that HMEC lines were relatively resistant to TRAIL-induced 
apoptosis (65–100% viability compared with control cells) with the MCF-10A cell line showing the 
highest sensitivity to TRAIL (Keane et al., 1999). However, subsequent studies have questioned 
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whether the MCF-10A cell line is a suitable model for human mammary cell studies (Qu et al., 2014). 
Ideally, TRAIL should be tested in normal tissues taken directly from patients.   
It is known that mammospheres are enriched in progenitor cells, capable of differentiation 
along multiple lineages and 0.4% of the bulk population are stem cells (Dontu et al., 2003). To 
investigate whether TRAIL displays any cytotoxicity in normal mammary stem cells (MaSCs), we have 
used two methods: (1) pre-treating cells in adherent conditions (2D) and then passaging cells into non-
adherent conditions (3D); (2) treating cells directly into 3D at the moment cells are plated in single 
cells. These models crudely recapitulate when drugs target the whole tumour (2D) and cancer stem 
cells circulating in the blood stream (3D). However, this effect is not a very representative assay for 
MaSCs as they are unlikely to ever be under these stresses.  The purpose of these assays therefore 
was two-fold:  to be able to compare a normal cell response with subsequent cancer cell assays in 
order to estimate a therapeutic window; and to compare the responses of bulk cells and MaSCs at the 
appropriate drug concentrations to establish if normal stem cells are protected from killing.  
In the first method, pre-treating HMECs in 2D with 20 ng/ml of TRAIL did not affect the number 
of spheres but 100 ng/ml of TRAIL decreased sphere number by 38% (Figure 4.2 A, left side). To 
confirm the presence of stem cells, spheres were dissociated into single cells for a second passage 
where only stem cells are able to self-renew and form new spheres. In passage 2, 100 ng/ml of TRAIL 
decreased the spheres but not significantly (Figure 4.2 A, right side) demonstrating that this 
concentration is only affecting the cells undergoing anoikis and not stem cells.  In the second method, 
using up to a concentration of 60 ng/ml of TRAIL did not affect the number of spheres but 70, 80 and 
100 ng/ml of TRAIL drastically decreased the number of spheres (Figure 4.2. B).  In addition, increasing 
TRAIL dose, the spheres become smaller (using 20 ng-  60 ng/ml TRAIL), until the sphere forming 
efficiency becomes compromised (70 ng/ml - 100 ng/ml TRAIL) (Figure 4.2 C). These differences on 
TRAIL-mediated cytotoxicity in 2D and 3D, could be explained by the susceptibility or stress caused by 
the anoikis inducing conditions that single cells suffer during 3D conditions. An alternate explanation 
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is that higher concentrations of TRAIL are non-specifically toxic to the proliferative/progenitor stem 
cell compartment. A passage 2 for the 3D conditions would help to test these two hypotheses. Also, 
an experiment where TRAIL would be either removed from cultures or added every 18h would answer 
whether the toxicity is mediated by TRAIL or anoikis resistance. If the anoikis-resistant population dies 
after TRAIL treatment, this would be a drug-mediated killing.  
Additionally, 20 ng/ml and 100 ng/ml of TRAIL did not have a significant effect on spheres in 
fibroadenomas, cystic hyperplasia or in sclerotic breast tissue (Figure 4.3), which is an indication that 
HMECs are more susceptible to higher concentrations of TRAIL than benign breast conditions. 
Although the HMCs are closer to normal breast cells, the freshly harvested benign breast samples are 
a more relevant model of primary tissues. Additionally, one limitation of this experiment was not 
testing  20 ng/ml and 100 ng/ml of TRAIL on the same. Each sample should have been tested with the 
two concentrations but it was not possible as the number of cells was very low to allow enough 
technical replicates.  
 It is well known that some breast cancer cells show resistance to TRAIL due to c-FLIP 
expression (Safa et al., 2008; Yerbes et al., 2010; Piggott et al., 2011). c-FLIP plays an important role in 
T cell proliferation and heart development (Zhang et al., 2008). Yet it is of note that abnormal c-FLIP 
expression has been found in various diseases such as cancer, multiple sclerosis, Alzheimer's disease, 
diabetes mellitus, and rheumatoid arthritis (Safa et al., 2011). In regards to apoptosis, c-FLIP is an 
important caspase-8 regulator: c-FLIP short is anti-apoptotic being able to inhibit caspase 8 and c-FLIP 
long can either inhibit or activate apoptosis depending on its expression levels and location in the cell 
(French et al., 2014, Hughes et al., 2016). 
Having demonstrated that TRAIL displayed a minimal non-significant cytotoxicity in pre-
treated MaSCs, we aimed to investigate whether c-FLIP suppression was detrimental to these cells. c-
FLIP was inhibited using two methods: (1) knocking-down c-FLIP gene expression using siRNA for both 
long and short form of c-FLIP (siFLIP) over 48 hours and (2) using OH14, a pharmacological compound 
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developed by our lab, that is a competitive inhibitor of caspase-8 mediated apoptosis. To investigate 
the specific effects of the inhibition, cells were treated with a pan caspase inhibitor. Using the first 
method, siFLIP treatment alone resulted in a non-significant decrease of viability by 24% and it 
sensitised cells to TRAIL by 30% (Figure 4.4 A).  Importantly, the caspase inhibitor was able to almost 
completely rescue the cell death caused by the c-FLIP suppression confirming a caspase-mediated 
apoptosis (Figure 4.4 A). Our findings partially agree with Yerbes et al. 2010, where they showed that 
using siRNA targeting c-FLIP with different constructs resulted in a drastic increase in cell death with 
100 ng/ml of TRAIL. However, c-FLIP suppression using siRNA or preferably, shRNA still remains to be 
tested on MaSCs in HMECs or any other normal primary breast tissue. 
Using the second method, 100 µM OH14 reduced viability by 42% while 10 µM OH14 only 
reduced it by 18%. Additionally, OH14 also resulted in a minimal sensitisation of HMECS to TRAIL since 
the overall sensitivity at 100 µM and 10 µM was 14% and 10%, respectively (Figure 4.5 B). Thus, siRNA 
and 10 µM OH14 exhibited similar effects on HMECs viability while 100 µM OH14 showed significantly 
higher toxicity in HMECs. Despite both methods inhibiting the role of c-FLIP, the first method was able 
to inhibit c-FLIP genetically whereas OH14 only inhibits c-FLIP binding in the DISC. After OH14 
treatment, c-FLIP is still active inside the cell and can still interfere with other signalling pathways. Our 
lab has seen no increase in c-FLIP levels after OH14 treatment in cancer cells (unpublished data). These 
data suggest that OH14 may exhibit non-specific toxicity.  To test this, c-FLIP could be supressed 
genetically in a long and inducible manner using shRNA in samples taken directly from patients. This 
could test whether is c-FLIP suppression itself or c-FLIP is interfering with other pathways that is 
causing the decrease in viability.  Future studies could involve investigations of c-FLIP effects after 
OH14 treatments, in both normal and cancerous tissues. Additionally, investigation of the caspase 
inhibitor effects only with OH14 would be important to check whether the apoptosis is mediated by 
caspases. 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
128 
 
 Yerbes et al., in 2010 demonstrated that, in MCF-10As, knockdown of c-FLIP long form (siFLIPL) 
up-regulates the expression of the TRAIL receptor DR5 and activates caspase-8 in the absence to TRAIL 
induction (exogenous TRAIL). Endogenous TRAIL is required for the activation of spontaneous 
apoptosis by siFLIPL and increased DR5 expression by siFLIPL could result in the formation of a DISC 
that contains endogenous TRAIL, DR5, FADD and procaspase-8 activation. Furthermore, they suggest 
that c-FLIP levels are up-regulated following detachment from the extracellular matrix and during 
morphogenesis.  This up-regulation of c-FLIP could be due to preventing cells from undergoing anoikis 
in 3D (Mawji et al., 2007). This presumption could explain the differences in response of 2D and 3D 
generated spheres to c-FLIP/TRAIL.  Using OH14 resulted in a sensitisation of MaSCs to TRAIL in 2D but 
not in 3D after passage 1. Passage 2 of 2D suggested a similar sensitisation to TRAIL but this 
experiment was only performed once.  Future experiments could involve: more repeats of passage 2; 
passage 2 assays for the 3D conditions; OH14 treatment in breast tissues from mastectomies or breast 
reductions and an investigation of c-FLIP levels after treatments. Additionally, more stem cell assays 
could be performed such as FACS analysis for stem cell markers and transplantation of MaSC in cleared 
fat pads.  
Overall, 20-100 ng/ml of TRAIL does not affect the bulk population of HMECS nor MaSCs when 
pre-treated in 2D. However, concentrations of 70-100 ng/ml affect cells in non-adherent culture (3D) 
likely because TRAIL more easily targets cells undergoing anoikis rather than targeting stem cells. 
Additionally, 20 ng/ml and 100 ng/ml of TRAIL does not affect MaSCs in primary biopsies from patients 
with benign breast conditions. Suppressing c-FLIP using siRNA sensitises the bulk population to TRAIL, 
while OH14 significantly reduced bulk and stem cell viability alone and sensitised to TRAIL.   
Therefore, this data suggests that pharmacological suppression of c-FLIP may reduce normal 
mammary epithelial cell and stem/progenitor cell viability.  
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Breast Tumour Tissues ex vivo  
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5. Investigating TRAIL and c-FLIP Suppression in Breast Tumour Tissues ex vivo 
5.1. Introduction 
It is well known that TRAIL has failed numerous clinical trials with patients showing no 
improvement (Hayes and Lewis-Wambi, 2015; De Miguel et al., 2016). Reasons for failure have been 
attributed to lack of potency of agents but also a lack of stratification. These trials were driven based 
on the potent effects in vitro, however, none of these trials have stratified patients within each 
histological or molecular subtype or based on previous cancer treatments. We hypothesise that there 
is sub-group of patients that could benefit from TRAIL as a monotherapy.   
Additionally, there is robust evidence supporting a potent effect of c-FLIP suppression using 
siRNA in combination with TRAIL (siFLIP/TRAIL) on bCSCs in cell lines.   It has been shown that this 
treatment efficiently eliminated CSC-like (tumoursphere forming and surrogate marker) activity from 
breast cancer cell lines (Safa et al., 2009; Piggott et al., 2011).  Moreover, intravenous injection of 
MDA-MB-231 cells pre-treated with siFLIP/TRAIL into immunocompromised mice led to a 98% 
reduction in metastatic tumour burden (Piggott et al., 2011).  As these studies have so far only been 
performed on breast cancer cell lines, the key question still remains whether these findings have direct 
clinical relevance for breast cancer patients. Taking this into account, the study tested the hypothesis 
that c-FLIP suppression combined with TRAIL reduces cell viability of primary bCSCs ex vivo.  
To achieve these aims, primary diagnostic breast biopsies, surgical resection samples and 
pleural effusions from breast cancer patients were cultured under conditions supporting and 
conditions that enriched for bCSCs and then subjected to TRAIL +/- c-FLIP suppression. C-FLIP was 
inhibited using siRNA (siFLIP) or a pharmacological inhibitor of c-FLIP (OH14), that had previously been 
developed in the host laboratory. A range of tumour types were tested to determine if there was a 
cohort of patients that this strategy may prove most effective against. 
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5.2.  Results 
5.2.1. TRAIL sensitivity correlates with acquired resistance in bCSCs to 
endocrine treatments  
 Firstly, we aimed to find a particular subtype of breast cancer that could benefit most from 
TRAIL treatment alone as a monotherapy, without c-FLIP suppression. For this purpose, several breast 
tumours from diagnostic biopsies, surgical and metastatic pleural effusion samples were treated with 
100 ng/ml of TRAIL.  We chose a range of TRAIL concentrations that we had previously determined 
did not affect normal mammary epithelial cell viability (Chapter 4), but were effective in breast cancer 
cell lines (Piggott et al., 2011). 
Despite having received and processed 176 breast biopsies/surgical samples, only 30 samples 
generated a satisfactory number of spheres (>20 spheres in the three control wells) to enable 
statistically robust data to be generated. TRAIL treatment did not have any effect in 26 of the 30 
samples, a reduction of tumoursphere-forming cells (tumoursphere-forming units-TFUs) was 
observed in the remaining 4 samples (Figure 5.1. A). However, overall an average, TRAIL significantly 
reduced the number of spheres by 21% (Figure 5.1 B). 
Samples were divided by tumour histological and molecular subtype to investigate any possible 
correlation with TRAIL sensitivity. Within the 30 samples, 10 were Invasive Ductal; 12 were Invasive 
Ductal + DCIS; 2 were Invasive Lobular; 1 was Invasive Ductal + DCIS + LCIS; 1 was Invasive Ductal + 
Lobular; 2 were Invasive Ductal + Mucinous; 1 was Papillary Proliferation and 1 was High grade comedo 
DCIS. Overall, the data indicated that TRAIL had no significant effect in any particular subtype (Figure 
5.2 A). To investigate whether there was a correlation between TRAIL treatment and Ductal or Lobular 
histological subtype, these samples were grouped by Ductal, Lobular and Ductal + Lobular. A 
significant result was found in the Ductal subtype, however, while the fold decrease in tumourspheres 
was lowest in this sub-group, the significance of this decrease was likely due to a higher number of 
samples in this group than in the other subtypes (25 out of 30) (Figure 5.2 B).  
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We also tried to correlate TRAIL sensitivity with molecular subtype to investigate whether the 
treatment correlated with the ER or HER2 status. Six samples were ER -ve and 24 samples were ER +ve 
(Figure 5.3 A). Both groups responded similarly to TRAIL (Figure 5.3. B). Furthermore, TRAIL did not 
correlate with HER2 receptor status (Figure 5.4). Similarly, when samples were further stratified on 
the basis of both HER2 and ER status, no significant differences were observed (Figure 5.5).  
 Some of these samples were derived from patients with recurrent breast cancer, which had 
acquired resistance to endocrine treatments such as tamoxifen and/or aromatase inhibitors. Within 
the 4 samples that were TRAIL-sensitive, 2 were tamoxifen resistant (TAMR) and 2 were aromatase 
inhibitor resistant (AIR). TRAIL decreased the number of spheres in 2 out of 2 TAMR samples and 1 out 
of 2 AIR samples (Figure 5.6 A). Overall, endocrine- resistant samples were significantly more sensitive 
to TRAIL than their naïve counterparts, with endocrine-resistant samples exhibiting a significant 50% 
reduction in sphere forming activity compared to untreated controls. Additionally, endocrine-resistant 
samples have responded 35% less than the other endocrine-naïve samples (Figure 5.6 B). 
Moreover, TRAIL treatment was tested in primary samples from patients with metastatic 
breast cancer. These samples were removed from the pleural cavity and processed in order to obtain 
the epithelial population for ex vivo culture purposes. As there were larger populations of cells 
available from these ex vivo cultures, these cells were treated with 20 ng/ml and 100 ng/ml of TRAIL 
in adherent conditions (2D) and then passaged into sphere conditions (3D) or treated directly in 3D. 
To assess cell self-renewal, spheres were disaggregated and plated in the same conditions for a second 
passage. Analysing 3D treatments that recapitulates the treatments performed for the 
biopsies/surgical samples, TRAIL significantly decreased the number of spheres in 5 out of 7 samples 
(Figure 5.7 A) and in 2D, TRAIL decreased TFUs in 4 out of 6 samples (Figure 5.7 B). Furthermore, TRAIL 
correlated with ER status decreasing sphere number in 2 out of 2 ER -ve samples but there is no 
correlation with HER2 expression (Figure 5.8 and 5.9). Similarly, when samples were further stratified 
on the basis of both HER2 and ER status, no significant differences were observed (Figure 5.10).  
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Importantly, TRAIL decreased sphere number in 3 out of 4 endocrine resistant samples with no effect 
in AE-naïve samples. All of the metastatic pleural effusion samples had received endocrine treatments, 
except for BB3RC90 and BB3RC94. Additionally, 2 out of 2 TNBC samples were significantly sensitive 
to TRAIL regardless of their treatment history (Figure 5. 11 A). Comparing all endocrine-naïve and 
endocrine-resistant metastatic samples, there is a sensitivity in endocrine-resistant samples but it is 
not statistically significant due to the limited number of endocrine naïve samples assessed (Figure 5.11 
C). 
Overall, 9 of 11 samples (82%) from all clinical groups (solid tumours and pleural effusions) 
that had replaced following endocrine treatment responded to TRAIL ex vivo, compared to the 
samples that had not previously seen endocrine therapy (Figure 5.12 A). Additionally, grouping all 
samples together, endocrine-resistant tumours benefit from TRAIL treatment alone compared to the 
naïve samples with a 30% decrease in tumourspheres (Figure 5.12 B).  Taken together, the findings 
from these ex vivo models provide pre-clinical evidence that TRAIL may be valuable in controlling 
endocrine-resistant breast cancers and potentially provide long-term benefits by targeting the bCSC 
subset.   
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Figure 5.1. TRAIL decreases bCSCs (TFUs) in breast tumour samples. Y axes represents relative change 
of Tumoursphere Forming Units (TFUs) relative to the untreated control. 30 breast tumours were 
dissociated into single cells, plated into non-adherent conditions (tumoursphere assay) and treated 
with 100 ng/ml of TRAIL. | A. TRAIL treatment in 30 samples represented in a waterfall plot by TRAIL 
sensitivity normalised to the untreated control. | B. Overall relative change in TFUs after TRAIL 
treatment was calculated in the 30 samples. For the untreated control group, each sample was 
normalised to the mean of all untreated samples. | Bars represent mean +/- SD of one single 
experiment for each sample with three internal replicates. (*- significant vs untreated control *p<0.05; 
**p<0.005; ***p<0.0005; t-test). 
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Figure 5.2. TRAIL treatment does not correlate with tumour histological subtype. 30 breast tumours 
were dissociated and plated as single cells in non-adherent conditions (tumoursphere assay) and 
treated with TRAIL. Y axes represents relative change of Tumoursphere Forming Units (TFUs) relative 
to the untreated control. | A. Waterfall plot representing TRAIL treatment in 30 samples in the same 
order as 5.1. Different colours based on different histological subtype of each sample. | B. Overall 
TRAIL sensitivity for in Ductal, Lobular, Ductal + Lobular and other samples. Graph represents relative 
change in TFUs normalised to the untreated control for each group. Within each untreated group, 
each sample was normalised to the mean of untreated samples. | Bars represent mean +/- SD of one 
single experiment for each sample with three internal replicates. (*- significant vs untreated control 
*p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.3. TRAIL treatment does not correlate with tumour estrogen receptor status. 30 breast 
tumours were dissociated and plated as single cells in non-adherent conditions (tumoursphere assay) 
and treated with TRAIL. Y axes represents relative change of Tumoursphere Forming Units (TFUs) to 
the untreated control. | A. Waterfall plot representing TRAIL treatment in 30 samples in the same 
order as 5.1. Different colours based on ER status for each sample. | B. Overall sensitivity for ER +ve 
and ER -ve samples.  For each untreated group, each sample was normalised to the mean of untreated 
samples. | Bars represent mean +/- SD of one single experiment for each sample with three internal 
replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.4. TRAIL treatment does not correlate with tumour HER2 receptor status. 30 breast tumours 
were dissociated and plated as single cells in non-adherent conditions (tumoursphere assay) and 
treated with TRAIL. Y axes represents relative change of Tumoursphere Forming Units (TFUs) to the 
untreated control. | A. Waterfall plot representing TRAIL treatment in 30 samples in the same order 
as 5.1. Different colours based on HER2 status for each sample. | B. Overall sensitivity for HER2 +ve 
and HER2-ve samples.  For each untreated group, each sample was normalised to the mean of 
untreated samples. | Bars represent mean +/- SD of ne single experiment for each sample with three 
internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). # - 
HER2 status is unknown.  
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Figure 5.5. TRAIL treatment does not correlate with tumour molecular subtype. 30 breast tumours 
were dissociated and plated as single cells in non-adherent conditions (tumoursphere assay) and 
treated with TRAIL. Y axess represents relative change of Tumoursphere Forming Units (TFUs) to the 
untreated control. | A. Waterfall plot representing TRAIL treatment in 30 samples in the same order 
as 5.1. Different colours based on ER and HER2 status for each sample. | B. Overall relative change in 
TFUs was calculated for each group.  For each untreated group, each sample was normalised to the 
mean of untreated samples. | Bars represent mean +/- SD of one single experiment for each sample 
with three internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; 
t-test). # - HER2 status is unknown.  
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Figure 5.6. TRAIL reduces bCSCs in endocrine-resistant tumours. | TRAIL treatment of tumour 
samples in tumoursphere culture after 100ng/ml of TRAIL. Y axes represents relative change of 
Tumoursphere Forming Units (TFUs) relative to the untreated control. | A. Waterfall plot representing 
TRAIL treatment in 30 samples in the same order as 5.1. Different colours based in the ressitance to 
endocrine treatments (anastrozole or tamoxifen) | B. Overall relative changes in TFUs after TRAIL 
treatment based on endocrine resistance.  TRAIL responses in endocrine-naïve samples vs TRAIL 
responses in endocrine-ressitant samples.| Bars represent mean +/-  SD of one single experiment for 
each sample with three internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; 
***p<0.0005; t-test). 
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Figure 5.7. TRAIL reduces bCSCs (TFUs) in metastatic tumours from pleural effusions (n=9). Y axes represents relative 
change of Tumoursphere Forming Units (TFUs) relative to the untreated control. Spheres were counted after 7-10 days in 
culture for Passage 1. For passage 2 spheres were dissociated using trypsin and plated in the same conditions for self-renewal 
| A. Tumoursphere culture after 20 ng/ml (bars with stripes) and 100 ng/ml (bars with dots) of TRAIL treatment directly into 
non-adherent conditions (3D). Waterfall plot representing relative change in TFUs after TRAIL treatment in 7 samples. | B. 
Cells were pre-treated with TRAIL in adherent culture (2D) and then passaged into 3D. | C. Overall sensitivity to TRAIL in 2D 
(P1)  and 3D in (P1 and P2) normalised to the untreated control. |Bars represent mean +/- SD of three single experiments for 
each sample with three internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.8. TRAIL treatment does not correlate with ER receptor status in metastatic tumours. Y axes represents 
relative change of Tumoursphere Forming Units (TFUs) relative to the untreated control. Spheres were counted after 7-10 
days in culture for Passage 1. For passage 2 spheres were dissociated using trypsin and plated in the same conditions for self-
renewal | A. Tumoursphere culture after 20 ng/ml (bars with stripes) and 100 ng/ml (bars with dots) of TRAIL treatment 
directly into non-adherent conditions (3D). Waterfall plot representing relative change in TFUs after TRAIL treatment in 7 
samples. Colours bases in ER status.  | B. Cells were pre-treated with TRAIL in adherent culture (2D) and then passaged into 
3D. | C. Overall sensitivity to TRAIL in 2D (P1)  and 3D in (P1 and P2) based on ER status normalised to the untreated control. 
|Bars represent mean +/- SD of three single experiments for each sample with three internal replicates. (*)- significant vs 
untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.9. TRAIL treatment does not correlate with HER2 receptor status in metastatic tumours. | Y axes 
represent relative change of Tumoursphere Forming Units (TFUs) relative to the untreated control. Spheres were 
counted after 7-10 days  in culture for Passage 1. For passage 2 spheres were dissociated using trypsin and plated 
in the same conditions for self-renewal | A. Tumoursphere culture after 20 ng/ml (bars with stripes) and 100 
ng/ml (bars with dots) of TRAIL treatment directly into non-adherent conditions (3D). Waterfall plot representing 
relative change in TFUs after TRAIL treatment in 7 samples. Different colours based on HER2 status for each 
sample. | B. Cells were pre-treated with TRAIL in adherent conditions (2D) and then passaged in to non-adherent 
conditions.  | C. Overall sensitivity to TRAIL in 2D (P1)  and 3D in (P1 and P2) based on HER2 status normalised 
to the untreated control. | Bars represent mean +/- SD of three single experiments for each sample with three 
internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
143 
 
Metastatic tumours
R
e
la
ti
v
e
 c
h
a
n
g
e
 i
n
 T
F
U
s
90 59 29 71 81 96 79 90
 
59
 
96
 
79
0.0
0.5
1.0
1.5
20 ng/mL TRAIL
100 ng/mL TRAIL
ER +ve HER2 - ve
ER +ve HER2 +ve
ER +ve HER2 - ve
ER -ve HER2 +ve
A
3D Passage 1 Passage 2
**
*
***
***
* *
***
** ***
*
***
**
***
 
Metastatic tumours
Passage 1
R
e
la
ti
v
e
 c
h
a
n
g
e
 i
n
 T
F
U
s
90 94 29 81 71 79
0.0
0.5
1.0
1.5
B
2D
100 ng/mL TRAIL
ER +ve HER2 - ve
ER -ve HER2 -ve
ER +ve HER2 +ve
**
*
***
***
R
e
la
ti
v
e
 c
h
a
n
g
e
 i
n
 T
F
U
s
0 .0
0 .5
1 .0
1 .5
E R + H E R 2
E R + H E R 2 -
E R -H E R 2 +
E R -H E R 2 -
C
1 0 0  n g /m l T R A IL
3 D 2 D
P a s s a g e  1 P a s s a g e  2 P a s s a g e  1
 
Figure 5.10. TRAIL treatment does not correlate with molecular subtype in metastatic tumours. | Y axes 
represent relative change of Tumoursphere Forming Units (TFUs) relative to the untreated control. Spheres were 
counted after 7-10 days in culture for Passage 1. For passage 2 spheres were dissociated using trypsin and plated 
in the same conditions for self-renewal | A. Tumoursphere culture after 20 ng/ml (bars with stripes) and 100 
ng/ml (bars with dots) of TRAIL treatment directly into non-adherent conditions (3D). Waterfall plot representing 
relative change in TFUs after TRAIL treatment in 7 samples. Different colours based on ER/HER2 status for each 
sample. | B. Cells were pre-treated in adherent culture (2D) with TRAIL and then passaged in to non-adherent 
culture. | C. Overall sensitivity to TRAIL based on ER/HER2 status in 2D (P1)  and 3D in (P1 and P2) normalised to 
the untreated control. |Bars represent mean +/- SD. Three single experiments for each sample with three 
internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.11. TRAIL reduces bCSCs (TFUs) in endocrine resistant metastatic tumours from pleural effusions. | Y 
axes represent relative change of Tumoursphere Forming Units (TFUs) relative to the untreated control. Spheres 
were counted after 7-10 days in culture for Passage 1.| A. Tumoursphere culture after 100 ng/ml of TRAIL 
treatment directly into non-adherent conditions (3D). Waterfall plot representing relative change in TFUs after 
TRAIL treatment in 7 samples. Different colours based on endocrine resistance for each sample and TNBC. | B. 
Cells were pre-treated with TRAIL and then passaged in to non-adherent conditions  adherent culture (2D). | C. 
Overall sensitivity to TRAIL in 3D and 2D. TRAIL response in endocrine naïve vs. TRAIL response in endocrine-
resistant samples. |Bars represent mean +/- SD of three single experiments for each sample (except BB3RC59) 
with three internal replicates. (*- significant vs untreated control *p < 0.05; **p<0.005; ***p<0.0005; t-test). 
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Figure 5.12. TRAIL reduces bCSCs (TFUs) in endocrine-resistant tumours from core biopsies/surgical 
samples and pleural effusions. Y axes represent relative change of Tumoursphere Forming Units 
(TFUs) for each sample normalised to its own untreated control. Numbers represent the metastatic 
samples only. All other samples (biopsies/surgical samples) are in the same order as Figure 5.1. Cells 
were treated with 100 ng/ml of TRAIL directly into non-adhrent conditions. | A. Waterfall plot 
representing relative change in TFUs after TRAIL treatment in 37 samples | B. Overall relative changes 
in TFUs after TRAIL treatment based on endocrine resistance.  TRAIL responses in endocrine-naïve 
samples vs TRAIL responses in endocrine-resistant samples.| Bars represent mean +/-  SD of one single 
experiment for each sample with three internal replicates. (*- significant vs untreated control *p < 
0.05; **p<0.005; ***p<0.0005; t-test). 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
146 
 
5.2.2. In vivo PDX models of endocrine-resistant breast cancer demonstrate 
sensitivity to TRAIL treatment 
 It was demonstrated that tumours that have acquired resistance to endocrine treatments 
are particularly sensitive to TRAIL. Therefore, this finding establishes the value of TRAIL treatment in 
this cohort of patients that are endocrine-resistant. To further evaluate this finding, TRAIL was tested 
in vivo using two patient-derived xenograft (PDX) models.  
In the first PDX experimental model, performed by our collaborators (I. Fichtner and M. Becker 
– EPO Berlin-bush, Berlin), a primary ER +ve tumour was kept orthotopically by serially passaging in 
immunocompromised mice receiving either estradiol (MaCa 3366) or tamoxifen (MaCa 3366 TAMR) 
for up to 3 years, generating estradiol dependant and tamoxifen-resistant models, respectively, from 
the same parental tumour tissue (Naundorf et al., 2000). Mice were subjected to systemic 
administration of 8 intraperitoneal (IP) injections of TRAIL over 2 weeks (treatment windows 
highlighted in pink, Figure 5.13 A and B). Tumour growth kinetics were monitored from the beginning 
of treatment by measuring tumours. In the tamoxifen-naive estrogen-dependent control tumours, 
systemic in vivo TRAIL treatment did not have an effect at inhibiting tumour growth compared to the 
vehicle control (Figure 5.13 A). In contrast, a transient (10 day) significant suppression of MaCa 3366 
TAMR tumour growth was observed following TRAIL treatment resulting in a significant reduction of 
tumour size (Figure 13 B) evident after 4 weeks post-treatment.  
Tumours from the MaCa 3366 study were shipped to our laboratory whereupon we 
dissociated the tissue into single cells (confirmed using microscope) and plated in non-adherent 
conditions to investigate stem cell activity. TRAIL treated, in vivo, tumours showed a 2-fold increase in 
percentage of spheres compared to the control (Passage 1 and 2) demonstrating that in vivo treatment 
of MaCa 3366 tamoxifen-naive tumours significantly increased the proportion of bCSCs within the 
tumours (Figure 5.13 C and D). However, this increase was not significant, possibly due to the intra-
tumour biological variability of the tumours. Tumours from MaCa 3366 TAMR mice, both untreated 
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vehicle and TRAIL treated, were also shipped, dissociated and plated in tumoursphere culture. TRAIL 
treated, in vivo, tumours showed a 40% reduction in spheres compared to the vehicle (Passage 1 and 
2) demonstrating that in vivo treatment of MaCa 3366 TAMR tumours significantly reduced the bCSCs 
within the tumours (Figure 5.9 E and F). In addition, the MaCa 3366-TAMR vehicle tumours were 
treated with TRAIL ex vivo and the treatment led to a 35% reduction in the number of spheres in 
Passage 1 and Passage 2, showing similar sensitivity as the endocrine-resistant breast tumours in 
section 5.2.1 (Figure 5.12).  
For the second PDX model (Biopsy and PDX 151), a biopsy obtained from a locally ER -ve 
relapsed tumour from an ER +ve (prior to endocrine treatment) breast cancer patient who had 
relapsed on the aromatase inhibitor (AI) anastrazole. This biopsy was transplanted in recipient 
immunocompromised mice to model AI-resistant breast cancer. In order to determine AI-resistant 
breast cancer sensitivity to TRAIL, mice transplanted with biopsy 151 tumours (PDX 151) were 
administered 8 intraperitoneal injections of TRAIL over 2 weeks. This resulted in a significant reduction 
in AI-resistant tumour growth compared to vehicle control (Figure 5.14 B). Ex vivo vehicle PDX 151 
tumour cells also demonstrated significant sensitivity of bCSCs to ex vivo treatment with TRAIL (Figure 
5.14 B). Furthermore, the sensitivity of PDX 151 bCSCs ex vivo was consistent with the sensitivity of 
the primary tumour (Biopsy 151) treated ex vivo prior to transplantation (original biopsy straight from 
the patient) (Figure 5.14 C). This was paralleled by a drastic reduction in both the number and size of 
spontaneous lung metastases in vivo (Figure 5.14 D and E) confirming TRAIL sensitivity of AI-resistant 
tumours, bCSCs reduction after treatment and decreased ability to metastasise in other organs. 
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Figure 5.13. Endocrine-resistant PDX models demonstrate sensitivity to TRAIL. | Y-axes represent relative % 
change of Tumoursphere forming Units (TFUs)| A. Change in tumour volume: Established Tamoxifen-sensitive 
and B. Acquired Tamoxifen-resistant MaCa 3366 PDX tumours (n=8 each) were treated 8 times in 2 weeks with 
16 mg/kg of TRAIL I.P (pink = 4 x daily treatment windows) and growth kinetics monitored weekly by caliper 
measurement compared with vehicle control. | C. Tumours from A. Vehicle and TRAIL-treated tumours 
harvested 24 hours following the final TRAIL administration were dissociated and tumoursphere forming 
capacity assessed (P1) | D. Tumourspheres from C. were then disaggregated and passaged to assess self-renewal 
capacity (P2). | E. Tumours from B. Vehicle and TRAIL-treated tamoxifen resistant tumours harvested 24 hours 
following the final TRAIL administration were dissociated and TFUs  assessed (P1) | F. Tumoursphers from E. into 
P2. | G. Vehicle tumours from B. were treated with TRAIL ex vivo for a P1 and H. Tumourspheres from G. into a 
P2 | Bars represent mean +/- SEM of 3 independent experiments with at least 3 internal replicates. * -  significant 
vs vehicle (p) < 0.05, ** (p) < 0.005; t-test.   
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Figure 5.14. TRAIL reduces tumour growth of endocrine-resistant tumours in vivo and tumourspheres pre- and 
post-transplantation of the same sample. | A. An anastrozole resistant (AR) tumour was used to generate an 
aromatase Inhibitor (AI)-resistant PDX model (biopsy and PDX 151). Mice were treated 8 times in 2 weeks with 
16 mg/kg of TRAIL IP (pink = 4 x daily treatment windows) and growth kinetics monitored weekly by caliper 
measurement compared with vehicle control (n=3). |B. AR tumour (biopsy 151) was tested ex vivo with 100 
ng/ml of TRAIL prior transplantation for stem cell activity by tumoursphere assay. Graph represents change of 
Tumoursphere forming Units (TFUs) |C. Vehicle control PDX 151 - AI-resistant tumours were excised, dissociated 
and TFU assessed following treatment with 100 ng/ml TRAIL for 18 hours ex vivo (n=3 performed in triplicate). 
|D. Assessment of lung metastatic burden (mean number of six metastasis +/- SEM) in H+E serial sections from 
vehicle control and TRAIL treated PDX151 tumours 2 weeks following last TRAIL treatment. | E. Relative size of 
the individual metastases after treatment in A. |* -  significant vs control (p) < 0.05, ** (p) < 0.005, t-test.
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5.2.3. siFLIP/TRAIL reduces bulk cell viability in primary metastatic cells 
 
Since an inducible and long-term suppression of c-FLIP could not been achieved for this project 
(see Chapter 3), cells were treated with a transient knockdown to genetically suppress c-FLIP (siFLIP) 
for 48  hours or 72hours. Metastatic primary samples from pleural effusions (BB3RC29, BB3RC90, 
BB3RC81 and BB3RC79) were treated with siRNA targeting c-FLIP. Firstly, c-FLIP was suppressed using 
reverse transfection (M1) where plating and transfection of cells are performed on the same day and 
siRNA is diluted in culture medium without serum. Reverse transfection allows cells to be plated and 
transfected simultaneously saving a day in the procedure. Cells were treated with siRNA and scramble 
control (SC) for 48 hours or 72 hours and treated with 100 ng/ml of TRAIL for 18 hours before viability 
analysis by cell titre blue.  Suppressing c-FLIP using a construct (A) (Table 5.5) that targets both long 
and short form of c-FLIP led to a reduction in viability in the presence and absence of TRAIL (Figure 
5.15). In BB3RC29, 48 hours and 72 hours  c-FLIP suppression lead to a reduction in viability by 21.8% 
and 20.1%, respectively. The addition of TRAIL led to further sensitisation in viability by 55.6% at 48 
hours and 49.5% at 72 hours (Figure 5.15 A). In BB3RC90, 48 hours and 72 hours c-FLIP suppression 
lead to a 15.1% and 32.9%, reduction in viability respectively. The addition of TRAIL led to a 
sensitisation in viability of 30.6% at 48 hours and 20.1 at 72 hours (Figure 5.15 B). In BB3RC81, 48 
hours and 72 hours c-FLIP suppression lead to a 15.0% and 20.6% reduction in viability, respectively. 
The addition of TRAIL led to a 47.3% reduction in viability at 48 hours and 60.3% at 72 hours (Figure 
5.15 C). In BB3RC79, 48 hours and 72 hours c-FLIP suppression lead to a reduction in viability by 46.6% 
and 59.7%, respectively.  Unlike the other primary samples tested, in which TRAIL and siFLIP effects 
were synergistic, the combination of these interventions in the triple-negative breast cancer BB3RC79 
was no more than additive presumably due to the fact that these cells were already sensitive to TRAIL 
alone, as previously reported for TNBC cell lines (Figure 5.15 D; Rahman et al., 2009). C-FLIP 
suppression was confirmed by qPCR (Figure 5.15 E). However, c-FLIP protein levels were only 
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performed for BB3RC81 (Piggott et al., 2018). In order to improve these results, a second method of 
transfection using siRNA was tested.  
 For the second method, fast-forward transfection (M2), cells were plated 24 hours prior to 
transfection. Using efficient, fast-forward transfection protocols, some cell lines are more effectively 
transfected, siRNA concentrations can often be decreased (which may reduce the chance of off-target 
effects). In addition, two different constructs of siRNA for c-FLIP were used: (A) the construct 
previously used that targets long and short form of c-FLIP and (B) a smartpool siRNA that targets four 
siRNA duplexes all designed to target distinct sites within the specific gene of interest which target 
both long of short form of c-FLIP (Table 5.5). 
 M1 method resulted in an overall sensitisation in BB3RC90 and BB3RC29 cells by 59.96% and 
30.16%, respectively (M1A in Figure 5.16 A and B). In BB3RC90, using M2 and the construct B 
decreased this sensitisation to 55.02% (Figure 5.16 A). Analysing c-FLIP gene expression by qPCR 
showed that M1 knocked down c-FLIP by 30% and M2 by 60% explaining why using the construct B 
had a higher impact on viability (Figure 5.16 C). Additionally, this viability change was due to M2 
causing less toxicity to the cells.  
In BB3RC29, the better sensitisation of cells to TRAIL of M2 compared to M1 was primarly due 
to the lack of cytotoxicity alone (Figure 5.16 B). Analysing c-FLIP gene expression by qPCR showed that 
construct M1A and M2B resulted in a 45% and 90%, respectively, gene knockdown at 48 hours (Figure 
5.16 D). In this cell line, the result suggests that partial depletion of c-FLIP (M1A, Figure 5.16 D) results 
in a lower viability than a more complete depletion of c-FLIP (M2B Figure 5.16 D). This counterintuitive 
result could be explained by the recent findings from the MacFarlane laboratory who have shown that 
very efficient depletion of c-FLIP levels leads to an increase in cell viability compared to partial 
depletion, due to c-FLIP having a stabilising effect on DISC formation at low concentrations (Hughes 
et al., 2016). However, simply differences in stress given on cells by M1 vs M2 could also contribute 
to this efficiency.  
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Therefore, in general it seems that using a reverse reaction (M1) with the construct A would 
be a better strategy to knockdown cells to ensure optimal sensitisation to TRAIL, by ensuring that 
knockdowns do not exceed 90%.  
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Figure 5.15. siRNA-mediated suppression of the c-FLIP gene and TRAIL treatment in pleural effusion 
samples. | A-D. BB3RC29, BB3RC90, BB3RC81 and BB3RC90 viability (cell titre blue assay) following 
TRAIL, siFLIP (reverse transfection, M1), iCAS (caspase inhibitor) and siFLIP/TRAIL treatment 
normalised to the scrambled untreated control (SC). C-FLIP was suppressed by siRNA for 48 hours and 
72 hours prior to TRAIL addition. Cells were treated with 100 ng/ml TRAIL for 18 hours and with 10 
ng/ml of iCAS at 0h and 10 ng/ml 1 hour prior TRAIL. | E. c-FLIP gene expression analysed by qPCR 
after siFLIP normalised to SC. | * -  significant vs SC (p) < 0.05, ** (p) < 0.005; ***(p)<0.0005, t-test. * 
- red asterisks highlight combination treatments (siFLIP + TRAIL) that are more than the sum of the 
respective individual treatments. * - an additional 20-35% loss of viability; **- an additional 35-50% 
loss in viability; ***- an additional 50-65% loss in viability.  
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Table 5.1. Methods of transfection using two different c-FLIP siRNA constrcuts for c-FLIP. Cells were transfected 
using  reverse transfection (M1) where plating and transfection of cells are performed on the same day. siRNA 
is diluted in culture medium without serum. On the second method, fast-forward transfection (M2), cells are 
plated 24 hours prior to transfection. Two different constructs of siRNA for c-FLIP were used: (A) targets long 
and short form of c-FLIP and (B) is a smartpool siRNA that targets four siRNA duplexes all designed to target 
distinct sites within the specific gene of interest which target both long of short form of c-FLIP. 
Transient trasnfection 
c-FLIP siRNA construct 
siRNA_A siRNA_B 
Transfection 
Method 
Reverse M1 M1A M1B 
Fast-forward M2 M2A M2B 
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Figure 5.16. Relative efficiency of two different transfection methods and two c-FLIP siRNA constructs. 
BB3RC29 and BB3RC90 were transfected using the methods described in Table 5.5 and viability was assessed 
using cell titre blue. Cells were treated with 100 ng/ml of TRAIL and 10 ng/ml of caspase inhibitor (iCAS) at 0h 
and 10 ng/ml 1hour prior TRAIL. | C. qPCR for c-FLIP gene expression after treaments in A and B. | * -  significant 
vs SC (p) < 0.05; ** (p) < 0.005; *** (p) < 0.0005; t-test. * - red asterisks highlight combination treatments (siFLIP 
+ TRAIL) that are more than the sum of the respective individual treatments. * - an additional 20-35% loss of 
viability; **- an additional 35-50% loss in viability; ***- an additional 50-65% loss in viability. 
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5.2.4. siFLIP/TRAIL reduces breast cancer stem cells in primary metastatic 
cells 
To investigate the effect of c-FLIP suppression on bCSCs, cells were plated in non-adherent 
conditions after the siRNA +/- TRAIL treatments detailed in section 5.2.4. In BB3RC29, TRAIL and siFLIP 
led to a reduction in viability of 58% in sphere number (Figure 5.17 A). In BB3RC90, inhibiting c-FLIP 
did significantly reduce the number of spheres, however, siFLIP significantly sensitised cells to TRAIL 
leading to a 98% reduction in viability (Figure 5.17 B). In BB3RC81 and BB3RC79 siFLIP led to a 
reduction of the spheres by 47% and 64%, respectively, and TRAIL significantly sensitised both to TRAIL 
eliminating all the spheres (Figure 5.17 C and D).  
Overall, siFLIP sensitised bCSCs to TRAIL treatment in all the primary metastatic breast 
samples. The combined treatment had a synergetic effect of the individual treatments and not an 
additive effect of both (red asterisks in Figure 5.17). 
In BB3RC29, BB3RC81 and BB3RC79 the tumoursphere assay was performed after the reverse 
transfection with siRNA(A) method, while BB3RC90 was after using fast-forward transfection with the 
smartpool. Since reverse transfection may give some toxicity to the cells it is likely that cells were more 
susceptible to TRAIL and maybe explain why BB3RC90 does not show any cytotoxicity after c-FLIP 
suppression.  
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Figure 5.17. siRNA-mediated suppression of the c-FLIP gene sensitises bCSCs (Tumoursphere 
forming Units- TFUs) to TRAIL treatment in four metastatic cell lines. |A- D. Tumoursphere assay: 
Relative change in TFUs after TRAIL, siFLIP, iCAS (caspase inhibitor) and siFLIP/TRAIL pre-treatments 
on adherent conditions. Treatments were normalised to the scrambled untreated control. C-FLIP was 
suppressed by siRNA for 48 hours prior TRAIL addition. Cells were treated with 100 ng/ml TRAIL for 18 
hours and with 10 ng/ml of iCAS at 0 hours and 1 hour prior TRAIL). | Bars represent mean +/- SD for 
n=1 experiments and mean +/- SEM for n=3 experiments. * -  significant vs SC (p) < 0.05, ** (p) < 0.005; 
***(p)<0.0005; t-test. * - red asterisks highlight combination treatments (siFLIP + TRAIL) that are more 
than the sum of the respective individual treatments - siFLIP resulted in a sensitisation of cells to TRAIL 
* - an additional 20-35% decrease of TFUs; **- an additional 35-50% decrease of TFUs; ***- an 
additional 50-65% decrease in TFUs. 
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5.2.5. OH14/TRAIL has a more modest effect on viability in primary 
metastatic cells 
 
Having demonstrated that a transient suppression of c-FLIP sensitises breast metastatic cells 
to TRAIL, cells were treated with OH14 to investigate whether treatments lead to a similar result. 
Seven primary metastatic breast samples: BB3RC29, BB3RC90, BB3RC94, BB3RC81, BB3RC79, 
BB3RC96 and BB3RC68 were treated with 100 µM and 10 µM of OH14 1 hour prior to addition of 100 
ng/ml of TRAIL. These concentrations were used because they were efficient at sensitising bCSCs to 
TRAIL treatment in cell lines. After 18 hours of TRAIL treatment, viability was assessed by cell titre blue 
assay. 100 µM of OH14 sensitised the bulk population to TRAIL in 5 out of 7 samples and 10 µM in 3 
out of 6 samples (Figure 5.18 A-H).  
BB3RC81 showed the best result for the combined therapy with a sensitisation of 19.71% at 
100 µM and BB3RC96 a sensitisation of 7.38% at 10 µM (Figure 5.18 C and E). 
Therefore, siFLIP is demonstrated to be more efficient at sensitising bulk population to TRAIL.  
This is probably because siFLIP genetically suppresses the total levels of c-FLIP levels within the cells 
while OH14 is a competitive inhibitor leaving some c-FLIP still active inside the cells.   
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Figure 5.18. iFLIP-OH14/TRAIL does not affect the viability in primary metastatic cells. | A.- G. Viability (cell titre blue assay) 
following DMSO, TRAIL, OH14 and OH14/TRAIL treatment normalised to the DMSO control set as 1. Cells were treated with 
100 ng/ml TRAIL for 18 hours and with 100 µM and 10 µM of OH14 1 hour prior TRAIL. | Bars represent mean +/- SD for 
experiments with n=1 and n=2 and +/- SEM for experiments with at least n=3. * - significant vs DMSO (p) < 0.05, ** (p) < 
0.005; *** (p) < 0.005; t-test. | * - red asterisks highlight combination treatments (OH14 + TRAIL) that are more than the sum 
of the respective individual treatments - OH14 resulted in a sensitisation of cells to TRAIL. * -sensitisation < 5%, ** -  
sensitisation between 5% and 15%; *** - sensitisation between 15% and 20%. 
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5.2.6.  OH14/TRAIL reduces bCSCs in primary metastatic cells 
 
Suppressing c-FLIP using OH14 in combination with TRAIL treatment had a small but 
detectable sensitisation effect on the bulk population of primary metastatic breast cancer cells.  Given 
that TRAIL alone decreased bCSCs in 5 out of 7 samples (Figure 5.6 A), the aim here was to either 
further increase this sensitivity or to sensitise the resistant cells to TRAIL with the addition of OH14. 
Cells were pre-treated with 100 µM and 10 µM of OH14 1h before TRAIL in adherent conditions (2D) 
or treated directly in non-adherent conditions (3D) and cancer stem cell activity assessed.  
Pre-treating cells in 2D and using 100 µM of OH14 led to a sensitisation to TRAIL in all samples. 
Using 10 µM of OH14 sensitised bCSCs in 3 out of 5 samples tested: BB3R3RC94, BB3RC29 and 
BB3RC90 (Figure 5.17-19). However, 10 µM of OH14 is more effective than 100 µM at sensitising bCSCs 
to TRAIL. Therefore, OH14 and TRAIL are a good combination at eliminating bCSCs in a cohort of 
primary metastatic tissues. 
Treating cells directly in 3D with 100 µM of OH14 sensitised cells to 20 ng/ml of TRAIL in 
BB3RC29, BB3RC71, BB3RC79 and BB3RC81. Additionally, using 100 ng/ml of TRAIL did not have a 
synergetic effect since cells were already sensitive at that concentration. Using 10 µM of OH14 only 
sensitised BB3RC71 and BB3RC79 cells to 20 ng/ml of TRAIL (Figure 5.20). 
In conclusion, despite pre-treatment of adherent cells resulting in a comparatively higher 
proportion of tumour samples responding, the fact that less spheres remained after treatment in 3D 
suggests that, TRAIL and OH14 may be more effective at targeting bCSCs circulating in the blood 
stream than in the solid tumour.  
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Figure 5.19. OH14 sensitises bCSCs in metastatic tumour cells from pleural effusions to TRAIL when 
pre-treated in adherent culture (2D). | A-F. Cells were pre-treated in 2D with TRAIL, OH14, and 
caspase inhibitor (iCAS, FMK-ZVAD, 20 ng/ml 1 hour prior TRAIL) and then cells were plated into non-
adherent conditions for tumoursphere assay. Treatment was normalised to DMSO control. Cells were 
treated in adherent culture with 100 ng/ml TRAIL for 18 hours and with 100 µM or 10 µM OH14 1 hour  
prior TRAIL. Tumourspheres from at least three replicate wells per condition were counted following 
7-10 days in culture. |Bars represent mean +/- SD for experiments with n=1 and n=2 and +/- SEM for 
experiments with more than n=3. | * -  significant vs DMSO (p) < 0.05, ** (p) < 0.005; t-test. * - red 
asterisks highlight combination treatments (OH14 + TRAIL) that are more than the sum of the 
respective individual treatments.* - siFLIP resulted in a sensitisation of cells to TRAIL; siFLIP + TRAIL is 
not an additive effect of the single treatments. 
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Figure 5.20. OH14 sensitises bCSCs in metastatic tumour cells from pleural effusions to TRAIL when 
treated in non-adherent culture (3D). | A-F. Relative change in Tumourspehre Forming Units (TFUs) 
after TRAIL, OH14 and caspase inhibitor (iCAS, FMK-ZVAD, 20 ng/ml 1 hour prior TRAIL). Single cells 
were plated into non-adhrent conditions for tumoursphere assay (Passage 1). Treatment was 
normalised to DMSO control. Cells were seeded at a density of 40000 cells/well and treated with 20 
ng/ml and 100 ng/ml of TRAIL for 18 hours and with 100 µM or 10 µM of OH14 1 hour prior TRAIL. 
Tumourspheres from at least three replicate wells per condition were counted following 7-10 days of 
culture. | Bars represent mean +/- SEM. * -  significant vs DMSO (p) < 0.05, **(p) < 0.005; ***(p) < 
0.0005; t-test. * - red asterisks highlight combination treatments (siFLIP + TRAIL) that are more than 
the sum of the respective individual treatments.  
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5.2.7.  OH14/TRAIL reduces the stem cell marker ALDH1 in primary 
metastatic cells 
It was demonstrated that OH14 sensitises bCSCs to TRAIL through depletion and in some 
instances ablation of functional tumourspheres (Figure 5.19 and 5.20). To confirm this result, cells 
were stained for Aldehyde dehydrogenase (ALDH) activity after 100ng /ml of TRAIL +/- 10 µM of OH14. 
ALDH isozymes metabolize several different intracellular aldehydes and can therefore provide 
resistance to alkylating chemicals such as cyclophosphamide. High ALDH1 activities have been 
reported in CSCs from many cancers including those found in breast, lung, liver, colon, pancreatic, 
ovarian, head and neck and prostate (Luo et al., 2012). In breast cancer, elevated ALDH activity was 
mainly found in CSC of HER2 subtype and basal/epithelial breast cancer cell lines (Ricardo et al., 2011). 
In BB3RC29 and BB3RC71, both cell lines exhibited significant reductions in the relative proportion of 
ALDH +ve cells in the surviving populations following TRAIL. Additionally, OH14 resulted in a 
sensitisation of ALDH positive cell to TRAIL (Figure 5.21 B). This result corroborated the tumoursphere 
assay followed by the treatments in bulk population using the same conditions (Figure 5.21 A). 
Moreover, BB3RC71 had a higher level of ALDH positive cells (34.91%) than BB3RC29 (17.96%) 
probably due to the expression of HER2 (Figure 5.21 B). BB3RC71 belongs to Luminal B subtype and 
BB3RC29 belongs to Luminal A breast cancer. 
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Figure 5.21. TRAIL and OH14 treatment decreases ALDH1 expression. Cells were treated with 100 ng/ml TRAIL 
for 18 hours and with 10 µM of OH14 1 hour prior TRAIL. | A. ALDH expression in cells was measured by flow 
cytometry in BB3RC29. Data represents one of  three independent experiments. | B. Percentage of ALDH +ve 
cells in BB3RC29 and BB3RC71 cells after treatments. Data represents two independent experiments.| Bars 
stood for mean +/- SD. * -  significant vs DMSO (p) <0.05.  ** (p) <0.005; t-test.  * - red asterisks highlight 
combination treatments (OH14 + TRAIL) that are more than the sum of the respective individual treatments -  
OH14 resulted in a sensitisation of bCSCs to TRAIL.  
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5.2.8. Investigating c-FLIP impact in cancer cells and normal cells 
 
In chapter 4, it was demonstrated that suppressing c-FLIP affects HMECs viability and MaSCs 
and sensitises to TRAIL. However, it is important to compare c-FLIP suppression (siFLIP and OH14) in 
normal and cancer cells. Suppressing c-FLIP using siRNA (M1 and M2), M1 led to a similar toxicity in 
normal cells and cancer cells with 24.0% and 28.0% increase cell death, respectively. M2 also led to a 
similar toxicity in normal and cancer cells with 8.8% and 2.7% increase in cell death, respectively 
(Figure 5.22 A). As mentioned in section 5.2.3., the method of transfection M1 decreases cell viability 
by either partially suppressing c-FLIP or by causing off-target effects to cells. Therefore, if we only 
consider method M2, siFLIP has a minimal effect on normal and cancer cells (9% and 3%, respectively).  
 Suppressing c-FLIP using 100 µM OH14 increased death by 42.2% in normal cells and 12.1% in 
cancer cells. Additionally, using 10 µM increased death in normal cells and cancer cells by 17.7% and 
3.7%, respectively although this effect was non-significant (Figure 5.22 A).  
Thus, despite 100 µM OH14 having demonstrated a better result at sensitising cancer cells to 
TRAIL, this concentration should not be used due to its extensive toxicity to normal cells.  
Furthermore, using 10 µM of OH14 in a mammosphere assay led to a similar decrease of MaSCs 
in 2D and 3D by 16.5% and 25.0%, respectively. In cancer cells 100 µM led to a decrease of spheres by 
12.4% in 2D and 3.9% in 3D. Additionally, 10 µM only decreased spheres in 3D with 10.6% reduction 
(Figure 5.22 B). Despite OH14 having a higher effect on MaSCs than CSCs this is only in theory since 
MaSCs are unlikely to be circulating as a single cell in the body. 
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Figure 5.22. c-FLIP suppression in HMECs and metastatic cancer cells (BB3RCs). Data represents 
relative number of Tumousphere forming units (TFUs) normalised to untreated controls. Cells were 
treated with 100 ng/ml TRAIL for 18 hours and with 100 µM and 10 µM of OH14 1hour prior TRAIL. | 
A. Increase in cell death after c-FLIP suppresion in HMECs and Cancer cells in bulk population | B.  
HMECs vs cancer cells in tumoursphere culture conditions. * (p) <0.05; t-test. 
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5.3. Discussion 
The main goal of this study was to test the effects of TRAIL treatment as a monotherapy and 
in conjunction with c-FLIP inhibition in primary breast cancer tissues, with a specific focus on the 
potential specificity for this combination for breast cancer stem cells. TRAIL had a significant effect on 
bCSCs on 4 out of 30 samples tested. Trying to stratify these samples by histological or molecular 
subtype did not result in any correlation.  However, analysis based on endocrine treatments showed 
that 3 out of the 4 TRAIL responders have received endocrine treatments in the past (Figure 5.6). An 
analysis of 7 primary metastatic breast tumours, showed that TRAIL did not have any effect in any 
endocrine-naïve samples. Importantly, TRAIL decreased bCSCs in 3 out of 4 samples that have received 
endocrine treatments before (Figure 5.11 A).  Overall, the bCSCs from 82% (9/11) endocrine resistant 
samples responded to TRAIL while only 10% (1/31) treatment naive samples significantly responded 
(Figure 5.12).  These results demonstrate, in a cohort of patients currently with poor prognosis, the 
specific targeting of CSCs following acquisition of resistance supporting future clinical investigations 
into the use of TRAIL receptor agonists to improve the long-term survival of patients who relapse on 
endocrine therapy. Additionally, TRAIL has shown to be more effective in decreasing bCSCs when cells 
are treated in 3D compared to when treated in 2D. This could potentially mean that TRAIL is more 
efficient targeting bCSCs circulating tumour cells rather than bCSCs in the whole tumour or also more 
efficient at targeting cells undergoing anoikis resistance, which is a property of bCSCs. 
To further evaluate TRAIL efficiency in endocrine-resistant tumours, PDX models were 
generated to investigate TRAIL efficiency in vivo. In the first model, the resistance to tamoxifen was 
acquired in vivo and TRAIL administration did not have an effect at inhibiting tumour growth in the 
estradiol-dependent control group but did lead to a significant reduction of tumour size in the 
tamoxifen-resistant tumours (Figure 5.13 A and B). Additionally, the tumours from the tamoxifen-
naïve group were harvested and used to investigate stem cell activity ex vivo and TRAIL-treated 
samples showed a higher proportion of bCSCs (Figure 5.13 C and D). This agrees with studies that 
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demonstrated for endocrine therapies, such as tamoxifen and fulvestrant, in ER +ve patient samples 
and in early and metastatic, PDXs increases in bCSCs proportions within the tumours. This suggests 
that endocrine therapies do not target bCSCs, which might explain how residual endocrine-resistant 
cells are responsible for the relapse of ER +ve tumours (O’Brien et al., 2011; Simões et al., 2015). 
Tumours from the TAMR-resistant model were also harvested and TRAIL was able to compromise 
bCSCs ability to self-renew (Figure 5.13 E and F). To further evaluate TRAIL efficiency in vivo, an 
anastrozole-resistant sample was transplanted into mice.  TRAIL caused a significant reduction in 
tumour volume and led to a reduction of bCSCs ex vivo (Figure 5.14). This finding confirmed our 
hypothesis since we have found a group of patients that may benefit from TRAIL as a monotherapy. It 
is well known that TRAIL has failed numerous clinical trials with patients showing no improvement. 
However, none of these clinical trials have preselected patients based on TRAIL- sensitivity in ER +ve 
tumours. In this study, we show evidence that patients who acquire resistance to endocrine therapies 
such as tamoxifen or aromatase inhibitors may benefit from TRAIL alone.   
It is also of note therefore that the metastatic samples corresponding to TNBC have shown a 
particular susceptibility to TRAIL (Figure 5.8). These findings are in accordance with a study, which 
shows that bCSCs from basal-like breast cancer cell lines were sensitive to the TRAIL DR5 receptor 
agonist TRA8 (Londoño-Joshi et al., 2012). Moreover, it has been reported that bCSCs are sensitive to 
TRAIL due to the reduced cytoplasmic location of c-FLIP. It is proposed that in order to inhibit the 
extrinsic apoptosis pathway, c-FLIP must be available in the cytoplasm in order to form a complex with 
DISC components and therefore determinate caspase-8 recruitment to the complex (French et al., 
2016). It would be important to analyse c-FLIP levels in all the samples that have received TRAIL 
treatment. However, after testing and optimising 20 antibodies for c-FLIP in our laboratory by 
immunohistochemistry, none have proved to be specific for c-FLIP (data not shown). We hypothesised 
a correlation between TRAIL sensitivity and low levels of c-FLIP protein or RNA. The acquisition of 
TRAIL sensitivity by endocrine-resistant cell lines and clinical samples was attributed to a reduction in 
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the intra-cellular levels of the TRAIL pathway inhibitor, c-FLIP, and a concomitant increase in the Jnk-
mediated phosphorylation of E3 ubiquitin ligase, ITCH (p-ITCH), previously shown to target c-FLIP for 
proteosomal degradation.  Restoration of c-FLIP protein levels in TAMR cells through Jnk inhibition 
lead to the reacquisition of TRAIL resistance in TAMR cells, illustrating a dependence of TAMR TRAIL-
sensitivity on Jnk-mediated degradation of c-FLIP (Piggott et al., 2018). It would be interesting to 
determine whether the endocrine-resistant samples that have responded to TRAIL have low levels of 
c-FLIP and the TNBC samples have low levels of cytoplasmic c-FLIP. A clinical trial investigating TRAIL 
administration in patients with TNBC has failed (Forero-Torres et al., 2015). However, pre-selection of 
patients based on c-FLIP levels within this group would be crucial. Perhaps recurrent ER -ve tumours 
that have been previously diagnosed as ER +ve and treated with hormonal treatments could then 
benefit from TRAIL alone. Since we only had a few representative samples from each of these 
subtypes, a robust statistical analysis for TRAIL treatment was not possible. 
Consistent with previous work in cell lines (Piggott et al., 2011) the combined treatment of 
siFLIP/TRAIL led to a reduction in the viability in three out of four metastatic primary breast samples 
(Figure 5.15). In addition, siFLIP sensitised bCSCs to TRAIL in all samples and importantly in a TRAIL-
resistant and endocrine-naïve cell line, BB3RC90 (Figure 5.16 B). Additionally, siFLIP and TRAIL resulted 
in a complete ablation of bCSCs in a metastatic endocrine resistant breast cancer primary cell line and 
in a metastatic primary TNBC (Figure 5.17 C and D). It has been reported that cytoplasmic c-FLIP levels 
were particularly low in anoikis-resistant cells, which could clarify why c-FLIP inhibition and TRAIL 
treatment results in the complete ablation of bCSCs (French et al., 2015).  
Suppressing c-FLIP using 100 µM and 10 µM of OH14 led to a reduced sensitisation of bulk 
cells to TRAIL compared to siFLIP (Figure 5.18 and Figure 5.15). Investigating c-FLIP levels in the 
cytoplasm/nucleus after treatment with OH14 in order to investigate a correlation between c-FLIP 
localisation and TRAIL sensitivity may help to understand the relative inefficiency of OH14 in these 
conditions.  
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Furthermore, OH14 has been shown to be more efficient at sensitising bCSCs to TRAIL 
compared to the bulk population (Figure 5.19 and 5.20). This concurs with the study that shows 
cytoplasmic c-FLIP levels were particularly low in anoikis-resistant cells explaining why the double 
treatment is more effective for bCSCs than the bulk population (Piggott et al., 2011; French et al., 
2015).  
Additionally, our lab has seen that OH14 treatment does not change cytoplasmic levels of c-
FLIP in MCF-7 cells (data not shown). A recent study proposes that the amount of the unbound c-FLIP 
long form available inside the cell can determine caspase-8 activity. Low levels of c-FLIP would result 
in cell death and high levels of c-FLIP would inhibit apoptosis (Hughes et al., 2016). This achievement 
may explain why siFLIP is more efficient than OH14 at sensitising cells to TRAIL. In regards to OH14-
mediated suppression, c-FLIP can no longer promote its apoptotic activity at the DISC complex and 
therefore c-FLIP is potentially available inside the cell to modulate other signalling pathways.  
Finally, it is important to analyse the effects of c-FLIP suppression in normal and cancer cells. 
There is literature supporting that siFLIP does not display any toxicity in the MCF-10As (Piggott et al., 
2011) but other study demonstrated that siFLIP is detrimental to the same cell line (Yerbes et al., 
2011). In chapter 4 and 5, we have shown that siFLIP displays a similar toxicity to normal or cancer 
cells using siRNA. However, 100 µM of OH14 was significantly more detrimental for normal cells rather 
than cancer cells (Figure 5.22). This toxicity to normal cells was hypothesised by drug off-target effects 
or by cytotoxicity, the caspase inhibitor was able to rescue part of the caspase-mediated killing. HMECs 
may not have been the best model to study drug mechanisms in normal cells since it lacks other 
components from the mammary gland, such as the stroma. A better model, for example breast 
samples from mastectomies, may be best placed to evaluate the mechanisms of c-FLIP inhibition in 
normal cells. 
Overall, TRAIL could be used as a single agent for tumours that have acquired resistance to 
endocrine therapies such as tamoxifen and anastrozole. c-FLIP suppression results in a sensitisation of 
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epithelial and bCSCs to TRAIL, but there may be issues regarding cancer cell specificity when targeting 
c-FLIP.  
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CHAPTER 6                                
The Role of Tumour Microenvironment 
in TRAIL Response 
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6. The Role of Tumour Microenvironment in TRAIL Response 
6.1. Introduction 
Fibroblasts have a dual role in controlling normal and malignant development: fibroblasts can 
hamper neoplastic growth in normal tissues, whereas in cancer they can potentiate invasion and 
tumour growth (Kuperwasser et al., 2004; Schauer et al., 2011), EMT,  invasion (Bhowmick et al., 
2004), and metastasis (Straussman et al., 2012). Furthermore, cancer associated fibroblasts (CAFs) 
have a role in constructing the extracellular matrix and metabolic and immune reprogramming of the 
tumour microenvironment with an effect on adaptive resistance to drug responses (Kasani et al., 2015, 
Kalluri, 2016).  
There are studies that have demonstrated a relationship between a mesenchymal-like 
phenotype and sensitivity to TRAIL (Rahman et al., 2009; Piggott et al., 2011; French et al., 2015).  In 
addition, our laboratory has seen that soluble factors produced by MDA-MB-231-conditioned medium 
are capable of inducing upregulation of mesenchymal markers in MCF-7 cells and sensitise to TRAIL 
(Rhiannon French, unpublished data). whereas Wang and co-workers have reported an association 
between a resistance to TRAIL and EMT (Wang et al., 2014). Using a TRAIL-resistant breast cancer cell 
line, generated from the TRAIL-sensitive MDA-MB-231, Wang et al., demonstrated that TRAIL 
resistance induced EMT and invasiveness through deregulation of PTEN compared with the parental 
cell line (Wang et al., 2014). Additionally, reversion of EMT has been proposed as a novel strategy for 
TRAIL sensitisation. A study using a HDAC inhibitor led to angiogenesis, reversed EMT, attenuated 
metastasis, and sensitised TRAIL-resistant breast cancer MDA-MB-468 xenografts in vivo (Srivastava 
et al., 2010).  
When epithelial cells commit to a mesenchymal phenotype, the process is designated as a 
complete EMT. Partial EMT can also exist, and this happens when one or more of the key 
characteristics of complete-EMT are not exhibited, such as loss of cell-cell contact. For example, during 
re-epithelialisation of cutaneous wounds, keratinocytes undergo several changes reminiscent of EMT 
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including loss of polarity, rearrangement of the actin cytoskeleton, alterations in cell-cell contacts, and 
breakdown of basement membrane; however, some intercellular junctions are kept and migrate as a 
cohesive cell sheet (Welch-Reardon et al., 2015). Recent studies in defining EMT as more of a 
“spectrum of phenotypes instead of a binary process” has driven an hypothesis that unlike during 
development, in which terminally differentiated epithelial and mesenchymal states exist, cancer cells 
could undergo more partial transitions to an incomplete mesenchymal phenotype. However, while 
several cancers may undergo only a partial transition, some cancers reflect a more complete 
phenotypic transition based on typical morphological and molecular features. For example, a rare 
population of cells expressing low levels of E‐cadherin  that underwent spontaneous full EMT without 
any exogenous induction from EMT-inducing transcription factors were converted to an epithelial 
state when located at the metastatic site (Jolly et al., 2017).  
These findings, raise intriguing questions about the complex relationship between 
mesenchymal phenotype/EMT and TRAIL sensitivity of breast tumours and whether an EMT induced 
by CAFs would result in TRAIL sensitisation or resistance. This chapter will study the role of the 
microenvironment on TRAIL responses, specifically, it will test whether: fibroblasts induce 
mesenchymal-like phenotype changes in luminal cells and whether fibroblasts might or might not 
sensitise the epithelial tumour population to TRAIL. 
 
6.2. Results 
6.2.1. Co-culture of cancer cells with fibroblasts sensitises to TRAIL  
To explore how the microenvironment can modulate TRAIL responses, fibroblasts were 
separated from the epithelial population of a range of breast biopsy/surgical samples (Table 6.1). We 
aimed to test the direct effect of CAFs on TRAIL response. For this purpose, CAFs were co-cultured 
with the resistant breast cancer cell line MCF-7 (Piggott et al., 2011; French et al., 2015) to test 
whether CAFs from different tumour types can sensitise the MCF-7 to TRAIL. Five different CAF 
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cultures (CAF 168, 148, 209, 207 and 253) were used in co-culture experiments.  Fibroblasts were 
cultured on 96 well-plates for four days until reaching 90-100% confluency. Pure fibroblast monolayer 
was confirmed using a microscope. Then, 80000 or 1600000 of MCF-7 cells expressing GFP were plated 
on top of the fibroblasts. Epithelial cells were in contact with fibroblasts for 24h and co-cultures were 
treated with 20 ng/ml of TRAIL for 18h. Cells expressing GFP were quantified using flow cytometry to 
efficiently separate epithelial cells from fibroblasts. GFP positivity was checked prior to the assay to 
confirm a homogeneous epithelial (MCF-7) population expressing GFP (98% for GFP +ve cells similar 
to the result in Chapter 3).  
Overall, all five of the CAFs tested led to a sensitisation of the MCF-7 cells to TRAIL (Figure 6.1). 
Fewer MCF-7 cells in the co-culture (80000) resulted in a higher sensitivity. The fibroblast sample that 
led to the highest sensitisation was the CAF 253 derived from a tamoxifen-resistant sample, 253 (red 
bar). This experiment showed a sensitisation to TRAIL by direct contact with fibroblasts. 
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Table 6.1. Histological and molecular characteristics of the samples used to collect the fibroblasts. 
Histological features, Grade, Receptor (ER and HER2) status and respective responses to 100 ng/ml of 
TRAIL in tumoursphere conditions.  
CAF Histology Grade Receptor Response to TRAIL % 
98 Benign Intralobular Microcalcification 
  
- 
213 Fibroadenoma 
  
- 
214 Fibroadenoma 
  
25 
61 Invasive Lobular 2 ER+HER2- - 
148 Invasive Mucinous 3 ER+HER2+ - 
153 Invasive Ductal 1 ER+HER2+ 
 
168 Invasive Lobular + LCIS 2 ER+HER2- - 
206 Invasive Lobular 2 ER+ - 
207 Invasive Ductal + DCIS 3 ER+HER2- 32 
209 Invasive Ductal 2 ER+HER2- 0 
253 Invasive Ductal + DCIS 2 ER+HER2+ 64 
89 Invasive Ductal + DCIS high grade 3 ER-HER2+ - 
105 Invasive Ductal + DCIS high grade 2 ER+HER2- - 
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Figure 6.1. Co-culture of cancer cells with fibroblasts sensitises to TRAIL: relative change in MCF-7 
GFP +ve cells (flow cytometry) in co-culture with different CAFs following TRAIL treatment normalised 
to the untreated control. On day 1, 800000 fibroblasts were plated in 6-well plates for 4 days until 
reaching 90%-100% of confluency. On day 4, 80000/1600000 of GFP +ve MCF-7 cells were cultured on 
top of the fibroblasts. Cells were left in co-culture for 24 hours prior 20 ng/mL of TRAIL treatment. 
After 18 hours, GFP +ve MCF-7 cells were analysed by flow cytometry. Wells with MCF-7 +/- TRAIL 
were used as controls to measure TRAIL response in the absence of fibroblasts. TRAIL treatments were 
normalised to the co-culture control (168, 148, 207, 209, 253). Bars represent mean +/- SD  of two 
experiments with three internal replicates. and p-value (p) - significant vs untreated untreated control 
(calculated using t-test). *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test.  
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6.2.2. Fibroblast-conditioned medium increases cell viability in primary 
metastatic epithelial cells 
Previously, it was seen that direct contact of CAFs and MCF-7s resulted in an increase in the 
sensitivity of these cells to TRAIL. However, it is important to test whether this might be due to soluble 
factors released by fibroblasts. We wanted to investigate whether fibroblast-conditioned medium 
(CM) could result in a similar sensitisation as the co-cultures.  
Firstly, we investigated CM treatment alone in different cell lines. Confluent fibroblasts were 
incubated with fresh medium for 24h to generate CM. CM was generated from three non-cancer-
associated fibroblasts or normal fibroblasts (NFs): 98, 214 and 213; seven cancer-associated 
fibroblasts: 61, 148, 153, 168, 206, 207 and 209 and one cancer-associated fibroblast derived from a 
tamoxifen-resistant sample, 253.  Each CM was then incubated with MCF-7 cells or three primary 
metastatic cell lines BB3RC90, BB3RC29 and BB3RC81 for 24 hours and viability determined by a cell 
titre blue assay (Figure 6.2)   In MCF-7 cultures all the fibroblasts increased viability except fibroblast 
214 (Figure 6.2 A). In BB3RC81, CM from fibroblasts 214, 148, 168,253, 207 and 209 increased cell 
viability (Figure 6.2 B). In BB3RC29, fibroblasts 148, 168, 206, 61 and 253 increased viability (Figure 6.2 
C). In BB3RC90, CAF 61, 206, 253, 209 (Figure 6.2 D) were able to increase metabolic activity.  
Additionally, in order to determine whether CAFs having a stronger ability of increasing cell 
metabolic activity/viability compared to normal fibroblasts, the combined data from CAFs and normal 
fibroblasts were compared, to reveal that this indeed was the case (Figure 6.2 E). Moreover, we aimed 
to determine if the grade of the tumour of origin for each CAF sample correlated with its effect on 
metabolism/viability. Thus, by scoring each fibroblast sample according to grade: (benign tissue- score 
0; fibroadenoma –  score 1; grade 1 – score 2; grade 2 – score 3; grade 3 –  score 4) we ranked 
fibroblasts versus relative viability.  In MCF-7 and BB3RC81 cultures, (rs=0.577), the hypothesis must 
be rejected because significance levels were greater than 5% (rs< rs critical). In BB3RC29 (rs=0.605) 
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and BB3RC90 (rs= 0.618) cultures, grade can be correlated with the ability to increase cell metabolic 
activity with a confidence of 95%.  
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Figure 6.2. Fibroblast-conditioned medium increases cell viability in primary metastatic epithelial 
cells. Relative change in viability (cell titre blue assay) following fibroblasts conditioned medium (CM) 
treatment normalised to the untreated control. Confluent fibroblasts (98, 213, 153, 214, 61, 148, 168, 
206, 207, 209 and 253) were incubated with fresh fibroblast medium for 24 hours to generate CM. 
Untreated control cells were cultured with only fibroblast medium and treated cells with CM for 24 
hours. |A. MCF-7. Relative change in viability in MCF-7 cells after CM treatment. Graph is 
representative of n=3 with 4 internal replicates. | B. BB3RC81 Relative change in viability in BB3RC81 
cells after CM treatment. Graph represents n=1 with 3 internal replicates. | C. BB3RC29 Graph 
represents n=2 with 3 internal replicates | D. BB3RC90. Left side: Relative change in viability in MCF-
7 cells after CM treatment. Right side: n=1 with 3 internal replicates. | E. Graph shows change in 
viability of NFs vs CAFs of the four cell lines together. Bars represent mean +/- SD. (p)-value - significant 
vs untreated control.  *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test. 
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6.2.3. Fibroblast-conditioned medium sensitises primary epithelial cells to 
TRAIL 
   Having established that CAFs induce an increased metabolism/viability in untreated epithelial 
cancer cell cultures, our next step was to test whether the CM could sensitise these cell lines to TRAIL.  
For this purpose, cells were treated with TRAIL alone and TRAIL in the presence of conditioned medium 
taken 24 hours after incubation with the respective fibroblasts. After 18 hours of 20 ng/ml and 100 
ng/ml TRAIL treatment, viability was assessed by cell titre blue. In this section, we show two graphs 
for each cell line. In the first graph, each treatment is normalised to its own CM control. The second 
graph is a waterfall plot which shows the change in viability after TRAIL treatment. The final graph 
shows the average sensitising ability of each CAF over all cell lines tested. Fibroblast-CM treatment 
resulted in a sensitisation to TRAIL, irrespective of the fibroblasts origin (Figure 6.3 – 6.7). Overall, 
CAFs 209, 207 and 253 exhibited the highest sensitisation to TRAIL, while fibroblasts 98, 213 and CAF 
148 showed the least. We propose that the cell line MCF-7 showed the highest degree of sensitisation 
potentially because it is the cell line that is the most resistant to TRAIL.  
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Figure 6.3. Fibroblast-conditioned medium sensitises MCF-7 cells to TRAIL. A. Relative change in 
viability (cell titre blue assay) following TRAIL, Fibroblasts conditioned medium (CM) and TRAIL/CM 
treatments. Confluent fibroblasts (98, 213, 214, 61, 148, 168, 206, 207, 209 and 253) were incubated 
with fresh fibroblast medium for 24 hours to generate CM. Untreated control cells were cultured with 
only fibroblast medium and treated cells with CM for 24 hours before 20 ng/mL and 100 ng/mL of 
TRAIL treatment. CM treatments were normalised to the untreated control and TRAIL treatments 
were normalised to the CM control.| B. Waterfall plot representing overall sensitivity to TRAIL. Bars 
represent mean +/- SD. (p)-value - significant vs untreated control. * (p)-value - significant vs TRAIL 
alone.   *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test.  
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Figure 6.4. Fibroblast-conditioned medium sensitises primary epithelial cells (BB3RC81) to TRAIL. A. 
Relative change in viability (cell titre blue assay) following TRAIL, Fibroblasts conditioned medium (CM) 
and TRAIL/CM treatments. Confluent fibroblasts (214, 148, 168, 207, 209 and 253) were incubated 
with fresh fibroblast medium for 24 hours to generate CM. Untreated control cells were cultured with 
only fibroblast medium and treated cells with CM for 24 hours before 20 ng/mL and 100 ng/mL of 
TRAIL treatment. In the first graph of each cell line CM treatments were normalised to the untreated 
control and CM+TRAIL treatments were normalised to the CM control. The second graph shows overall 
TRAIL sensitivity. | B. Waterfall plot of the overall sensitivity to TRAIL. | Bars represent mean +/- SD. 
(p)-value - significant vs untreated control. * (p)-value - significant vs TRAIL alone.  *(p) <0.05; 
**(p)<0.005; ***(p)<0.0005; t-test. 
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Figure 6.5. Fibroblast-conditioned medium sensitises primary epithelial cells to TRAIL. A. BB3RC29. 
Relative change in viability (cell titre blue assay) following TRAIL, Fibroblasts conditioned medium (CM) 
and TRAIL/CM treatments. Confluent fibroblasts (98, 213, 153, 214, 61, 148, 168, 206, 207, 209 and 
253) were incubated with fresh fibroblast medium for 24 hours to generate CM. Untreated control 
cells were cultured with only fibroblast medium and treated cells with CM for 24 hours before 20 
ng/mL and 100 ng/mL of TRAIL treatment. In the first graph of each cell line CM treatments were 
normalised to the untreated control and TRAIL treatment was normalised to the CM control. | B. 
Waterfall plot representing the overall change in TRAIL sensitivity. |Bars represent mean +/- SD. (p)-
value - significant vs untreated control. *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test. * (p)-value - 
significant vs TRAIL alone.  
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Figure 6.6. Fibroblast-conditioned medium sensitises primary epithelial cells to TRAIL: A. Relative change in 
viability (cell titre blue assay) following TRAIL, Fibroblasts conditioned medium (CM) and TRAIL/CM treatments. 
Confluent fibroblasts (98, 213, 153, 214, 61, 148, 168, 206, 207, 209 and 253) were incubated with fresh 
fibroblast medium for 24 hours to generate CM. Untreated control cells were cultured with only fibroblast 
medium and treated cells with CM for 24 hours before 20 ng/mL and 100 ng/mL of TRAIL treatment. CM 
treatment was normalised to the untreated control and TRAIL treatment was normalised to the CM control. n=3 
and for 207, 209, 214 and 253 n=4 with 3 internal replicates. | B. Waterfall plot of the overall sensitivity to TRAIL. 
| Bars represent mean +/- SD. (p)-value - significant vs untreated control. *(p) <0.05; **(p)<0.005; 
***(p)<0.0005; t-test. * (p)-value - significant vs TRAIL alone.    
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Figure 6.7. Fibroblast-conditioned medium sensitises primary epithelial cells to TRAIL: relative 
change in viability (cell titre blue assay) following TRAIL, Fibroblasts conditioned medium (CM) and 
TRAIL/CM treatments. Confluent fibroblasts (98, 213, 153, 214, 61, 148, 168, 206, 207, 209 and 253) 
were incubated with fresh fibroblast medium for 24 hours to generate CM. Untreated control cells 
were cultured with only fibroblast medium and treated cells with CM for 24 hours before 20 ng/mL 
and 100 ng/mL of TRAIL treatment. Average sensitivity to TRAIL of BB3RC81, BB3RC90, BB3RC29 and 
MC-7 cells. | Bars represent mean +/- SD.  
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6.2.4. Fibroblasts-conditioned medium induced partial EMT-like markers in 
MCF-7 cells 
In the previous section, we have found that CM sensitised cells to TRAIL. We next wished to 
determine the mechanism of CM induced sensitivity to TRAIL treatment by establishing whether 
specific markers of EMT were altered following CM treatment. Our laboratory has seen that MDA-MB-
231 conditioned medium changes luminal MCF-7 cells into a more mesenchymal-type phenotype: 
involving upregulation of vimentin and fibronectin; downregulation of E-cadherin and twist but no 
changes in the EMT-related factors slug and snail (Rhiannon French, unpublished data). An 
independent study however, reported a stronger relation between slug expression and loss of E-
cadherin in breast cancer cell lines (Hajra et al., 2002). This latter study reported that MCF-7 cells 
express E-cadherin with no expression of Slug and MDA-MB-231 cells express Slug with no expression 
of E-cadherin. To investigate whether EMT markers were upregulated or downregulated by CM 
factors, MCF-7 cells were treated with CM from several fibroblasts and cells phenotype and gene 
expression of EMT markers (E-cadherin, N-cadherin, Vimentin, Slug, Snail, IL-6 and IL-8) were assessed.  
MCF-7 cells were treated with CM from fibroblasts 98, 61, 214, 207, 209 and 253 for 24 hours 
and analysed by phase-contrast microscopy to check any changes in morphology (for example change 
in cell shape). MCF-7 cells did not change in morphology in response to any of the treated samples 
(Figure 6.8 A). The mRNA expression of specific EMT markers was also analysed in MCF-7 cells and 
directly compared with the expression of the same markers in fibroblasts 214 and 253. The fibroblasts 
exhibited lower expression of E-cadherin and increased expression of N-cadherin, Vimentin, Slug, 
Snail, IL-6 and IL-8 compared to the MCF-7 cells (Figure 6.8 B). This was consistent with MCF-cells 
exhibiting a luminal phenotype whereas fibroblasts have a mesenchymal phenotype.  
MCF-7 cells treated with CM for 24 hours had a lower expression of E-cadherin, N-cadherin 
and Vimentin compared to untreated cells. Additionally, these cells had higher expression of Slug, 
Snail, IL-6 and IL-8 compared to control (Figure 6.9 A). Of these markers, IL-6 had the highest 
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upregulation and Snail had the least compared to the untreated control. CM 98, 214, 207 and 209 
induced similar expression of these markers but CM 253 showed lower expression of N-cadherin and 
this was the only sample with downregulation of IL-8 (Figure 6.9 A). The same experiment was 
repeated but for 48 hours of CM treatment with CM 209 and CM 253. The gene expression pattern 
was similar to 24 hours, with downregulation of E-cadherin, N-cadherin and Vimentin; up-regulation 
of Slug and IL-6 with minimal up-regulation of Snail. IL-8 was downregulated in 209 and in 253 (Figure 
6.9 B). 
To determine if the changes in E-cadherin gene expression manifested in changes in protein 
expression, cells were treated with CM for 24 hours and 48 hours and then fixed and stained with E-
cadherin antibodies by immunofluorescence.  These semi-quantitative experiments failed to confirm 
that E-cadherin was downregulated by CM or that e-cadherin was redistributed within the tumour 
cells (Figure 6.10 A and B).  
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Figure 6.8. Fibroblasts-conditioned medium induced partial EMT-like markers expression in MCF-7 
cells. | A. MCF-7 cells were incubated with CM from fibroblasts 98, 214, 207, 209 and 253 for 24 hours. 
Analysis of MCF-7 cells through a light microscope. Scale bar = 200 µM. | B. qPCR: Relative fold change 
of E-cadherin, N-cadherin, Vimentin, Slug, Snail, IL-6 and IL-8 expression after 24 hours in Fibroblast 
214 and CAFS (253_1 and 253_2). Relative fold change was normalised to MCF-7 cells used as a 
control. | n=1 for 214 and n=2 for 253 (253_1 and 253_2) with 3 internal replicates. Bars represent 
mean +/- SD and p-value - significant vs MCF-7 control.  *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test. 
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Figure 6.9. Fibroblasts-conditioned medium induced partial EMT-like markers expression in MCF-7 
cells. | A. qPCR: Relative fold change of E-cadherin, N-cadherin, Vimentin, Slug, Snail, IL-6 and IL-8 
expression after 24 hours and 48 hours of CM treatment normalised to the untreated control using 
MCF-7 cells were incubated with CM from fibroblasts 98, 214, 207, 209 and 253. |B. Same conditions 
as A but MCF-7 cells were treated with CM for 48 hours. CM 209 represents n=2 and 253 represents 
n=3. Bars represent mean +/- SD and p-value - significant vs MCF-7 control.  *(p) <0.05; **(p)<0.005; 
***(p)<0.0005; t-test. 
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Figure 6.10 A. Fibroblasts-conditioned medium did not change E-cadherin expression in MCF-7 cells. 
Immunofluorescence: Cells were treated with CM for 24 hours and then fixed and stained with E-
cadherin. CM did not change membrane bound E-cadherin. n=1 
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Figure 6.10. B Fibroblasts-conditioned medium did not change E-cadherin expression in MCF-7 cells. 
Immunofluorescence: Cells were treated with CM for 48 hours and then fixed and stained with E-
cadherin. CM did not change membrane bound E-cadherin. n=1 
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6.2.5. Induction of EMT in MCF-7 cells does not sensitise to TRAIL 
We have demonstrated that CM is able to change expression of EMT markers at the mRNA 
level. However, in order to determine whether it was EMT itself that prompted sensitivity to TRAIL, 
we wished to independently correlate these changes with TRAIL sensitivity. MCF-7 cells were 
therefore treated with a EMT-inducing medium which contained: anti-human E-Cadherin, anti-human 
sFRP-1, anti-human Dkk-1, recombinant human Wnt-5a and recombinant human TGF-β. Cells were 
treated with this EMT supplement for 96 hours prior 20 ng/mL of TRAIL. Our laboratory has seen that 
this EMT-inducing medium is able to increase the expression of N-cadherin, Vimentin, Slug and Twist 
but no change in Snail and E-cadherin in MCF-7 cells (Dan Turnham, unpublished data). Moreover, if 
this medium is removed from cells, cells undergo a mesenchymal-epithelial transition recovering the 
original state (Dan Turnham, unpublished data).  
Induction of EMT with the EMT-inducing medium had no significant effect on overall cell 
viability or the ability of the cells to respond to TRAIL (Figure 6.11). Therefore, MCF-7 cells that have 
undergone conventional EMT retained resistance to TRAIL.  
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Figure 6.11. Induction of EMT in MCF-7 does not sensitises to TRAIL. MCF-7 relative change in viability 
following TRAIL and EMT supplement treatments. MCF-7 cells were cultured with StemXVivoTM EMT 
inducing medium supplement that contains EMT inducing factors for 96 hours before 20 ng/ml of 
TRAIL. After 18 hours, metabolic activity/viability was measured by cell titre blue assay. Graph 
represents single experiment with 3 internal replicates. Bars stood for mean +/-  SD.  
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6.2.6. Longer treatment with conditioned medium does not sensitise MCF-
7 cells to TRAIL 
As complete induction of EMT using an EMT-inducing medium over 96 hours did not sensitise 
cells to TRAIL, we were intrigued to establish whether a 96 hours treatment with CM would result in 
the same sensitisation to TRAIL seen with 24 hours CM treatment, or whether this prolonged 
treatment resulted in lack of sensitivity to TRAIL perhaps due to the induction of EMT. To test this, 
MCF-7 cells were treated with CM from fibroblasts 105, 89, 214 and 61 for 96 hours to mimic the assay 
performed with the EMT-inducing medium. CM was changed at 72 hours in order to not compromise 
cells viability. Cells were treated with 100 ng/ml of TRAIL at 24 hours and 96 hours for 18 hours before 
cell titre blue. As previously seen, 24 hours treatment was able to sensitise MCF-7 cells to TRAIL but a 
96 hour treatment was not able to sensitise the same cells (Figure 6.12).  Therefore, CM only sensitises 
cells to TRAIL over a short time-frame.  
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Figure 6.12. Longer treatment with conditioned medium does not sensitise MCF-7 cells to TRAIL: 
relative change in viability. Cell titre blue: MCF-7 cells were plated in 48 well-plates and incubated 
with fibroblasts CM for 24 hours and 96 hours. CM was changed at 72 hours to not compromise cell 
viability. At 24 hours and 96 hours cells were treated with 100 ng/mL of TRAIL for 18 hours. Bars 
represent mean +/- SD of one single experiment with 3 internal replicates. *(p)-value - significant vs 
TRAIL control: *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigating c-FLIP Suppression and TRAIL Treatment in Breast Cancer 
 
 
 
197 
 
6.2.7. Fibroblast-conditioned medium has a minimal effect at sensitising 
breast cancer stem cells to TRAIL 
To investigate whether the CM and TRAIL is detrimental to breast cancer stem cells, MCF-7s 
were incubated with CM medium for 24 hours in adherent conditions, treated with TRAIL for 18 hours. 
The cells were then passaged into sphere-forming conditions to test whether the treatment was 
capable of reducing the stem-like population. CM from CAF 209, 214 and 253 with 100 ng/mL of TRAIL 
was able to slightly decrease sphere number by 4 – 10% (Figure 6.13). TRAIL had a bigger effect with 
CM from 253, than in sample 209 and 214 which corresponds with the effect of CM/TRAIL seen with 
bulk MCF-7 cells.   
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Figure 6.13. Fibroblast-conditioned medium sensitises breast cancer stem cells to TRAIL. | A. 
Relative change in MCF-7 tumoursphere forming units (TFUs) after TRAIL treatment performing 
tumoursphere assay. MCF-7 cells were plated in 96 well-plates and incubated with fibroblasts-
conditioned medium for 24 hours prior 20 ng/mL of TRAIL. 18 hours later, cells were trypsinized and 
1000 cells were cultured in low attachment plates. Spheres were counted 10 days after culture 
(Passage 1) |B. Waterfall plot representing verall sensitivity of MCF-7s to TRAIL after CM treatments.| 
Bars represent mean +/- SD of one single experiment with 4 internal replicates. (p)-value - significant 
vs untreated control: *(p) <0.05; **(p)<0.005; ***(p)<0.0005; t-test. 
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6.3. Discussion 
In this chapter, we wished to explore the potential link between CAFs, EMT and TRAIL 
sensitivity or resistance. It has been shown that a mesenchymal-like phenotype is present in cells that 
are sensitive to TRAIL (Rahman et al. 2009, Piggott et al., 2011, French et al., 2015) but an EMT process 
is linked to resistance to TRAIL (Wang et al., 2014). Our model, tried to use CAFs as an inducer of EMT 
which is a different approach to that used by Wang et al., where an induced resistance to TRAIL 
resulted in an EMT state.  
In this chapter, fibroblasts were co-cultured with MCF-7 cells to investigate whether CAFs 
sensitised cells to TRAIL. Co-cultures with different CAFs led to a sensitisation of cells to TRAIL (Figure 
6.1). To test whether this sensitisation was due to soluble factors, CM was generated from fibroblasts 
and different cell lines were treated with CM and CM +/- TRAIL. CM and TRAIL experiments led to a 
similar sensitisation to the co-cultures meaning that this sensitisation does not require direct contact 
with fibroblasts (Figure 6.2).  Therefore, fibroblasts may release soluble factors that may modulate the 
sensitivity of cells to TRAIL. As previously mentioned, our laboratory has seen that CM from a 
mesenchymal TRAIL-sensitive cell line resulted in TRAIL-sensitisation in a resistant cell line. Cytokine 
arrays of the CM detected high expression of IL-8, a well-known EMT marker. Since CAFs release IL-8, 
this soluble factor may be responsible for increasing the sensitivity to TRAIL. A cytokine array would 
be helpful in establishing this in the future. 
To study what markers were upregulated after CM treatments, gene expression of a panel of 
well-known EMT-markers were analysed by RT-qPCR. We hypothesised that there would be a switch 
of luminal to mesenchymal markers and also an upregulation of Slug, Snail, IL-6 and IL-8. In all CM 
treated cells there was a downregulation of E-cadherin, N-cadherin and Vimentin (Figure 6.9 B). 
However, this was not confirmed at the protein level for E-cadherin by semi-quantitative 
immunofluorescence (Figure 6.10). Additionally, the experiment lacks of a positive control for E-
cadherin to confirm whether it is actually E-cadherin expressing green fluorescence. 
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Additionally, CM treatment during 48h resulted in a similar pattern as 24 hours meaning that 
CM treatment for 24 hours is enough to change those markers and sensitise to TRAIL. Furthermore, 
there is an upregulation of Slug and IL-6 and maintenance of Snail levels. In regards to IL-8, we were 
expecting an upregulation of this maker and concordantly it was up-regulated 24 hours after all 
treatments except after CM 253. Unexpectantly, at 48 hours, IL-8 was downregulated in both CM 209 
and CM 253.  
 A recent study conducted by Fernando et al. investigated the role of IL-8 in tumour EMT and 
demonstrated that directly treating breast epithelial tumour cells with purified, recombinant human 
IL-8 in vitro, significantly decreased E-cadherin expression and increased fibronectin expression in 
MCF-7 and T47D luminal breast cancer cells (Fernando et al., 2017). Since our laboratory has seen a 
link between TRAIL sensitivity and IL-8 expression in CM, we predicted MCF-7 to express the highest 
levels of IL-8 after CM 253 treatment, which was the CM that resulted in the highest sensitisation to 
TRAIL. However, out of the all CMs studied, CM 253 showed to be the least effective at inducing IL-8 
expression in MCF-7 meaning this sensitivity was likely not mediated by IL-8.  
Additionally, the highest upregulated gene after CM treatment was IL-6. A study has shown 
that, in human cholangiocarcinoma, IL-6 enhances Mcl-1 expression via an Akt-dependent 
mechanism, which regulates cellular Mcl-1 expression and therefore disruption of IL-6/Akt signalling 
sensitises cells to TRAIL cytotoxicity (Kobayashi et al., 2005). If this scenario of IL-6 expression linked 
to TRAIL resistance exists in breast cancer cells, the IL-6 induced by CAFs is not the factor that drives 
TRAIL sensitivity in MCF-7 cells.  
Our laboratory has experience of treating MCF-7 cells with an EMT-inducing medium for 96 
hours and seeing an upregulation of N-cadherin, Vimentin and Slug with no change in E-cadherin and 
Snail (Figure 6.11). The results using CM at 24 hours and 48 hours were different to the EMT-inducing 
medium (with the exception of Snail, where the result was similar). MCF-7 treatment with CM for 96 
hours did not sensitise cells to TRAIL, which could mean that CM in a longer term could induce the 
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same traditional EMT changes seen with the EMT-inducing medium resulting in a resistance to TRAIL. 
However, this 96 hours assay requires additional repeats to confirm this finding – and ultimately one 
would need to determine the extent of this EMT by molecular analysis.  
 Thus, currently it is only known that fibroblasts induced a partial EMT (when one or more of 
the key characteristics of complete-EMT are not exhibited) rather than a complete EMT (when 
epithelial cells commit to a mesenchymal phenotype), which resulted in a sensitisation of cells to 
TRAIL.  
As it is likely that IL-6, IL-8 and Snail do not mediate TRAIL sensitivity it would be important in 
the future to study other EMT markers such as: twist; fibronectin; runx, Zeb-1 and Zeb-2 etc., to fully 
understand the mechanism behind CM and TRAIL sensitivity.  
 Also in this chapter, the effect of fibroblast-CM on four different breast cancer cell lines was 
investigated. CM increased the viability of the cells, which could be due to an increase in cell 
proliferation or prevention of apoptosis. These results corroborate previous studies which have shown 
that fibroblasts directly modulate tumour growth by secreting factors with oncogenic and mitogenic 
functions capable of increasing tumour cell proliferation and protecting from apoptosis (Pietras, 
2010). Moreover, Majety et al. have demonstrated that co-culturing with fibroblasts/CAFs increased 
the proliferation of several types of cancer cells (Lung, Pancreas, Breast). In addition, they have shown 
that co-culture induced differential expression of soluble factors in a cancer type-specific manner. For 
example, epidermal growth-factor was primarily secreted by co-cultures of pancreatic and breast 
cancer cells whereas hepatocyte growth factor was mainly secreted by lung cancer cells and 
fibroblasts, and that IL-6 is primarily secreted by the breast cancer co-cultures indicating a cancer-
specific pattern in cytokine secretion. Treatment with blocking antibodies against a few factors or their 
receptors resulted in the inhibition of cancer cell proliferation in the co-cultures.  Specifically, blocking 
IL-6 led to a significant decrease in the survival of BT20 cells that were co-cultured with fibroblasts, 
demonstrating that the increase in cell proliferation was mediated by IL-6 (Majety et al., 2015). 
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Additionally, another study shows that PI3K/Akt and MAPK/Erk pathways may be the common key 
pathways by which both normal and cancer fibroblasts regulate cancer cell proliferation. High 
secretion of one or more cytokines by CAFs (IL-6, IL-8, VEGF, CCL2 (RANTES) and CCL5 (MCP-1)) may 
potentially mediate the activation of these pathways to induce cancer cell proliferation (Subramaniam 
et al., 2013). These findings agree with our expression data where IL-6 was the highest upregulated 
gene after CM treatment (Figure 6.9 A and B). However, to complement the viability assay, it would 
be essential to perform a proliferation assay to measure proliferation in these cells after CM 
treatment, for example, labelling cells with the proliferation marker ki67. In addition, despite having 
these promising results, it would be important to test more ratios of Fibroblasts:Epithelial cells in the 
co-cultures to study the ability of different concentrations of CAFs at sensitising the same number of 
epithelial cells. It was also seen that fibroblasts from normal tissue or fibroadenomas have less ability 
of increasing cell metabolic activity/proliferation compared with CAFs (Figure 6.2 E). These findings 
agree with a study that shows fibroblasts derived from benign endometrial hyperplasia tissues were 
not able to increase cancer cell proliferation (Subramaniam et al., 2013). Additionally, in vitro 
experiments co-culturing MDA-MB-231 breast cancer cells with human CAFs isolated from mammary 
tissue resulted in an increased proliferation rate with a higher population of tumour cells in S phase 
compared to tumour cells co-cultured with normal fibroblasts (Peng et al., 2013).  In addition, our 
experiments showed that in two of the four cell lines, an increase in fibroblasts grade was correlated 
with an increase of cell proliferation (Figure 6.2 A-D).  
 We have shown that CM treatment led to a sensitisation to TRAIL cytotoxicity in all cell lines 
tested (Figure 6.3 – 6.7). Overall, fibroblasts 207, 209 and 253 have shown to increase sensitivity of 
epithelial cells to TRAIL. Interestingly, CM from fibroblasts derived from a benign sample (98) and 
fibroadenomas (213, 214) were also able to sensitise cells to TRAIL (Figure 6.3 6.7). This may suggest 
that this TRAIL sensitisation mediated by fibroblasts is not related to a tumour microenvironment but 
related to factors that normal fibroblasts and CAFs induce a response in epithelial cells.  
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 Several studies have reported a link between CAFs and drug resistance. However, there are 
experiments linking CAFs to drug sensitivity. One study has shown that mesenchymal stem cells and 
CAFs increased the cytotoxic effect of a RAF inhibitor on MDA-MB-231 cells by downregulating ERK1/2 
phosphorylation and sensitised MCF-7 cells to a mTOR inhibitor. This result showed that CAFs may not 
contribute to all mechanisms of drug-resistance. However, the potential reason may be attributed to 
heterogeneity of CAFs in drug response (Dittmer, et al. 2011).  The CAF 253, which showed to induce 
the highest sensitivity, was derived from a TAMR sample.  As seen in Chapter 5, TAMR cells are 
particularly sensitive to TRAIL. Additionally, the biopsy 253 (the original sample of CAF 253) was the 
most susceptive to TRAIL at a stem cell level (Table 6.1), which agrees with the fact that this CAF gives 
the best sensitisation to TRAIL sensitivity. It has been reported that tamoxifen resistance was related 
to increased levels of Snail, Vimentin, N-cadherin and decreased levels of E-cadherin, which are 
considered as EMT characteristics (Liu et al., 2013). Our gene expression of MCF-7 cells after CM 253 
treatment has partially shown the opposite: downregulation of E-cadherin, Vimentin and N-cadherin 
and maintenance of Snail levels. Furthermore, a study has shown that mitochondrial activity in 
epithelial breast cancer cells drives tamoxifen resistance and that mitochondrial inhibition is able to 
re-sensitise cancer cells to tamoxifen. CAFs induce tamoxifen-resistance by increasing mitochondrial 
activity in epithelial cancer cells (Martinez-Outschoorn et al., 2011). Additionally, in breast cancer, IL-
6 secretion by CAFs promotes tamoxifen resistance through degradation of ER-α (Wang et al., 2014). 
These fibroblasts from the tamoxifen-resistant sample 253 could be able to increase the mitochondrial 
activity of epithelial cells making them more susceptible to TRAIL. However, to test the previous 
hypothesis more CAFS from tamoxifen derived samples would be needed.  
 Several studies have also shown the activation of EMT could induce the generation of the 
CSC population (Wellner et al., 2009). In prostate cancer, CAFs can stimulate EMT and increase the 
stemness properties of cancer cells through the secretion of MMPs (Giannoni et al., 2010). 
Furthermore, CAFs from breast cancer have been reported to promote the EMT in cancer cells via the 
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secretion of stromal-derived factor 1 (SDF-1) and TGF-β1 providing additional support, suggesting that 
CAFs play a crucial role in promoting cancer stemness (Soon et al., 2013). Our next step was to 
investigate whether CM and TRAIL affects the stem cell population. We hypothesised that CM could 
potentially increase stemness in the bulk population. Therefore, MCF-7 cells were treated with CM in 
adherent conditions and then passaged into sphere conditions. CM alone did not increase the number 
of tumourspheres and CM plus TRAIL had a minimal effect on bCSCs (4-10%) (Figure 6.13) Therefore, 
at least under these conditions, CAFs do not appear to induce a stem/progenitor like state in epithelial 
cancer cells. Other experiments that could be performed to confirm this finding are colony forming 
assays and analysis of the stem cell markers ALDH and CD44 after CM/TRAIL treatment. Furthermore, 
CAFs sensitivity was only tested on cell lines that were ER positive and HER2 negative. Testing CM 
treatments on a panel of cell lines with different receptor status would be important to find a 
particular subtype that gives a better senstitisation to TRAIL and also, on cell lines that are resistant 
to TRAIL at a stem cell level.   
  CAFs are more genetically stable and proliferate more slowly than cancer cells. As such, 
fibroblasts or fibroblast secreted factors represent appealing drug targets (Kalluri and Zeisberg, 2006; 
Lu et al., 2009). It would be advantageous to correlate soluble factors released by the fibroblasts with 
TRAIL sensitivity in order for TRAIL to become a candidate for cancer patients with a particular type of 
CAFs within the tumour. Another advantage of studying CAFs and TRAIL sensitivity is to try to find a 
signature correlated to TRAIL sensitivity. Furthermore, a recent study investigated TRAIL-resistance 
mechanisms in human benign fibroblasts from colon and lung and has shown that these fibroblasts 
express pro-apoptotic TRAIL receptor DR5 and less expression of DR4. Normal fibroblasts expressed 
reduced c-myc and caspase-8 activity as compared to TRAIL-sensitive colon cancer cells (Crowder et 
al., 2016). It would be interesting to measure the levels of DR4/DR5 and caspase-8 activity in each of 
these fibroblasts to correlate these levels with TRAIL response.  
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 In summary, CM treatment resulted in an increase in cell viability in all cell lines tested. Co-
culture of fibroblasts with different cell lines and conditioned medium led to a similar sensitisation to 
TRAIL which suggest that this sensitivity is due to soluble factors released by fibroblasts. This 
sensitisation to TRAIL was not related to a tumourigenic microenvironment and to a traditional EMT 
trait. Preliminary data has shown that exposing cells to CM for 96 hours did not sensitise cells to TRAIL 
cytotoxicity, which could mean that long exposure to CM could result in a full EMT-like phenotype.  
Fibroblasts derived from a tamoxifen-resistant tumour have shown the highest sensitisation to TRAIL, 
which mimics the sensitisation of the original sample. These findings support but do not unequivocally 
prove the importance of the tumour microenvironment in modulating drug responses. In the future, 
it will be important to perform a more extensive investigation of the soluble factors present in each 
conditioned medium. We hypothesise that different fibroblasts may release different levels of soluble 
factors and we wish to find the soluble factors that can lead to the highest sensitisation to TRAIL. In 
the future, these fibroblasts could function as a biomarker to predict TRAIL responses along with other 
studies that have demonstrated the ability of a stroma-derived signature to accurately predict disease 
outcome in breast cancer (Wald et al., 2011; Soon, 2016).  
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7. General Discussion 
7.1. General Discussion 
Breast cancer 5-year survival, in the UK, has doubled in the past last 40 years; yet this survival 
is heavily associated with the stage of the disease at diagnosis. Five-year relative survival in patients 
is 99% at Stage I but only 15% at Stage IV (Cancer Research UK). Perhaps the most notable 
improvement in recent years has been the introduction of tamoxifen as the first choice for adjuvant 
therapy in ER positive patients, especially, for premenopausal women as it decreases breast cancer 
recurrence and annual mortality rate by 50% and 31%, respectively. However, 20-30% of tumours 
show resistance to tamoxifen therapy, which either existed prior to the treatment (de-novo resistance) 
or developed during the therapy (acquired tamoxifen resistance) (reviewed in Ali et al., 2016). Breast 
cancer stem cells (bCSCs) have been shown to be responsible for relapse after tamoxifen resistance 
and metastasis (Singh and Settleman, 2010; Weinberg, 2011; Visvader et al., 2012; Mitra et al., 2015; 
Simões et al., 2015, Doherty et al., 2016).  Additionally, endocrine therapies, such as tamoxifen 
increase the proportion of bCSCs within the tumours (Section 5.2.2; Simões et al., 2015). Many 
signalling pathways also have been reported to be upregulated as a consequence for this resistance 
to endocrine treatments such as EGFR/HER2, PI3K/AKT; MAPK, mTOR (Oh et al., 2001; Campbell et al., 
2001; Herynk and Fuqua, 2007). 
Furthermore, an acquisition of endocrine resistance accompanied by the appearance of 
mesenchymal-like features has been suggested, which might correlate with an increased 
predesposition to metastatic disease (Hiscox et al., 2006). This mesenchymal-like phenotype was due 
to an EGFR-driven modulation of the phosphorylation status of beta-catenin, which could contribute 
to a higher aggressive phenotype and transition towards a mesenchymal phenotype in vitro (Hiscox et 
al., 2006). Many drugs have been investigated in order to target cancer cells. One of these drugs is 
TRAIL that has become an interesting anti-cancer agent that specifically induces apoptosis in cancer 
cells with no toxicity to normal cells (Ashkenazi et al. 1999; Keane et al., 1999; Zhang et al., 2005), and 
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also to primary cells as we have demonstrated in Chapter 4 using HMECs (Figure 4.1 – 4.3).  
Additionally, TRAIL had previously been shown to selectively target breast cancer cell types with a 
mesenchymal-like phenotype (Rahman et al., 2009). This was the rationale behind why our group 
started to investigate TRAIL sensitivity in breast cancer cells with endocrine resistance as they present 
with mesenchymal features. Despite TRAIL having demonstrated cytotoxicity in breast cancer cell lines 
in vitro, it has failed numerous clinical trials. However, none of these trials have pre-selected patients 
based on TRAIL sensitivity (reviewed in De Miguel, et al., 2016). Therefore on order TRAIL to become 
a promising drug to the clinic a better stratification of breast cancer is needed.  
It was our intention to investigate TRAIL treatment and c-FLIP suppression in primary breast 
tumours ex vivo directly from the clinic and therefore bridge the gap between in vitro success of TRAIL 
treatment and lack of it in patients. These ex vivo models better mimic the characteristic features of 
primary breast cancer (Perou et al., 2000; Prat et al., 2010). Assays utilising primary cultures can 
provide important models for the study of breast cancer pathogenesis including metastatic disease, 
in vivo assessment of drug sensitivities and discovery of new therapeutics (Drews-Elger et al., 2014). 
However, in Chapter 3, we have showed that the efficiency of obtaining viable cultures for diagnostic 
biopsies and surgical samples was 36.7% and 44.5%, respectively. Within these viable samples 
diagnostic biopsies and surgical samples the successful samples (more than 20 spheres) was 76.5% 
and 28.9%, respectively (Table 3.2). During this project, it was only possible to test TRAIL treatment in 
diagnostic biopsies/surgical samples, due to a lack of sufficient viable tissue and lack of propagation 
in adherent culture. In contrast, we were able to test both c-FLIP suppression and TRAIL in primary 
breast cancer cells from pleural effusions from patients with metastatic breast cancer. These cells 
were able to efficiently survive under adherent culture and propagate under tumoursphere 
conditions.  
In Chapter 5, we showed evidence that TRAIL efficiently targets bCSCs in 82% of the endocrine 
resistant tumours ex vivo (Section 5.2.1). To further evaluate TRAIL efficiency in endocrine-resistant 
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tumours, PDX models were generated to investigate TRAIL efficiency in vivo. In the model where the 
resistance to tamoxifen was acquired in vivo, TRAIL administration lead to a significant reduction of 
tumour size in the tamoxifen-resistant tumours.  Additionally, single cells from these tumours showed 
less ability to form tumourspheres ex vivo, demonstrating TRAIL efficiency in eliminating bCSCs in vivo 
(Figure 5.13 A and B).  Moreover, an anatrozole-resistant breast sample was transplanted into mice 
and TRAIL decreased primary tumour size and number and size of metastases (Section 5.2.1 and 5.2.2).  
 Previous studies have demonstrated increased JNK signalling following the long-term 
acquisition of resistance to endocrine therapies (Musgrove et al., 2009, Shou et al., 2002). Piggott et 
al., demonstrated that one consequence of this JNK activation is the ITCH-dependent destabilisation 
of the c-FLIP protein which correlates with TRAIL sensitivity both in cell line models in vitro and in 
clinical samples ex vivo (Piggott et al., 2018).  Therefore, these data suggest that pre-selecting patients 
with resistance to endocrine treatments could be the solution to TRAIL finally becoming successful in 
clinical trials for breast cancer patients.  Also, these sub-group of patients could be based on sensitivity 
to TRAIL agonists and investigation of c-FLIP, p-ITCH and/or p-JNK levels in tumours could help specify 
the selection process (Figure 7.1).  
As previously mentioned, TRAIL has been proven to be efficient at targeting bulk and bCSCs in 
mesenchymal cells that lack ER positivity (Rahman et al., 2009, Piggott et al., 2011; French et al., 2015). 
We have also demonstrated TRAIL efficiency in targeting bCSCs in ER-negative tumours. This sensitivity 
has been explained by low levels of cytoplasmic c-FLIP and not being able to inhibit the DISC complex 
and subsequent caspase activation (French et al., 2015). However, despite the successes of TRAIL in 
pre-clinical studies, TRAIL has failed numerous clinical trials for patients with triple negative breast 
cancer (TNBC). In Chapter 5, we showed evidence that TRAIL could be efficient at targeting recurrent 
tumours that are ER-negative (Figure 5.8) but have been ER positive in the past and relapsed following 
acquisition of resistance to endocrine therapies.   
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There are still 60-70% of patients with the ER-positive breast cancer that potentially will show 
resistance to TRAIL as a monotherapy. It is established now that the survival factor c-FLIP significantly 
contributes to bCSCs resistance to TRAIL. Additionally, prevention of bCSCs de novo formation is 
another of the key goals to overcome cancer recurrence. There is preliminary evidence in breast 
cancer cell lines that c-FLIP plays a role in the transition of cancer cells between stem- and non-stem-
like states. This study shows that long-term suppression of c-FLIP results in ablation of bCSCs de novo 
formation from a population devoid of bCSCs (L. Piggott, unpublished data).  This has implications for 
long-term survival of patients receiving cancer stem cell therapies, and suggests that c-FLIP could be 
considered as an adjuvant therapy in its own right and future studies could include investigation to 
see whether following bCSC ablation after c-FLIP suppression/TRAIL treatment, prolonged suppression 
of c-FLIP could inhibit this recurrence of cancer stem cells from non-stem-like states. 
 
Figure 7.1. Hypothesised mechanism to overcome TRAIL resistance in endocrine-naïve cells and 
explanation of TRAIL-sensivity in endocrine resistant cells. |  A. C-FLIP suppression (siFLIP or OH14) 
can be used to sensitise cells to TRAIL. | B. Endocrine resistant cells are sensitive to TRAIL because 
there a proteossomal degradation of c-FLIP and therefore c-FLIP is not able to interfere with the DISC 
formation.  
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We demonstrated that pharmacological suppression of c-FLIP using OH14 was able to 
decrease viability and MaSCs in HMECS. However, genetic suppression of c-FLIP (siFLIP) despite 
decreasing viability did not have a significant effect on viability. This might suggest that OH14 could 
have off-target effects in normal cells. To test the last theory, OH14 needs to be tested with the pan-
caspase inhibitor to test whether is off-target effects or cytotoxicity.  Yet, we question if HMECs is the 
best model for normal breast cells. C-FLIP inhibition could be ideally tested in normal tissues harvested 
directly from mastectomies or breast reduction as primary cultures, as they are a better model to test 
compounds in normal tissues directly from patients. Our laboratory has administrated OH14, a c-FLIP 
inhibitor developed in house, to NSG mice at 10mg/kg for 65 days consecutively (a dose which exhibits 
tumour efficacy in other tumour types) and there was no toxicity associated to the drug (R. Clarkson, 
personal communication). More studies are needed to prove safety and efficiency at this dose such 
experiments on OH14 stability in mouse plasma or data of distribution of the drug metabolism in the 
mouse. Therefore, our data led us to conclude that c-FLIP inhibition per se is not detrimental to normal 
cells and preliminary data suggests that OH14 might not be detrimental to normal cells in vivo.  
The combined treatment of c-FLIP suppression and TRAIL treatment affected HMECs viability 
in bulk and stem cell population having a similar effect in normal and in cancer cells. However, OH14 
can display some off-target effects in normal cells or HMECs and therefore it is not the best model for 
test compounds in normal tissue. Suppressing c-FLIP and TRAIL treatment decreased viability and 
tumourspheres in primary metastatic tumour cells derived from pleural effusions of patients with 
metastatic breast cancer. siFLIP sensitised bulk cells to TRAIL in 80% of the samples (roughly 30 -50%) 
and OH14 sensitised 70% the samples to TRAIL reducing viability by 5– 10%. siFLIP and OH14 sensitised 
bCSCs to TRAIL in all samples.  This result shows robust evidence how this strategy could be applied 
to patients with metastatic breast cancer. However, in vivo experiments would be key to validate this 
finding. Additionally, as this dual treatment was not able to eliminate 100% of bCSCs, the treatment 
could be allied to other conventional treatments already used in the clinic.  
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 The tumour microenvironment has been suggested to promote metastatic disease and the 
maintenance of a cancer stem-like cell phenotype (Kuperwasser et al., 2004; Wellner et al., 2009; 
Schauer et al., 2011; Kruijf et al., 2011). We were intrigued about studies reporting TRAIL sensitivity 
associated with a mesenchymal phenotype (Rahman et al., 2009, Piggott et al., 2011, French et al., 
2015) and others associating EMT states with TRAIL resistance (Wang et al., 2014). Our laboratory has 
seen that soluble factors released by a mesenchymal TRAIL-sensitive breast cancer cell line were able 
to sensitise the resistant cell line MCF-7 to TRAIL (Rhiannon French, unpublished data). Additionally, 
the development of endocrine therapy resistance in primary breast cancer is associated with poor 
prognosis by a transition to more aggressive tumour phenotypes that have undergone partial EMT. 
Therefore, we aimed to test whether EMT is linked to TRAIL resistance or sensitivity. Many studies 
have shown that cancer associated fibroblasts (CAFs) are able to induce EMT in cancer cells, here, we 
used CAFs to induce EMT in MCF-7s and thus to study how the tumour microenvironment could 
modulate sensitivity to TRAIL treatment.  In Chapter 6, we have demonstrated that fibroblasts-
conditioned medium (CM) was able to sensitise MCF-7 cells and primary metastatic breast samples to 
TRAIL. However, this sensitisation was not mediated by an EMT state induced by CAFs because an 
EMT-inducing medium did not sensitise cells MCF-7 cells to TRAIL. Despite studying expression of E-
cadherin, N-cadherin, Vimentin, Snail, Slug, IL-6 and IL-8 in MCF-7 after CM treatments, we were not 
able to associate any of those markers to the TRAIL sensitivity after 24 hours and 48 hours. 
Additionally, a longer treatment with CM at 96 hours did not sensitise MCF-7 cells to TRAIL, potentially 
due to the EMT state induced by CAFs, which is supported by literature where they demonstrated that 
CAFs induces EMT in MCF-7 cells (Soon et al., 2013).   
Furthermore, CM was able to induce viability of MCF-7 cells compared to the untreated 
control, perhaps due to increase of proliferation or protection from apoptosis (Figure 6.2; 
Subramaniam et al., 2013). This showed the influence of the tumour microenvironment on cancer 
cells and implies that drug strategies need to target both stem cells and the tumour microenvironment 
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as this may be affecting cell plasticity and helping the transition from the non-stem (luminal-like) state 
to a stem (mesenchymal-like) state. Furthermore, identification of the types of CAFs that can confer 
this sensitisation to TRAIL, could be applied as a biomarker for TRAIL sensitivity and be beneficial to 
breast cancer patients.  
It is important that in the future we establish a better characterisation of the mechanisms 
behind the correlation between mesenchymal-state, EMT and TRAIL sensitivity. It is established that 
mesenchymal cells are sensitive to TRAIL, however, here we find that an EMT state confers resistance 
to TRAIL. Additionally, acquirement of endocrine resistance is linked to a partial EMT towards a 
mesenchymal phenotype, which confers TRAIL sensitivity. We propose that only a partial EMT is able 
to sensitise cells to TRAIL explaining why short exposure with CAFs and CM sensitise cells to TRAIL but 
longer exposure – and potentially a more ‘complete’ EMT - confers TRAIL resistance. However, a full 
characterisation of this partial EMT needs to be elucidated in order to create a panel of factors that 
promotes sensitivity to TRAIL and therefore be valuable to the clinic (Figure 7.2).  
 
Figure 7.2. Theory behind EMT and TRAIL resistance or sensitivity.  
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7.2.  Work Limitations and Future Work 
During this project, TRAIL treatment was only tested in diagnostic biopsies/surgical samples, 
due to a lack of sufficient viable tissue. Additionally, these samples failed to exhibit the capacity to 
passage in culture in either adherent or non-adherent culture. Currently, better protocols are needed 
to improve extraction of single cells from tumours and to prolong life of these cells under culture. 
Future work could involve generation of breast cancer organoid cultures (using the protocol created 
by Clevers group; Sachs et al., 2018) with tissue from patients as they are a promising 3D model 
recapitulating in vivo tissue structural organisation, functional differentiation, chemical and 
mechanical signals (reviewed in Walsh et al. 2016).  
Furthermore, Cell Titre Blue was the assay choosen to assess cell viability during the last three 
chapters but another assays should have been performed to detect apoptotic cells, such as: Annexin 
V; Live/Dead or TUNEL assays. Future experiments could also include proliferation assays (using Ki67 
marker) and metabolic assays (MTT). 
The tumoursphere assay was performed to assess stem cell activity after TRAIL, siFLIP and 
OH14 treatments. In this assay, cells capable to survive under anoikis conditions form spheroids and 
therefore this assay is a readout of stem/progenitor cells within the bulk population (Dontu et al., 
2003). It is well known that anoikis resistance is a characteristic of bCSCs and therefore during the last 
chapters we named these anoikis resistance cells as bCSCs. However, a second passage for some 
experiments would be needed to confirm the existence of stem cells as only stem cells are able to self-
renew. However, when a second passage was performed for some experiments (Section 5.2.1. and 
5.2.2.), the second passage confirmed the result obtained after passage one, leading us to speculate 
that if a second passage would have been performed for every experiment, the result would be similar 
to the passage one. Moreover, in parallel to every tumoursphere assay, another experiments to assess 
stemness should be included, for example the analyse of the surrogate stem cell markers ALDH and 
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CD44. Importantly, the ALDH performed in Section 5.2.7. after OH14 and TRAIL treatments 
corroborated the readout from the tumoursphere assays.  
Another gap in Chapter 4 and 5  was not confirming c-FLIP protein levels after siFLIP treatment 
but these levels were analysed after thesis submission and published in Piggott et al., 2018. C-FLIP 
protein levels were decreased after siFLIP treatment in the metastatic breast cells BB3RC81, 
confirming the results obtained for mRNA levels.  
Previous studies have demonstrated that c-FLIP survival mechanism at the DISC is primarly 
medialted by the  c-FLIP long isoform (Yerbes et al., 2011, Piggott et al., 2011; Hughes et al., 2016). 
Future experiments could explore the mechanisms of the different c-FLIP isoforms at sensitising 
primary cells to TRAIL. 
We have shown that TRAIL is efficient as a single agent in tumours that have acquired resistance 
to endocrine therapies, such as to tamoxifen and anastrozole by decreasing bCSCs in vitro and in vivo. 
However, TRAIL alone does not fully eliminate the CSC population or completely decreases tumour 
growth (Section 5.2.2.) and therefore it is not potent enough to prevent relapse in the future. In order 
to become a reliable candidate to clinical trials, TRAIL needs to be coupled with another existent anti-
cancer therapies to completely eliminate CSCs, such as: other endocrine agents, taxanes or platinium 
agents. 
In Chapter 4, we questioned whether HMECs is the best model to test drugs on normal breast 
cells. C-FLIP inhibition could be ideally tested on normal tissues harvested directly from mastectomies 
or breast reduction as primary cultures, as they are better model to test compounds in normal tissues 
directly from patients. Future work would involve OH14 treatments in tissues from breast reductions 
as tissue from mastectomies may not be considered completely normal tissue. Ideally, OH14 would 
be tested in normal tissues from the same patients when they undergo surgery for tumour resection. 
In chapter 6, the link between EMT and TRAIL sensitivity or resistance was investigated. We 
proved that fibroblasts can sensitise epithelial cells from breast cancer cell lines to TRAIL but there are 
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mechanisms behind CAFs and TRAIL sensitivity that we do not fully understand. An important 
experiment could involve primary tumours with fibroblasts from the same tumour. Then TRAIL 
treatment could be tested in epithelial cells, with and without the respective stroma component. We 
would expect that the stroma would sensitise tumour cells to TRAIL in a short manner. It would be 
also interesting to study whether CAFs from another type of cancer could sensitise breast cancer 
epithelial cells to TRAIL. We have tested some important EMT markers such as E-cadherin, N-cadherin, 
Vimentin, Slug, Snail, IL-6 and IL-8. However, a bigger panel of markers would be needed to help to 
find the responsible mechanism behind CAFs and TRAIL sensitivity, such as: cytokines, fibronectins, 
Twist, Zeb1 and Zeb2. This big panel of markers could help to define the partial EMT that is responsible 
for TRAIL sensitivity. 
Additionally, it would be interesting to isolate exossomes from the fibroblasts CM. Exosomes 
are membrane-enclosed vesicles secreted by cells and play complex roles in intercellular 
communication. Exosomes may act as natural vehicles for delivering protein, mRNA, or microRNA to 
recipient cells and it is well known that stromal fibroblasts secrete exosomes and these are responsible 
for drug resistance or promoting metastasis (Green et al., 2016). Future experiments could involve 
isolation of exossomes from fibroblasts and its’ nature confirmed using the exosome marker protein 
CD81. Then epithelial cells would be treated with exossomes alone,  CM with no exossomes and CM 
containing exossomes to evaluate whether the exossomes could contribute to TRAIL resistance. 
Additionally, we could also evaluate whether exossomes increase CSC levels and whether blocking 
exosome release could affect these CSC levels (for example, using the GW4869, a specific inhibitor for 
neutral sphingomyelinase 2 that regulates packaging of the prion protein into exosomes). 
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